ebmt 2022 hybrid annual meeting march 19

EBMT 2022 Hybrid Annual Meeting March 19 - 23, 2022 PragueScientific program

Saturday, 19. March 2022

Psy Day09:50 - 11:15 Congress Hall / Virtual Hall 1

Psy1 - Psychological issues in hematopoietic stem cell transplantation

Chair: Anna Barata, US

Psy1-01 09:50 - 10:00Psy Day Welcome note

Speaker: Martin Lou?ka, CZ

Psy1-02 10:00 - 10:20How do we evaluate psychological burden in HSCT patients andtheir families?

Speaker: Anna Barata, US

Psy1-03 10:20 - 10:40Trained to live again: An elite sport-inspired coaching for HSCTpatients

Speaker: Sarah Calvin, FR

Psy1-04 10:40 - 11:00Positive psychology intervention to support AllogeneicHematopoietic Cell Transplantation Recipients

Speaker: Hermioni Lokko, US

Psy1-05 11:00 - 11:15Discussion

Transplant and Search Coordinators Day09:50 - 11:15 Forum Hall / Virtual Hall 2

TSCD1 - EBMT-WMDA Transplant and Search Coordinators Day - Emerging challenges in donoridentification and selection

Chair: Anne-Marie van Walraven, NLChair: John Fitzgerald, IE

TSCD1-01 09:50 - 10:00Welcome

Speaker: Bronwen Shaw, US

TSCD1-02 10:00 - 10:20Is EU legislation taking care of donor safety?

Speaker: Sinéad Masterson, IE

TSCD1-03 10:20 - 10:40What does informed consent for treat and donation meanacross borders?

Speaker: Lela Saou, NL

TSCD1-04 10:40 - 11:00How professional societies can help to comply with regulatoryrequirements

Speaker: Nicoletta Sacchi, IT

TSCD1-05 11:00 - 11:15QA

Pharmacists Day09:50 - 11:15 Panorama / Virtual Hall 3

Pharm1 - Pharmacotherapy

Chair: Tiene Bauters, BEChair: Claudia Langebrake, DE

Pharm1-01 09:50 - 10:00Welcome

1 / 160


Speaker: Tiene Bauters, BE

Pharm1-02 10:00 - 10:20Role of the Pharmacist with CAR T Cells

Speaker: Estela Moreno, ES

Pharm1-03 10:20 - 10:40Prevention and management of mucositis

Speaker: Nadjoua Maouche, GB

Pharm1-04 10:40 - 11:00Pharmacological treatment of GVHD

Speaker: Joerg Halter, CH

Pharm1-05 11:00 - 11:15QA

Data Management09:50 - 11:15 South Hall 1A+B / Virtual Hall 4

DM1 - Data Management Session 1

Chair: Bas Middelkoop, NL

DM1-01 09:50 - 10:00Welcome by the Registry Director

Speaker: Bas Middelkoop, NL

DM1-02 10:00 - 10:15Covid-19 and the EBMT Registry - an update

Speaker: Per Ljungman, SE

DM1-03 10:15 - 10:30New data collection forms

Speaker: Carina Gross, NL

DM1-04 10:30 - 10:40Q&A - part I

DM1-05 10:40 - 11:10Presentation of Vendor for new Registry Database

Speaker: Freija Descamps, BE

DM1-06 11:10 - 11:15Q&A - part II

Patient, Family, and Donor Day09:50 - 11:15 North Hall / Virtual Hall 6

PFD1 - Patient, Family and Donor Day: Being the perfect match

Chair: Klara Kabatová-Maxová, CZChair: Gillian Adams, GB

PFD1-01 09:50 - 10:00Welcome

Speaker: Bregje Verhoeven, NLSpeaker: Pavel Jindra, CZ

PFD1-02 10:00 - 10:05Introduction by the session Chairs

PFD1-03 10:05 - 10:20From donor to patient: Exploring the stem cell journeys

Speaker: Christian Chabannon, FR

PFD1-04 10:20 - 10:35Motivations, experiences and perspectives of bone marrowdonation

Speaker: Jan Zeman, CZ

PFD1-05 10:35 - 10:50Donating to a Family Member: More than Just a MedicalProcedure

2 / 160


Speaker: Galen Switzer, US

PFD1-06 10:50 - 11:15QA

Poster Sessions09:50 - 18:00 ePoster Area

Myelodysplastic Syndromes

P640 09:50 - 09:50IMPACT OF SPECIFIC ADVERSE CYTOGENETIC FEATURES ONOUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION IN MYELODYSPLASTIC SYNDROME WITHVERY POOR RISK CYTOGENETICS.

Poster Presenter: Xavier Poiré, BE

P641 09:50 - 09:50INFLUENCE OF DONOR TYPE AND R-IPSS STRATIFICATIONON OUTCOMES FROM MYELODYSPLASTIC SYNDROME BONEMARROW TRANSPLANTATION LATIN AMERICAN REGISTRY

Poster Presenter: Fernando Barroso Duarte, BR

P642 09:50 - 09:50PRELIMINARY RESULTS OF BONE MARROWTRANSPLANTATION IN HYPOCELLULAR VARIANTMYELODYSPLASTIC SYNDROME FROM THE LATIN AMERICANREGISTRY


P643 09:50 - 09:50BIOLOGICAL AND CLINICAL FACTORS OF PROGNOSIS INPATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROME

Poster Presenter: Nikolai Tcvetkov, RU

P644 09:50 - 09:50PROGNOSIS AND RESULTS OF ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION IN PATIENTS WITH PRIMARYAND THERAPY–RELATED MYELODYSPLASTIC SYNDROME

Poster Presenter: Elena Morozova, RU

P645 09:50 - 09:50COMPARATIVE ANALYSIS OF DATA ON THE INFLUENCE OFTHE SARS-COV-2 PANDEMIC ON BONE MARROWTRANSPLANTATION AND PROTOCOLS ADOPTED IN BRAZILBETWEEN MAY/2020 AND APRIL/2021



Solid Tumours

P649 09:50 - 09:50AUTOLOGOUS HEMATOPOIETIC STEM CELLTRANSPLANTATION USING 18 MCI/KG 131I-MIBG AND HIGH-DOSE CHEMOTHERAPY IN HIGH-RISK NEUROBLASTOMA: ASINGLE-CENTER EXPERIENCE

Poster Presenter: Amir Ali Hamidieh, IR


New Drugs- and Cell-based Immune Therapies

3 / 160


P153 09:50 - 09:50A TRI-SPECIFIC KILLER ENGAGER (TRIKE®) AGAINST B7-H3(GTB-5550) ENHANCES NK CELL MEDIATED KILLING OFMULTIPLE MYELOMA

Poster Presenter: Aimee Merino, US

P154 09:50 - 09:50PRE-CLINICAL DEVELOPMENT AND CHARACTERISATION OFA DECITABINE-INDUCED REGULATORY HLAG+CD4+-T CELL-ENRICHED CELL PRODUCT AGAINST GVHD

Poster Presenter: Memnon Lysandrou, GR

P155 09:50 - 09:50PEMBROLIZUMAB FOR THE TREATMENT OF RELAPSED ANDREFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTERAUTOLOGOUS TRANSPLANT AND IN TRANSPLANT-NAÏVEPATIENTS

Poster Presenter: Khalid Halahleh, JO

P156 09:50 - 09:50HLA-MISMATCHED STEM CELL MICROTRANSPLANTATION ASA TREATMENT OPTION FOR DE NOVO ANDRELAPSED/REFRACTORY AML/MDS IN ELDERLY PATIENTS.

Poster Presenter: Rosalía Alonso Trillo, ES

P157 09:50 - 09:50USE OF VENETOCLAX IN COMBINATION WITHHYPOMETHYLATING AGENTS IN PATIENTS WITH ACUTEMYELOID LEUKEMIA RELAPSING AFTER ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Cemaleddin Ozturk, TR

P158 09:50 - 09:50RETROSPECTIVE COMPARISON OF THE AMICUS BLUE™ONLINE ECP SYSTEM TO CURRENT OFFLINE AND ONLINEECP METHODS, FOCUS ON AGVHD

Poster Presenter: Tarik Kanouni, FR

P159 09:50 - 09:50EFFECTIVE LYSIS OF MOLM-13 AND AML BLASTS BYTRIPLEBODY SPM-2 (CD123-16-33) IN COMBINATION WITHSUBSETS OF NK CELLS

Poster Presenter: Claus-Philipp Maier, DE

P160 09:50 - 09:50DARATUMUMAB-CONTAINING REGIMEN IN THE TREATMENTOF RELAPSED HEMATOLOGICAL MALIGNANCIES INCHILDREN AFTER ALLOGENEIC STEM CELLTRANSPLANTATION

Poster Presenter: Zhihui Li, CN

P161 09:50 - 09:50DRIVING CELL THERAPY IN TREATMENT OF MRD-POSITIVEACUTE PEDIATRIC LYMPHOBLASTIC LEUKEMIA AFTERALLOGENEIC-SCT: BLINATUMOMAB + DLI

Poster Presenter: Francesco Paolo Tambaro, IT


CAR-based Cellular Therapy – Preclinical

P079 09:50 - 09:50ENHANCEMENT OF LONG-TERM FUNCTIONALITY OF CD19CAR-T CELLS BY OVEREXPRESSION OF TCF-1

Poster Presenter: Hao Yao, DE

4 / 160


P080 09:50 - 09:50DISRUPTION OF CIN85 ENHANCES PROLIFERATION ANDCYTOTOXICITY OF CD19-SPECIFIC CAR-T CELLS

Poster Presenter: Min Lin, DE

P081 09:50 - 09:50IMPACT OF SERUM-FREE MEDIA ON THE EXPANSION ANDFUNCTIONALITY OF CD19.CAR T CELLS

Poster Presenter: Franziska Eberhardt, DE

P082 09:50 - 09:50THOMSEN-FRIEDENREICH ANTIGEN CD176 AS A NEWTARGET OF CAR-T CELLS TO CONTROL MULTIPLECARCINOMAS

Poster Presenter: Agnes Bonifacius, DE

P083 09:50 - 09:50CELL THERAPY BASED ON NKG2D-CAR TRANSDUCEDCYTOTOXIC CELLS AGAINST ACUTE MYELOID LEUKEMIA

Poster Presenter: Laura Córdoba, ES

P084 09:50 - 09:50COMPARISON OF SECOND AND THIRD GENERATION CAR33-TCELLS IN TERMS OF PROLIFERATION AND CYTOTOXICITY INACUTE MYELOID LEUKEMIA

Poster Presenter: Annika Lauk, DE

P085 09:50 - 09:50COMPARISON OF FACS AND PCR FOR DETECTION OF BCMA-CAR-T CELLS

Poster Presenter: Avinoam Reichman, DE

P086 09:50 - 09:50CD19-CAR-INKT CELL ACTIVITY IS ENHANCED BY PD-1CHECKPOINT INHIBITION WHILE PREVENTINGALLOREACTIVITY

Poster Presenter: Dominik Schneidawind, DE

P087 09:50 - 09:50FUNCTIONALITY AND ENDURANCE OF GMP-STANDARD BCMA-CAR-T CELLS AT DIFFERENT TIMEPOINTS

Poster Presenter: Genqiao Jiang, DE


Patient Advocacy: Patients' Reported Outcome and Expectations

P663 09:50 - 09:50IMPROVED QUALITY OF LIFE WITH LISOCABTAGENEMARALEUCEL COMPARED WITH SALVAGE CHEMOTHERAPYFOLLOWED BY AUTOLOGOUS STEM CELLTRANSPLANTATION IN PATIENTS WITHRELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Poster Presenter: Jeremy Abramson, US

P664 09:50 - 09:50PEGCETACOPLAN TREATMENT MEANINGFULLY IMPROVESQUALITY OF LIFE AND FATIGUE IN PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTSFROM TWO PHASE 3 CLINICAL TRIALS

Poster Presenter: Timothy Kubal, US

P665 09:50 - 09:50CHRONIC MYELOID LEUKEMIA ACCESS TO TYROSINE KINASEINHIBITORS AND POLYMERASE CHAIN REACTION TESTING. APATIENT ADVOCACY PERSPECTIVE FROM CENTRAL-

5 / 160


EASTERN EUROPE AND WEST ASIA REGION.

Poster Presenter: Celia Marín, CH

P666 09:50 - 09:50NEWSPRINGFORME, A DIGITAL SOLUTION TO MEETTRANSPLANTED PATIENTS EXPECTATIONS IN TERMS OFSUPPORT

Poster Presenter: Emilie Robert, FR

P667 09:50 - 09:50COST-EFFECTIVENESS OF EXTRACORPOREALPHOTOPHERESIS FOR THE TREATMENT OF CHRONIC GRAFTVERSUS HOST DISEASE IN THE AUSTRALIAN SETTING

Poster Presenter: Oscar A Mesa Zapata, GB

P669 09:50 - 09:50HEALTH-RELATED QUALITY OF LIFE AFTER ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTSICKLE CELL DISEASE PATIENTS

Poster Presenter: Samer Ghazi, CA


Statistics

P657 09:50 - 09:50HOW LONG IS LONG-ENOUGH? AN INVESTIGATION INTO THERELATIONSHIP BETWEEN TRIAL MATURITY ANDUNCERTAINTY IN COST-EFFECTIVENESS, THE CASE OFAXICABTAGENE CILOLEUCEL IN 3L DLBCL

Poster Presenter: Sachin Vadgama, GB

P658 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANTATION IN BRAZIL:AN ANALYSIS OF THE BRAZILIAN PUBLIC HEALTHCARESETTING DATABASE

Poster Presenter: Nicolle Queiroz Hazarbassanov, BR


Myeloproliferative Neoplasm

P569 09:50 - 09:50PARTIAL EMBOLIZATION OF SPLENIC ARTERY (PESA) -NOVEL METHOD FOR SPLEEN SIZE AND SPLENIC ACTIVITYREDUCTION IN PATIENTS WITH MYELOFIBROSISUNDERGOING HSCT

Poster Presenter: Patryk Sobieralski, PL

P570 09:50 - 09:50DOES FIBROSIS PERSIST AFTER ALLOGENEIC HSCT INPATIENTS WITH MYELOFIBROSIS, WHO ARE OTHERWISENEGATIVE FOR DRIVER MUTATIONS, WITH FULL DONORCHIMERISM?

Poster Presenter: federica sora, IT

P571 09:50 - 09:50MOLECULAR ANNOTATION OF EXTRAMEDULLARY AND BONEMARROW PRIMARY MYELOFIBROSIS RELAPSE AFTERALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Maria V. Barabanshikova, RU

6 / 160


P572 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN MYELOFIBROSIS: OUR 15-YEARSEXPERIENCE

Poster Presenter: Lucia Rita Morais Bras, ES

P574 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PRIMARY MYELOFIBROSIS: ABOUT 6CASES

Poster Presenter: Malek Benakli, DZ


Graft-versus-host Disease – Preclinical and Animal Models

P194 09:50 - 09:50SER-155, AN INVESTIGATIONAL CULTIVATED MICROBIOMETHERAPEUTIC, RATIONALLY DESIGNED TO REDUCEGASTROINTESTINAL INFLAMMATION AND PROMOTEEPITHELIAL BARRIER INTEGRITY IN PATIENTS UNDERGOINGHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Elizabeth Halvorsen, US

P195 09:50 - 09:50CHRONIC GRAFT-VERSUS-HOST DISEASE IMMUNOPROFILINGREVEALS T CELL CLONAL DYNAMICS THAT CORRELATEWITH DISEASE ACTIVITY: A NOVEL MOLECULAR MARKER?

Poster Presenter: Anna Vardi, GR

P196 09:50 - 09:50JAK1/2 INHIBITOR RUXOLITINIB INDUCEPOLYMORPHONUCLEAR MYELOID-DERIVED SUPPRESSORCELLS MOBILIZATION AND FUNCTION VIA JAK/STAT ANDMAPK/NF-?B DEPENDENT MANNER IN PROTECTING AGAINSTACUTE GRAFT-VERSUS-HOST DISEASE

Poster Presenter: Yigeng Cao, CN

P197 09:50 - 09:50SINGLE CELL TRANSCRIPTOMIC SURVEY OF THE HUMANGVHD LANDSCAPE

Poster Presenter: Jason Lam, GB

P198 09:50 - 09:50APRAGLUTIDE DECREASES SEVERITY OF INTESTINALDAMAGE FROM ACUTE GASTROINTESTINAL GRAFT VERSUSHOST DISEASE (GI-GVHD) FOLLOWING ALLOGENEICTRANSPLANTATION WITHOUT IMPACTING ENGRAFTMENT

Poster Presenter: Violetta Dimitriadou, CH

P199 09:50 - 09:50APRAGLUTIDE TREATMENT REDUCES CHEMOTHERAPY-INDUCED GASTROINTESTINAL (GI) DAMAGE IN MICE ANDPRESERVES CELLULAR INTEGRITY DURING CHEMOTHERAPY


P200 09:50 - 09:50TREATMENT WITH APRAGLUTIDE PRESERVES THE GLOBALHOMEOSTATIC ENVIRONMENT OF INTESTINAL MICROBIOTADURING CHEMOTHERAPY IN MICE


P201 09:50 - 09:50APRAGLUTIDE DOES NOT IMPACT ANTI-TUMOR ANDIMMUNOSUPPRESSIVE EFFICACY OF CONDITIONING

7 / 160


CHEMOTHERAPY IN MICE



Experimental Transplantation and Gene Therapy

P147 09:50 - 09:50WOLMAN CD34+ CELLS TRANSDUCED WITH CD11BLIPALENTIVIRUS DRIVES LYSOSOMAL ACID LIPASE ENZYMEEXPRESSION.

Poster Presenter: Anthea Guha, GB

P148 09:50 - 09:50ELTROMBOPAG IN FANCONI ANEMIA PATIENTS INFUSEDWITH VERY LOW NUMBERS OF GENE CORRECTED CELLS

Poster Presenter: June Iriondo, ES

P149 09:50 - 09:50HAPLOIDENTICAL STEM-CELL TRANSPLANTATION FORCHILDREN WITH ACUTE LEUKEMIA, USING ??+ T CELL /CD19+B-CELL DEPLETION, A SINGLE CENTER EXPERIENCE

Poster Presenter: Gal Dadi, IL

P150 09:50 - 09:50VENETOCLAX ADDED TO SEQUENTIAL FLAMSA +ALKYLATOR BASED CONDITIONING FOR ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION, ARETROSPECTIVE SINGLE CENTER CASE SERIES OF THEFLAMSACLAX APPROACH

Poster Presenter: Guido Kobbe, DE

P151 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PATIENTS WITH ADULT ONSETLEUKOENCEPHALOPATHY WITH AXONAL SPHEROIDS

Poster Presenter: Georg-Nikolaus Franke, DE

P152 09:50 - 09:50HAPLOIDENTICAL STEM CELL TRANSPLANT FORHAEMATOLOGICAL MALIGNANCIES: REAL WORLDEXPERIENCE FROM A DEVELOPING COUNTRY.

Poster Presenter: Pallavi Mehta, IN


Cellular Therapies other than CARs

P124 09:50 - 09:50UNMANIPULATED DONOR LYMPHOCYTE INFUSION (DLI)AFTER AB-T AND B-CELL DEPLETED HAPLOIDENTICAL STEMCELL TRANSPLANTATION

Poster Presenter: Federica Galaverna, IT

P125 09:50 - 09:50USE OF MESENCHYMAL STROMAL CELLS UNDER SPECIALSITUATIONS FOR COMPLICATIONS OF ALLOGENEIC HSCT. ASINGLE CENTER EXPERIENCE.

Poster Presenter: Rosalía Alonso Trillo, ES

P126 09:50 - 09:50OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2ANTIGEN SPECIFIC T CELL THERAPY: A NEW POSSIBILITY

8 / 160


FOR COVID-19 TREATMENT

Poster Presenter: Nayoun Kim, KR

P127 09:50 - 09:50THE ROLE OF DONOR GAMMA DELTA T CELLS IN ACUTEMYELOID LEUKEMIA CONTROL AFTER ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION

Poster Presenter: Nelli Bejanyan, US

P128 09:50 - 09:50SEQUENTIAL CONDITIONING WITH FLAMSA-FLUDARABINE-BUSULFAN DOES NOT IMPROVE OUTCOMES AFTERALLOGENEIC-STEM CELL TRANSPLANTATION WHENCOMPARED WITH TREOSULFAN-FLUDARABINECONDITIONING IN HIGHER RISK MDS PATIENTS

Poster Presenter: Radwan Massoud, DE

P129 09:50 - 09:50GENE EDITING OF THE IMMUNE CHECKPOINT NKG2AENHANCES ALLOGENIC NK CELL MEDIATED CYTOTOXICITYAGAINST PATIENT-DERIVED PRIMARY MULTIPLE MYELOMACELLS

Poster Presenter: Tobias Bexte, DE

P130 09:50 - 09:50ASSESSMENT OF THE SAFETY OF THERAPEUTIC COVID 19SPECIFIC T CELLS USING A HUMAN SKIN EXPLANT ASSAYFOR GRAFT VERSUS HOST DISEASE

Poster Presenter: Anne Dickinson, GB

P132 09:50 - 09:50CEREBROSPINAL FLUID PARAMETERS IN PATIENTS WITHPROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHYRECEIVING ALLOGENEIC T CELL THERAPY

Poster Presenter: Nora Möhn, DE

P133 09:50 - 09:50PATIENT-TAILORED ADOPTIVE IMMUNOTHERAPY WITH EBV-SPECIFIC T CELLS FROM RELATED AND UNRELATEDDONORS

Poster Presenter: Britta Maecker-Kolhoff, DE

P134 09:50 - 09:50SPECTRAL FLOW CYTOMETRY OF T-CELL SUBSETS INDONOR LYMPHOCYTE INFUSIONS REVEALS PHENOTYPICALDIFFERENCES ASSOCIATED WITH THERAPEUTIC OUTCOMEIN PATIENTS WITH MYELOID MALIGNANCIES

Poster Presenter: Ruth Sikora, DE

P135 09:50 - 09:50THE EFFICACY OF THIRD-PARTY MESENCHYMAL STEMCELLS IN STEROID-RESISTANT, SEVERE, ACUTE GRAFTVERSUS HOST DISEASE

Poster Presenter: Meltem Kurt Yuksel, TR

P136 09:50 - 09:50RELAPSE PROPHYLAXIS POST-HAPLOIDENTICAL BONEMARROW TRANSPLANTATION AND CYCLOPHOSPHAMIDE(HAPLO/CY) BY INFUSION OF DONOR-DERIVEDEXPANDED/ACTIVATED ?? T CELLS: A PHASE I TRIAL.

Poster Presenter: Lawrence Lamb, US

P137 09:50 - 09:50INFLUENCE OF T-MEMORY CELL DOSES ON POST-TRANSPLANT INFECTIONS AND GVHD RATES.

9 / 160


Poster Presenter: Poh Lin Tan, SG

P138 09:50 - 09:50PROCESSING OF ONE TOTAL BLOOD VOLUME IS SUFFICIENTTO PERFORM EXTRACORPOREAL PHOTOPHERESIS WITHSPECTRA OPTIA CMNC PROTOCOL. A STUDY WITH FOCUSON A PATIENT SAFETY.

Poster Presenter: Roman Ma?achowski, PL

P139 09:50 - 09:50CLINICAL EXPERIENCE OF USING MULTIVIRUS-SPECIFIC TCELLS PRODUCED BY IFN?-DIRECTED IMMUNOMAGNETICSEPARATION IN PATIENTS WITH POST-HSCT SEVERE VIRALINFECTIONS

Poster Presenter: Viktoria Vedmedskia, RU

P140 09:50 - 09:50STEM CELL THERAPY IN CHILDREN WITH NEUROLOGICALDISEASE: ASSOCIATION BETWEEN ADVERSE EFFECTS ANDTOTAL NUCLEATED CELLS PARAMETERS

Poster Presenter: Hernán Ramírez Durán, MX

P141 09:50 - 09:50ADOPTIVE TRANSFER OF ALLOGENIC HPYV-1-VIRUSSPECIFIC T CELLS IMPROVES CLINICAL OUTCOME OFPATIENTS SUFFERING FROM PROGRESSIVE MULTIFOCALLEUKOENCEPHALOPATHY

Poster Presenter: Lea Grote-Levi, DE

P142 09:50 - 09:50IMPACT OF DONOR-TO-RECIPIENT ABO MISMATCH ONOUTCOMES OF PERIPHERAL BLOOD STEM CELL-DERIVEDGRAFTS HAPLOIDENTICAL STEM CELL TRANSPLANTATION

Poster Presenter: Yi Luo, CN

P143 09:50 - 09:50INVARIANT NATURAL KILLER T CELLS PROTECT FROMCYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION

Poster Presenter: Dominik Schneidawind, DE

P144 09:50 - 09:50ALLOGENEIC STEM CELL TRANSPLANTATION WITH 3-DAYSBUSULFAN PLUS FLUDARABINE AS CONDITIONING REGIMENFOR PATIENTS WITH RELAPSED OR REFRACTORY T- ANDNK/T-CELL LYMPHOMAS

Poster Presenter: Ji Hyun Lee, KR

P145 09:50 - 09:50FIBROBLAST-LIKE CELLS PRESENT IN AN APHERESISCOLLECTED HAEMATOPOIETIC PROGENITOR CELLFRACTION

Poster Presenter: Riana Cockeran, ZA

P146 09:50 - 09:50GRANULOCYTE TRANSFUSION IN PATIENTS WITH MUCOSITISAFTER ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Ali Ünal, TR


Haemoglobinopathy

10 / 160


P575 09:50 - 09:50SICKLE CELL DISEASE AND THALASSEMIA IN PEDIATRICHEMATOPOIETIC STEM CELL TRANSPLANTATION:EVALUATION OF PULMONARY RISK FACTORS ANDMANIFESTATIONS

Poster Presenter: A.J. Tulling, NL

P576 09:50 - 09:50THIOTEPA AND SUPPRESSION OF ENDOGENOUSHAEMOPOIESIS WITH HYDROXYCARBAMIDE ANDHYPERTRANSFUSIONS ABROGATES RISK OF GRAFTFAILURE IN HAPLOIDENTICAL RIC HCT FOR PAEDIATRICPATIENTS WITH SCD

Poster Presenter: Daniel Dexter, GB

P577 09:50 - 09:5048 HLA-IDENTICAL RELATED HEMATOPOIETIC STEM CELLTRANSPLANTS IN SICKLE CELL DISEASE: IMPROVINGRESULTS DURING THE LAST DECADE

Poster Presenter: Marina García Morin, ES

P578 09:50 - 09:50HEMOGLOBIN, LACTATE DEHYDROGENASE, AND FACIT-FATIGUE NORMALIZATION RATES IN PATIENTS TREATEDWITH PEGCETACOPLAN: RESULTS FROM THE PEGASUS ANDPRINCE PHASE 3 CLINICAL TRIALS

Poster Presenter: Brian Mulherin, US

P579 09:50 - 09:50PEGCETACOPLAN TREATMENT IN PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA ANDBASELINE HEMOGLOBIN LEVELS AT OR ABOVE 10 GRAMSPER DECILITER: A POST HOC ANALYSIS

Poster Presenter: Jens Panse, DE

P580 09:50 - 09:50MATCHED-RELATED BONE MARROW TRANSPLANTATIONFOR LOW-RISK CHILDREN WITH SICKLE CELL DISEASE IS ANAPPROPRIATE STARTING POINT FOR ALLOGENEIC BMTPROGRAMS.

Poster Presenter: Mane S. Gizhlaryan, AM

P581 09:50 - 09:50T-HAPLO FOR SCD: A PHASE II TRIAL TO ASSESSHAPLOIDENTICAL AB T-DEPLETED STEM CELLTRANSPLANTATION IN PATIENTS WITH SCD WITH NOAVAILABLE MSD, UN UPDATE

Poster Presenter: Jürgen Föll, DE

P582 09:50 - 09:50PRE-TRANSPLANT IMMUNOSUPPRESSION AND RELATEDHAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATIONIN PEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES:SUCCESSFUL ENGRAFTMENT AND NO SEVERE GVHD.

Poster Presenter: Brandon Brown, US


Pharmacology

P683 09:50 - 09:50ROLE AND COMPETENCIES OF THE EBMT CLINICALPHARMACISTS AND CLINICAL PHARMACOLOGISTS: A PAN-EUROPEAN SURVEY

11 / 160


Poster Presenter: Nick Duncan, GB

P684 09:50 - 09:50SCREENING PHYTOCHEMICAL DRUG LIBRARY FORIDENTIFICATION AND DEVELOPMENT OF NOVELPHYTOCHEMICALS FOR THE PROPHYLAXIS OF ACUTE GRAFTVERSUS HOST DISEASE

Poster Presenter: Dievya Gohil, IN

P685 09:50 - 09:50GLUCOCORTICOIDS TRIGGER A CXCR4/PLC-MEDIATED CELLSURVIVAL PATHWAY INVOLVED IN RESISTANCE OF B-ACUTELYMPHOBLASTIC LEUKEMIA

Poster Presenter: Olivier Boyer, FR

P686 09:50 - 09:50PHARMACOKINETICS AND EXPOSURE–EFFICACYRELATIONSHIP OF MARIBAVIR IN TRANSPLANT RECIPIENTSWITH REFRACTORY AND RESISTANT CYTOMEGALOVIRUSINFECTIONS

Poster Presenter: Ivy Song, US

P687 09:50 - 09:50VEDOLIZUMAB FOR PEDIATRIC PATIENTS WITHGASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST-DISEASE

Poster Presenter: gefen bier, IL

P688 09:50 - 09:50SINGLE DOSE CD117-TARGETED ANTIBODY DRUGCONJUGATE (ADC) IN COMBINATION WITHLYMPHODEPLETING ANTIBODIES ENABLES ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION IN MICEWITHOUT CHEMOTHERAPY OR RADIATION

Poster Presenter: Leanne Lanieri, US

P690 09:50 - 09:50HIGH DOSE MELPHALAN CONDITIONING IN AUTOLOGOUSSTEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA - AUK SURVEY OF PRACTICE

Poster Presenter: Siobhan Smith, GB

P691 09:50 - 09:50LIMITED SAMPLING IN MODEL-INFORMED PRECISION DOSINGOF BUSULFAN

Poster Presenter: Adrin Dadkhah, DE

P692 09:50 - 09:50COADMINISTRATION OF REZAFUNGIN DOES NOT IMPACTCYCLOSPORINE OR MYCOPHENOLATE MOFETILPHARMACOKINETICS

Poster Presenter: Taylor Sandison, US

P693 09:50 - 09:50AN ASSESSMENT OF INITIAL VANCOMYCIN DOSING INPEDIATRIC STEM CELL TRANSPLANTATION

Poster Presenter: Vera Pires, PT

P694 09:50 - 09:50DURATION OF ANTIFUNGAL PROPHYLAXIS AFTERHEMATOPOIETIC CELL TRANSPLANT DISCHARGE ONINVASIVE FUNGAL INFECTION OUTCOMES

Poster Presenter: Justine Abella Ross, US

P695 09:50 - 09:50LONG-TERM CLOZAPINE USE IS A RISK FACTOR FORNEUTROPENIA IN THE POST-ENGRAFTMENT PHASE AFTERALLOGENEIC HEMATOPOIETIC STEM CELL

12 / 160


TRANSPLANTATION

Poster Presenter: Claudia Langebrake, DE


Psychological Issues

P671 09:50 - 09:50PSYCHOLOGICAL NEED IN THE HAEMATOPOIETIC STEM CELLTRANSPLANT PATHWAY – WHAT DO OUR PATIENTS THINK?OUTCOMES OF A PATIENT LISTENING EVENT.

Poster Presenter: Jenna Love, GB

P672 09:50 - 09:50PHYSICAL, PSYCHO-SOCIAL, AND LEARNING FUNCTIONINGAFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION INCHILDREN

Poster Presenter: MONIA OUEDERNI, TN

P673 09:50 - 09:50NEUROPSYCHOLOGICAL TARGETS IN THE EARLY STAGESOF REHABILITATION OF PATIENTS WITH HSCT

Poster Presenter: Alisa Volkova, RU

P674 09:50 - 09:50EXPECTATIONS OF THE MEDICAL STAFF REGARDINGCOOPERATION WITH CLINICAL PSYCHOLOGISTS AT THEBONE MARROW TRANSPLANT CLINIC

Poster Presenter: Alisa Volkova, RU

P675 09:50 - 09:50TITLE: SOCIODEMOGRAPHIC AND PSYCHOLOGICALFACTORS ASSOCIATED WITH PSYCHIATRIC DIAGNOSISBEFORE AND DURING HOSPITALIZATION FOR HSCT.

Poster Presenter: Mariana Brenda Ángeles-Basilio, MX

P676 09:50 - 09:50QUALITY OF LIFE AND SUBJECTIVE WELL-BEING INPEDIATRIC PATIENTS AT VARIOUS STAGES OF ALLOGENEICHSCT: FIRST RESULTS OF RUSSIAN PROSPECTIVE STUDY

Poster Presenter: Alina Khain, RU

P677 09:50 - 09:50PSYCHOLOGICAL NEED IN THE HAEMATOPOEITIC STEM CELLTRANSPLANT PATHWAY – VIEW OF THE CLINICAL TEAM

Poster Presenter: Jenna Love, GB

P678 09:50 - 09:50EVALUATION OF ANXIETY AND BURNOUT OF NURSESWORKING AT ADULT BONE MARROW TRANSPLANTATIONUNIT

Poster Presenter: EL?F NAZ ARSLAN, TR

P679 09:50 - 09:50HETEROGENEOUS PSYCHOLOGICAL ASPECTS OF PATIENTSUNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

Poster Presenter: Ahmad Ibrahim, LB

P680 09:50 - 09:50HOW MODERN PSYCHOANALYSIS COULD SUPPORT MODERNMEDICINE - COMMUNICATION, TRANSLATION ANDSEARCHING FOR A MEANING

Poster Presenter: Velislava Donkina, BG

13 / 160


P681 09:50 - 09:50NEUROCOGNITIVE FUNCTION AFTER ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION FORSICKLE CELL DISEASE AND TRANSFUSION DEPENDENTTHALASSEMIA

Poster Presenter: Elisabeth Kühn-Wolff, DE


Nurses Posters – Adult

NP001 09:50 - 09:50PEER AMBASSADOR SUPPORT – A NEW MODEL OFPSYCHOSOCIAL SUPPORTIVE CARE IN A HEMATOLOGICALCLINICAL CARE SETTING

Oral Presenter: Kristina Nørskov, DK

NP002 09:50 - 09:50VULVO-VAGINAL CHRONIC GRAFT VERSUS HOST DISEASE: AMONOCENTRIC LONGITUDINAL STUDY.

Oral Presenter: Francesca Palmisano, IT

NP003 09:50 - 09:50A DIGITAL EDUCATION PATHWAY FOR ALLOGENEICTRANSPLANT PATIENTS: IMPLEMENTATION TOMAINTENANCE, KEEPING THE MOMENTUM GOING

Oral Presenter: Zoe Evans, CA

NP004 09:50 - 09:50ANXIETY AND DEPRESSION IN HSCT PATIENTS AND THEIRCAREGIVERS. PRELIMINARY RESULTS OF THE 100 FIRSTDAYS AFTER HSCT IN A SPANISH COHORT.

Oral Presenter: Carla Ramos-Serrano, ES

NP005 09:50 - 09:50DIGITAL SOLUTIONS FOR CRS AND ICANS GRADING

Oral Presenter: Ruth Clout, GB

NP006 09:50 - 09:50DOING MORE FOR DONORS: RESULTS OF A SERVICEIMPROVEMENT INITIATIVE

Oral Presenter: Emma Kane, GB

NP007 09:50 - 09:50MISSION: POSSIBLE – THE ESTABLISHMENT AND OPERATIONOF A PALLIATIVE CARE PROJECT IN THE BONE MARROWTRANSPLANTATION UNIT

Oral Presenter: Limor Mintz-Manor, IL

NP008 09:50 - 09:50CENTRAL VENOUS CATHETER PATENCY AS A NURSINGQUALITY INDICATOR? AN AUDIT EXPERIENCE DUE TO ACHANGE IN THE LOCKING SOLUTION

Oral Presenter: Isabel Salcedo, ES

NP009 09:50 - 09:50THE DEVELOPMENT OF AN AMBULATORY COMMUNITYSERVICE FOR POST HSCT PATIENTS

Oral Presenter: Rebecca Hallam, GB

NP010 09:50 - 09:50LEARNING FROM ERROR: INVOLVING EXPERT NURSES IN ANINTEGRATED AUDIT PROCESS

Oral Presenter: Barbara Loconte, CH

NP012 09:50 - 09:50PSYCHOSEXUAL FUNCTION AND RELATIONSHIPS POST HSCT

14 / 160


- CAN WE DO BETTER?

Oral Presenter: emma thistlethwayte, GB

NP013 09:50 - 09:50FROM 2 PATIENTS RECIEVING ADVANCED HOSPITAL CAREAT HOME (AHS) IN 2018, TO OVER 40 PATIENTS IN 2020 -EXPERIENCES FROM OSLO UNIVERSITY HOSPITAL

Oral Presenter: Ellen Hammering, NO

NP014 09:50 - 09:50QUALITY OF LIFE PATTERN IN PATIENTS WITH MULTIPLEMYELOMA INFUSED WITH CAR-T THERAPY

Oral Presenter: Cassandra Ixena Andersson-Vila, ES

NP015 09:50 - 09:50NUTRITIONAL STATUS AND QUALITY OF LIFE IN ADULTSUNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION

Oral Presenter: Stefano Botti, IT

NP016 09:50 - 09:50PHOTOBIOMODULATION: A PROMISING INNOVATIVEAPPROACH FOR PREVENTING ORAL MUCOSITIS IN PATIENTSUNDERGOING HEMATOPOIETIC STEM CELLTRANSPLANTATION

Oral Presenter: Nicolas Stocker, FR

NP017 09:50 - 09:50PUTTING PREHABILITATION INTO PRACTICE: EVALUATION OFPRE-TRANSPLANT REFERRALS TO A SPECIALIST DIETETICAND PHYSIOTHERAPY TELEHEALTH PREHABILITATIONSERVICE IN A TERTIARY TRANSPLANT CENTRE

Oral Presenter: Shana Hall, GB

NP018 09:50 - 09:50NURSING APPOINTMENT IN AUTOLOGOUS HAEMATOPOIETICSTEM CELL TRANSPLANTATION

Oral Presenter: Lucília Carreiro, PT

NP019 09:50 - 09:50QUALITY OF LIFE: YOUR CARE, OUR CARE?IMPLEMENTATION AND THE FIRST RESULTS OF MEASURINGQUALITY OF LIFE IN PATIENTS AFTER AN ALLOGENIC STEMCELL TRANSPLANTATION

Oral Presenter: Tineke Nagtegaal-de Wit, NL

NP020 09:50 - 09:50LABMT NURSES GROUP 2021 CONTINUING EDUCATIONPROGRAM

Oral Presenter: Mariela Blanco, AR

NP021 09:50 - 09:50CAR-T SITE QUALIFICATION IN COVID ERA

Oral Presenter: Barbara Loconte, CH

NP022 09:50 - 09:50LIFELONG FOLLOW-UP IN ADULT ALLOGENEICHEMATOPOIETIC CELL TRANSPLANT SURVIVORS: A PILOTSINGLE CENTER INITIATIVE IMPROVING DATA REGISTRATION

Oral Presenter: Johanna Van Hulle, BE

NP023 09:50 - 09:50THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPYUSING THE EXAMPLE OF CAR-T CELL THERAPY

Oral Presenter: Monika Ochsner, CH

15 / 160


NP025 09:50 - 09:50COMPARATIVE OF ALTERATIONS IN VIRGINIA HENDERSONPATTERNS IN PATIENTS UNDERGOING CART THERAPY.PILOT STUDY.

Poster Presenter: Juana García García, ES

NP026 09:50 - 09:50COMPARISON OF TYPES OF PERIPHERAL CATHETERS USEDIN ALLOGENEIC DONORS DURING STEM CELLS EXTRACTIONAT THE BANC DE SANG I TEIXITS OF BELLVITGE DURING2019-2020

Oral Presenter: Ana Isabel Torres Egea, ES

NP027 09:50 - 09:50JOINING FORCES BETWEEN A PUBLIC HOSPITAL AND ATHIRD SECTOR FOUNDATION TO COVER THE NECESSITY OFCAREGIVERS IN AN AT-HOME HEMATOPOIETIC STEM CELLTRANSPLANTS PROGRAM.

Oral Presenter: Cristina Gallego, ES

NP028 09:50 - 09:50CLINICAL CHARACTERISTICS AND NURSING CAREIMPLEMENTED IN HAEMATOPOIETIC STEM-CELLTRANSPLANTATION RECIPIENTS WITH COVID-19: ANOBSERVATIONAL STUDY

Oral Presenter: Lidia Hurtado Ortega, ES

NP029 09:50 - 09:50HSV RESISTANCE IN HEMATOPOIETIC STEM CELLTRANSPLANT PATIENTS

Oral Presenter: Monika Marxová, CZ

NP030 09:50 - 09:50NURSING INTERVENTIONS OF THE MANAGEMENT OFTOXICITIES ASSOCIATED WITH CAR - T CELL THERAPY – ACASE SERIES

Oral Presenter: Seckin Erdal, TR

NP031 09:50 - 09:50THE DEVELOPMENT OF A HEALTH CARE ASSISTANT (HCAS)AND HOUSE KEEPER (HKS) STUDY DAY

Oral Presenter: Ann-Marie Hamilton, GB

NP032 09:50 - 09:50SEVERITY OF ORAL MUCOSITIS IN PATIENTSHEMATOPOIETIC STEM CELL TRANSPLANTATION; ARETROSPECTIVE STUDY

Oral Presenter: Sevgül Çil Kazan, TR

NP034 09:50 - 09:50IMPLEMENTATION OF A PROTOCOL FOR THE CARE OF SKINAND MUCOUS MEMBRANES IN PATIENTS UNDERGOINGHEMATOPOIETIC STEM CELL TRANSPLANTATION

Oral Presenter: Nuria Peña Alvarez, ES

NP035 09:50 - 09:50CASE STUDY: PROCEDURE FOLLOWING LEAKAGE OFTHAWED CELLS DURING INFUSION

Oral Presenter: Lyndsey Griffiths, GB

NP036 09:50 - 09:50MANAGEMENT OF MELPHALAN IN THE CONDITIONINGREGIMEN, VISUAL TOOL FOR NURSES.

Oral Presenter: Silvia Sangüesa Domínguez, ES

NP037 09:50 - 09:50PARENTERAL NUTRITION IN PATIENTS WITH LYMPHOMAS

16 / 160


AFTER AUTOLOGOUS TRANSPLANTATION, COMPARISON OFTEAM / BEAM REGIMENS


Nurses Posters – Paediatric

NP038 09:50 - 09:50EBMT MIDDLE-INCOME COUNTRIES PEDIATRIC ADVANCEDCARE TRAINING PROJECT

Oral Presenter: Eugenia Trigoso, ES

NP039 09:50 - 09:50GASTROSTOMY FEEDING IS SAFE AND EFFECTIVE INIMPROVING THE NUTRITIONAL STATUS OF CHILDREN WITHCANCER AND THOSE UNDERGOING BONE MARROWTRANSPLANT: A SYSTEMATIC REVIEW

Oral Presenter: James Evans, GB

NP040 09:50 - 09:50THE DELIVERY OF EFFECTIVE PATIENT EDUCATION FORPAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT(HSCT) PATIENTS AND THEIR CAREGIVERS

Oral Presenter: Yan Yin Lim, SG

NP041 09:50 - 09:50THE TYRANNY OF DISTANCE IN PAEDIATRIC BMT WITHINAUSTRALIA

Oral Presenter: Lucy Maurice, AU

NP042 09:50 - 09:50NURSE PRACTICE FOR USE OF INTRAVENOUS NEEDLE-LESSCONNECTORS IN CENTRAL VENOUS CATHETERS STUDY

Oral Presenter: Claudia Pina Pino, ES

NP044 09:50 - 09:50PAEDIATRIC UNRELATED UMBILICAL CORD BLOODTRANSPLANT RECIPIENTS HAVE A SIGNIFICANTLYPROLONGED LENGTH OF STAY COMPARED WITH MATCHEDSIBLING OR MATCHED UNRELATED DONOR RECIPIENTS

Oral Presenter: Aisha Hannan, GB

NP045 09:50 - 09:50ACCREDITATIONS AND INSPECTIONS: AN OPPORTUNITY TOIMPROVE. EXPERIENCE IN AN ITALIAN PEDIATRIC CENTERDURING THE LOCKDOWN PERIOD.

Oral Presenter: Giuseppe Marco Deiana, IT

NP046 09:50 - 09:50EDUCATIONAL PROGRAM FOR NURSES INVOLVED IN THECARE OF PEDIATRIC STEM CELL TRANSPLANT (SCT)PATIENTS

Oral Presenter: Nathalie Herman, BE


Nurses Posters – Research

NP047 09:50 - 09:50EVIDENCE-BASED TOPICAL APPROACH FOR SKIN GVHD: ALITERATURE REVIEW

Oral Presenter: Anna Campanati, IT

17 / 160


NP048 09:50 - 09:50THE EFFECT OF ORAL ICE APPLICATION ON PROTECTIONFROM MUCOSITIS IN PATIENTS WITH AUTOLOGIC STEM CELLTRANSPLANTATION REQUESTING MELPHELAN TREATMENT:A RANDOMIZED CONTROLLED STUDY

Oral Presenter: Solmaz Zeybekci, TR

NP050 09:50 - 09:50HOW THE PHARMACIES SUPPORT STEM CELLTRANSPLANTATION PROGRAMS IN ITALY: A GITMO NGSURVEY

Oral Presenter: Maura Faraci, IT

NP051 09:50 - 09:50HAND HYGIENE TEACHING TECHNOLOGIES FOR THEHEALTHCARE TEAM AND CAREGIVERS: SYSTEMATIC REVIEW

Oral Presenter: Renata Cristina de Campos Pereira Silveira, BR


Stem Cell Source

P165 09:50 - 09:50COMPARISON OF THE CLINICAL OUTCOMES OF HAPLOVERSUS CORD BLOOD TRANSPLANTATION IN PEDIATRICAML. A RETROSPECTIVE ANALYSIS ON BEHALF OF GETH

Poster Presenter: Luisa Sisinni, ES

P166 09:50 - 09:50OPTIMAL CORD BLOOD UNIT SELECTION RESULTS IN GOODENGRAFTMENT AND LOW TRM AND RELAPSE, BUTCONDITIONING INTENSITY MATTERS

Poster Presenter: Chloe Anthias, GB

P167 09:50 - 09:50IMPACT OF ALLO PBSC CRYOPRESERVATION ON GRAFTFUNCTION AND ACUTE GVHD

Poster Presenter: Massimiliano Gambella, IT

P168 09:50 - 09:50DOES HLA TISSUE GROUP CHANGE AFTER GRANULOCYTETRANSFUSION?



Lymphoma and Chronic Lymphocytic Leukemia

P595 09:50 - 09:50ALLOGENIC STEM CELL TRANSPLANTATION FORSECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA(SCNSL)

Poster Presenter: Kamal Alzahrani, US

P596 09:50 - 09:50HIGH RESPONSE RATE WITH LIMITED REMISSION DURATIONAFTER ANTI-PD-1-BASED COMBINATIONS INRELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTERNIVOLUMAB MONOTHERAPY FAILURE: THE ROLE ANDOPTIMAL TIMING OF ALLO-HSCT

Poster Presenter: Liudmila Fedorova, RU

P597 09:50 - 09:50ALLOGENEIC STEM CELL TRANSPLANTATION FOR

18 / 160


CUTANEOUS T-CELL LYMPHOMA - A NATIONAL ANALYSIS

Poster Presenter: Daniel Angelov, IE

P599 09:50 - 09:50OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED PRIMARYCENTRAL NERVOUS SYSTEM LYMPHOMA AFTERSEQUENTIAL HIGH-DOSE METHOTREXATE, CYTARABINE,THIOTEPA BASED CHEMOIMMUNOTHERAPY FOLLOWED BYAUTOLOGOUS STEM CELL TRANSPLANTATION

Poster Presenter: Ugne Ringeleviciute, LT

P601 09:50 - 09:50HIGH-DOSE THERAPY AND AUTOLOGOUS STEM CELLTRANSPLANTATION FOLLOWING PLATINUM-FREE HIGH-DOSE CYTARABINE INDUCTION RESULTS IN EXCELLENTLONG TERM SURVIVAL IN YOUNGER PATIENTS WITH MANTLECELL LYMPHOMA

Poster Presenter: Ben-Niklas Baermann, DE

P602 09:50 - 09:50TREATMENT PATTERNS AND CLINICAL OUTCOMES INPATIENTS WITH RELAPSED/REFRACTORY HODGKINLYMPHOMA RECEIVING STEM CELL TRANSPLANTATIONOUTSIDE EUROPE AND NORTH AMERICA: RESULTS FROMTHE B-HOLISTIC STUDY

Poster Presenter: Mubarak Al-mansour, SA

P603 09:50 - 09:50PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATIONIN THE TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS: AMULTICENTER EXPERIENCE

Poster Presenter: Ivan Moiseev, RU

P604 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLSTRANSPLANTATION (ALLO-HSCT) FOR HODGKIN LYMPHOMAIN SWITZERLAND: 20 YEARS OF EXPERIENCE 2001-2020. FORSBST WORKING GROUP.

Poster Presenter: Helena Simeunovic, CH

P605 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES INNORTH AMERICAN ADULT T-CELL LEUKEMIA/LYMPHOMA

Poster Presenter: Daniel Reef, US

P607 09:50 - 09:50DOES HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELLTRANSPLANTATION AFFECT BONE MINERAL DENSITY INPATIENTS WITH LYMPHOMA?

Poster Presenter: Rebecca Fredriksson, SE

P608 09:50 - 09:50HEMATOPOIETIC CELL TRANSPLANTATION IN MANTLE CELLLYMPHOMA: A LONG-TERM SINGLE CENTER EXPERIENCE

Poster Presenter: Eleni Gavriilaki, GR

P609 09:50 - 09:50AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATIONFOR PRIMARY CENTRAL NERVOUS LYMPHOMA. A SINGLEINSTITUTION EXPERIENCE.

Poster Presenter: BEATA OSTROWSKA, PL

P610 09:50 - 09:50GEMCITABINE, CISPLATIN AND DEXAMETHASONE AS ASALVAGE AND MOBILIZATION CHEMOTHERAPHY BEFORE

19 / 160


AUTOLOGOUS STEM-CELL TRANSPLANTATION IS EFFECTIVEAND SAFE OUTPATIENT REGIMEN INRELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS

Poster Presenter: Ayla Gokmen, TR

P611 09:50 - 09:50EFFICACY OF PD1-BLOCKADE IMMEDIATELY FOLLOWED BYAUTOLOGOUS STEM CELL TRANSPLANTATION INRELAPSED/REFRACTORY HODGKIN’S LYMPHOMA, BUTINVESTIGATIONS NEEDED TO ELUCIDATE THE IMPACT ONAUTOLOGOUS TRANSPLANTATION.


P612 09:50 - 09:50ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION INRELAPSED FOLLICULAR LYMPHOMA: UNICENTRIC ANALYSISWITH 20 YEARS OF FOLLOW-UP

Poster Presenter: Rita Pinho Peixeiro, PT

P613 09:50 - 09:50SECONDARY HYPOGAMMAGLOBULINEMIA IN CLL


P614 09:50 - 09:50POST-MARKET CLINICAL FOLLOW-UP OF THE AMICUS BLUE™ONLINE ECP SYSTEM FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL)

Poster Presenter: Tarik Kanouni, FR

P615 09:50 - 09:50THE EXPRESSION OF CD268 HELPS TO DISTINGUISHCHRONIC LYMPHOCYTIC LEUKEMIA FROM OTHER MATURE B-CELL LYMPHOMAS

Poster Presenter: Hui Wang, CN


CAR-based Cellular Therapy – Clinical

P088 09:50 - 09:503RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGENRECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORYCHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – RESULTS FROMAN ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)

Poster Presenter: Patrick Derigs, DE

P089 09:50 - 09:50PRIMARY ANALYSIS OF ZUMA-12: A PHASE 2 STUDY OFAXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINETHERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELLLYMPHOMA (LBCL)

Oral Presenter: Julio Chavez, US

P090 09:50 - 09:50COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL ASSECOND-LINE THERAPY FOR PATIENTS LARGE B-CELLLYMPHOMA (LBCL) IN THE UNITED STATES

Poster Presenter: Patrick Johnston, US

P091 09:50 - 09:50PREDICTING GRADE 2-4 CRS WITH THE MODIFIED EASIX(MEASIX) SCORE IN PATIENTS WITH NHL TREATED WITH ANTICD19 CAR-T CELLS.

Poster Presenter: Eugenio Galli, IT

20 / 160


P093 09:50 - 09:50LONG-TERM (5 YEAR) OVERALL SURVIVAL IN ZUMA-1, THEPIVOTAL STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL)IN PATIENTS WITH REFRACTORY LARGE B-CELL LYMPHOMA(LBCL)

Poster Presenter: Caron A. Jacobson, US

P094 09:50 - 09:50OUTCOME AFTER RELAPSE POST CD19 CAR T-CELLS INCHILDREN AND YOUNG ADULTS WITHRELAPSED/REFRACTORY B-CELL PRECURSOR ACUTELYMPHOBLASTIC LEUKEMIA (R/R B-ALL)

Poster Presenter: Anna Alonso-Saladrigues, ES

P095 09:50 - 09:50A GLIMPSE OF CLINICAL &AMP; LABORATORY FEATURES OFCARHLH SYNDROME IN PATIENTS RECEIVING BCMA CAR-TCELLS

Poster Presenter: Cheng Zu, CN

P096 09:50 - 09:50BASELINE CORRELATES OF COMPLETE RESPONSE TOIDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTSWITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA(RRMM): SUBANALYSIS OF THE KARMMA TRIAL

Poster Presenter: Nina Shah, US

P097 09:50 - 09:50UPDATED RESULTS OF CILTACABTAGENE AUTOLEUCEL(CILTA-CEL) CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T)THERAPY IN LENALIDOMIDE-REFRACTORY MULTIPLEMYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY

Poster Presenter: Katja Weisel, DE

P098 09:50 - 09:50CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) B-CELLMATURATION ANTIGEN (BCMA)-DIRECTED CHIMERICANTIGEN RECEPTOR T CELL (CAR-T) THERAPY IN PATIENTSWITH EARLY RELAPSE AFTER INITIAL MULTIPLE MYELOMA(MM) THERAPY

Poster Presenter: Tessa Kerre, BE

P099 09:50 - 09:50CYTOKINE SCORING SYSTEM CAN EFFECTIVELY EVALUATETHE SEVERITY OF CRS AFTER CART


P100 09:50 - 09:50SUBSEQUENT ANTI-MYELOMA THERAPY AFTERIDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENTIN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLEMYELOMA (RRMM) FROM THE KARMMA STUDY

Poster Presenter: Paula Rodríguez Otero, ES

P101 09:50 - 09:50CYTOMEGALOVIRUS IMPACT IN B-CELL LYMPHOMAPATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

Poster Presenter: Pere Barba, ES

P102 09:50 - 09:50AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES ANHIGHER PERCENTAGE OF EXHAUSTED T-CELLS IN DLBCLPATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELLS. DOWE NEED TIMELY LEUKAPHERESIS STRATEGIES?

21 / 160


Poster Presenter: Mirko Farina, IT

P104 09:50 - 09:50PATIENT-REPORTED OUTCOMES IN ZUMA-7, A PHASE 3,RANDOMIZED, OPEN-LABEL STUDY EVALUATING THEEFFICACY OF AXICABTAGENE CILOLEUCEL (AXI-CEL)VERSUS STANDARD-OF-CARE THERAPY INRELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Poster Presenter: Mahmoud Elsawy, CA

P105 09:50 - 09:50CHARACTERIZATION OF CD19CAR-T CELLS PRODUCED WITHTHE CLINIMACS PRODIGY® PLATFORM: EFFECTS OFPRODUCTION CYCLE LENGTH AND CLINICAL HISTORY OFTHE DONOR WITH REGARD TO HSCT

Poster Presenter: Ekaterina Malakhova, RU

P106 09:50 - 09:50DYNAMICS OF CAR-T CELLS THERAPY ASSOCIATEDCYTOPENIAS: A SINGLE-CENTER EXPERIENCE

Poster Presenter: Reyes Maria Martin-Rojas, ES

P107 09:50 - 09:50CD19-SPECIFIC CAR-T CELLS FOR THE TREATMENT OF CNSCHLOROMAS IN CHILDREN WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Poster Presenter: Sanam Shahid, US

P108 09:50 - 09:50EARLY LYMPHOCYTE COLLECTION FOR CART PRODUCTIONIN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGEB CELL LYMPHOMA IMPROVES T CELL PARAMETERS.

Poster Presenter: Sigal Grisariu, IL

P109 09:50 - 09:50COST-EFFECTIVENESS OF LISOCABTAGENE MARALEUCEL(LISO-CEL) VERSUS AXICABTAGENE CILOLEUCEL (AXI-CEL)FOR TREATMENT OF RELAPSED OR REFRACTORY (R/R)LARGE B-CELL LYMPHOMA (LBCL)

Poster Presenter: Fei Fei Liu, GB

P110 09:50 - 09:50CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN THECZECH REPUBLIC

Poster Presenter: Frantisek Folber, CZ

P111 09:50 - 09:50CD34 SELECTED STEM CELL BOOST CAN SAFELY IMPROVECYTOPAENIAS FOLLOWING CAR-T THERAPY

Poster Presenter: Khushnuma Mullanfiroze, GB

P112 09:50 - 09:50BRIDGING CHEMOTHERAPY STRATEGIES IN CHILDRENUNDERGOING CART-CELLS FOR ALL

Poster Presenter: Macarena Oporto Espuelas, GB

P113 09:50 - 09:50HUMORAL AND T CELL IMMUNE RESPONSES TO ANTI-SARS-COV-2 VACCINES IN PEDIATRIC &AMP PATIENTS WITH ANTI-CD19 CAR-T-INDUCED B-CELL APLASIA

Poster Presenter: Andrea Jarisch, DE

P114 09:50 - 09:50VALIDATION OF COLLECTION AND CRYOPRESERVATION OFAUTOLOGOUS MONONUCLEAR CELLS INTENDED FOR CAR-TCELLS PRODUCTION

22 / 160


Poster Presenter: Ines Bojanic, HR

P115 09:50 - 09:50STUDY OF SPECIFIC LINEAGE CHIMERISM AS AN EARLYBIOMARKER OF RISK OF RELAPSE AFTER ANTI-CD19 CARTTHERAPY IN PATIENTS PREVIOUSLY TREATED WITH ANALLOGENEIC HSCT

Poster Presenter: Antonio Perez-Martínez, ES

P116 09:50 - 09:50AUTOLOGOUS STEM CELL BOOST FOR PROLONGED SEVERECYTOPENIA AFTER TREATMENT WITH CD19-CAR-T-CELLSFOR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA–TWO CASE REPORTS

Poster Presenter: Lukas Gaksch, AT

P117 09:50 - 09:50CD72 IS A PROMISING SUBSTITUTE FOR CD19 AS AMALIGNANT B CELL TARGET IN IMMUNOTHERAPY AND AROUGH B GATING MARKER FOR FLOW CYTOMETRYDETECTION


P118 09:50 - 09:50DEVELOPING A DIETETIC SERVICE FOR PATIENTSUNDERGOING CAR-BASED CELLULAR THERAPY; EVALUATEDWITH PATIENT REPORTED EXPERIENCE AND OUTCOMEMEASURES.

Poster Presenter: Juliet Morgan, GB

P119 09:50 - 09:50CAR-T AS A BRIDGE THERAPY IN A CASE OF ALL LATERESISTANT RELAPSE

Poster Presenter: Marta Comini, IT

P120 09:50 - 09:50FEASIBILITY OF AUTOLOGOUS STEM CELLTRANSPLANTATION AS BRIDGING THERAPY PRIOR TO CD19CAR-T IN R/R LARGE B CELL LYMPHOMA

Poster Presenter: Eugenio Galli, IT

P121 09:50 - 09:50COMMERCIAL MANUFACTURING EXPERIENCE OFTISAGENLECLEUCEL IN EUROPE: &GT; 3 YEARS JOURNEY

Poster Presenter: Bernd Eschgfaeller, CH

P122 09:50 - 09:50UNIVERSAL ANTI-CD123 CAR-??T CELLS COMBINED WITHDONOR LYMPHOCYTES INFUSION FOR RELAPSED ACUTEMYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION

Poster Presenter: erlie jiang, AS

P123 09:50 - 09:50SUCCESSFULL MANAGEMENT OF POST- CAR-T CELL COLDAGLUTININ MEDIATED REFRACTORY AUTOIMMUNEHEMOLYTIC ANEMIA WITH DARATUMUMAB

Poster Presenter: Siret Ratip, TR


ePoster Viewing

23 / 160



Immunodeficiency Diseases and Macrophages

P588 09:50 - 09:50CLINICAL AND IMMUNOLOGICAL OUTCOMES OFHEMATOPOIETIC STEM CELL TRANSPLANTATION FORINBORN ERRORS OF IMMUNITY: 20 YEARS’ EXPERIENCEFROM A MONOCENTRIC COHORT OF 220 PATIENTS

P589 09:50 - 09:50MACHINE LEARNING-BASED APPROACH TO PREDICTPROGNOSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PRIMARY IMMUNODEFICIENCYDISORDERS

Poster Presenter: Xiaowen Zhai, CN

P590 09:50 - 09:50AN INTERNATIONAL MULTI-CENTRE REVIEW OFHAEMATOPOIETIC CELL TRANSPLANTATION FOR RIPK1DEFICIENCY

Poster Presenter: Rebecca B Walsh, GB

P591 09:50 - 09:50TARGETED BUSULFAN-BASED REDUCED-INTENSITYREGIMEN IN MHC CLASS II DEFICIENCY AND CHRONICGRANULOMATOUS DISEASE: SINGLE CENTER STUDY

Poster Presenter: Mohammed Essa, SA

P592 09:50 - 09:50AUTOINFLAMMATORY PERIODIC FEVER, IMMUNODEFICIENCYAND THROMBOCYTOPENIA (PFTI) WDR1-LINKED. CASEREPORT OF A SUCCESSFUL SECOND HAEMATOPOIETICSTEM CELL TRANSPLANTION

Poster Presenter: Sara Redondo, ES

P593 09:50 - 09:50ALLOGENEIC HSCT IN CHILDREN WITH SEVERE TREATMENT-REFRACTORY INFLAMMATORY BOWEL DISEASE (IBD)

Poster Presenter: Tanja Vallée, DE

P594 09:50 - 09:50WISKOTT ALDRICH SYNDROME CAUSED BY NOVEL WASPINTERACTING PROTEIN(WIP) MUTATION IS ASSOCIATED WITHJUVENILE MYELOMONOCYTIC LEUKEMIA - A CASE REPORT.

Poster Presenter: Srividhya Senthil, GB


Non-haematopoietic Stem Cells and Regenerative Medicine

P162 09:50 - 09:50CLINICAL APPLICATION OF MESENCHYMAL STEM CELLSFROM WHARTON'S JELLY IN PATIENTS WITH CEREBRALPALSY

Poster Presenter: Dariusz Boruczkowski, PL

P164 09:50 - 09:50CLINICAL APPLICATION OF MESENCHYMAL STEM CELLSFROM WHARTON'S JELLY IN PATIENTS WITHNEUROLOGICAL/GENETIC DISEASES

Poster Presenter: Micha? Pi?tek, PL

24 / 160



Quality Management

P659 09:50 - 09:50IMPACT ASSESSMENT OF SECOND AND THIRD WAVE OFSARS-COVID19 PANDEMIC ON ALLOGENEIC TRANSPLANTACTIVITY THROUGH THE JACIE ANNUAL MANAGEMENTREVIEW OF A SINGLE TRANSPLANT PROGRAM.

Poster Presenter: serena marotta, IT

P660 09:50 - 09:50THE IMPACT OF COVID 19 ON MULTIDRUG RESISTANTBACTERIAL INFECTION RATE IN A HSCT UNIT IN INDIA

Poster Presenter: Revathi Raj, IN

P661 09:50 - 09:50HOW HEMATOPOIETIC STEM CELL TRANSPLANTATIONACTIVITY WAS AFFECTED DURING THE PANDEMIC? JACIEACCREDITED CENTER REFLEX

Poster Presenter: ?lknur Kozanoglu, TR

P662 09:50 - 09:50A BIG FISH IN A BIG POND QUANTIFYING AND HIGHLIGHTINGALDER HEY’S CONTRIBUTION TO CLINICAL ACTIVITY ANDPATIENT EXPERIENCE THROUGHOUT THEIR JOURNEY TOTRANSPLANT

Poster Presenter: Helen Heartfield, GB


Data Management

P651 09:50 - 09:50OPTIMIZING TEAMWORK LEADS TO A HIGH QUALITY DATACOLLECTION

Poster Presenter: Meriem Kara, ES

P652 09:50 - 09:50A PILOT PROJECT TO EVALUATE THE BENEFIT OFADDITIONAL SUPPORT IN HCT RESEARCH DATAMANAGEMENT ON BEHALF OF ANTHONY NOLAN ANDBSBMTCT

Poster Presenter: Shelley Hewerdine, GB

P653 09:50 - 09:50ADAPTING INTERACTIVE PRE-STEM CELL TRANSPLANTSCREENING AND CLEARANCE DASHBOARD FOR PEDIATRICNON-MALIGNANT BLOOD DISORDER PATIENTS: EXPERIENCEFROM A TERTIARY CARE CENTER DURING THE COVID-19PANDEMIC

Poster Presenter: Mahasen AlSaleh, SA

P654 09:50 - 09:50THE ROLE OF THE UK TRANSPLANT TRIALS NETWORKIMPACT IN DELIVERING THE AMADEUS STUDY DURING THECOVID-19 PANDEMIC

Poster Presenter: Wendy Ingram, GB

P655 09:50 - 09:50A COST ANALYSIS FOR THE CELLULAR THERAPIES SUPPLYCHAIN: IDENTIFYING THE LOW HANGING FRUITS TO OPTIMIZECOST CONTROL

Poster Presenter: Elger Johannes Vink, US

25 / 160


P656 09:50 - 09:50OBSERVATIONAL TRENDS IN GVHD DATA SUBMISSIONS; DOCENTRES HAVE A DATA COLLECTION PROCESS AND IS THISRESPONSIBLE FOR SUBMISSION IMPROVEMENTS?

Poster Presenter: Clementina Abamba, GB


Non-infectious Early Complications

P349 09:50 - 09:50THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS ANDSAFETY OF DEFIBROTIDE IN PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME(VOD/SOS) FOLLOWING CHEMOTHERAPY

Poster Presenter: Ibrahim Yakoub-Agha, FR

P350 09:50 - 09:50THE ROLE OF CONJUGATED MONOCLONAL ANTIBODIES INDEVELOPMENT OF POST-TRANSPLANT VENO-OCCLUSIVEDISEASE: SINGLE CENTER STUDY

Poster Presenter: Mikhail M. Kanunnikov, RU

P351 09:50 - 09:50EASIX PREDICTS VENO-OCCLUSIVE DISEASE AND SURVIVALIN CHILDREN WHO UNDERWENT HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Koray Yalcin, TR

P352 09:50 - 09:50SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVEDISEASE AFTER UNMANIPULATED HAPLOIDENTICAL HSCTWITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A STUDYON BEHALF OF THE SPANISH HSCT AND CELLULARTHERAPY GROUP (GETH).

Poster Presenter: Ignacio Gómez-Centurión, ES

P354 09:50 - 09:50RISK FACTORS FOR POOR GRAFT FUNCTION IN 231PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION

Poster Presenter: Fabio Giglio, IT

P356 09:50 - 09:50CD34-SELECTED STEM CELL BOOST IN PEDIATRIC PATIENTSWITH POOR GRAFT FUNCTION AFTER ALLOGENEIC STEMCELL TRANSPLANTATION IS ASSOCIATED WITH DURABLEENGRAFTMENT AND EXCELLENT OVERALL SURVIVAL

Poster Presenter: Ellen Fraint, US

P357 09:50 - 09:50PROSPECTIVE EVALUATION OF UPPER AND LOWERGASTROINTESTINAL ENDOSCOPIES AND BIOPSIES IN THEDIAGNOSIS AND MANAGEMENT OF ALLOGENEICHEMATOPOIETIC STELL CELL TRANSPLANT RECIPIENTSWITH PERSISTENT DIARRHEA.

Poster Presenter: Ana Belén Bocanegra, ES

P358 09:50 - 09:50CYTOKINE RELEASE SYNDROME DURING ATG/ATLGSEROTHERAPY FOR GVHD PROPHYLAXIS BEFOREALLOGENEIC HSCT: INCIDENCE AND EARLY CLINICALIMPACT ACCORDING TO ASTCT GRADING CRITERIA

26 / 160


Poster Presenter: Philipp Wohlfarth, AT

P359 09:50 - 09:50RELATIONSHIP OF PRE-TRANSPLANT BODY COMPOSITIONAND BONE MINERAL DENSITY ASSESSED BY DUAL ENERGYX-RAY ABSORPTION WITH EARLY COMPLICATIONS AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Anna Czyz, PL

P360 09:50 - 09:50DEFIBROTIDE CAUSES DECREASED EXPRESSION OFINFLAMMATORY GENES AND PROTEINS BY ACTIVATEDPRIMARY HUMAN PULMONARY MICROVASCULARENDOTHELIAL CELLS

Poster Presenter: Alexandra Laberko, GB

P361 09:50 - 09:50USE OF EMAPALUMAB IN THE PERI-TRANSPLANT PERIOD TOPREVENT GRAFT FAILURE IN PATIENTS AT RISK

Poster Presenter: Pietro Merli, IT

P363 09:50 - 09:50EFFICACY OF RECOMBINANT HUMAN THROMBOPOIETIN FORTHE TREATMENT OF SECONDARY FAILURE OF PLATELETRECOVERY AFTER ALLOGENEIC HSCT


P365 09:50 - 09:50NEUROLOGICAL COMPLICATIONS IN CHILDREN AFTERALLOGENIC HSCT: A SINGLE CENTER EXPERIENCE

Poster Presenter: Natalia Bronina, RU

P366 09:50 - 09:50A NEW GENERATION LIGHTWALKER® LASER - EFFECTIVEPROPHYLAXIS OPTION IN PATIENTS UNDERGOINGHEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVERANDOMIZED OPEN-LABEL STUDY.

Poster Presenter: Anna Irga-Staniukiewicz, PL

P367 09:50 - 09:50SAFETY PROOF OF ROMIPLOSTIM IMMEDIATELY AFTERCORD-BLOOD TRANSPLANTATION: RESULTS OF A PHASE 1TRIAL

Poster Presenter: Naoki Kurita, JP

P368 09:50 - 09:50PURE RED CELL APLASIA AMONG ABO MISMATCHEDHEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A 10YEARS RETROSPECTIVE STUDY.

Poster Presenter: Elisabetta Metafuni, IT

P369 09:50 - 09:50PREVENTION OF HEPATIC SINUSOIDAL OBSTRUCTIVESYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION BY PROSTAGLANDIN E1

Poster Presenter: Sungnam Lim, KR

P370 09:50 - 09:50HSCT-ASSOCIATED ENDOTHELIAL DAMAGE IN REAL LIFE:RETROSPECTIVE ANALYSIS IN 155 CONSECUTIVE PATIENTS

Poster Presenter: Giorgia Mancini, IT

P371 09:50 - 09:50COMPLETE LIVER-DONOR CHIMERISM AFTER LIVERTRANSPLANTATION FOLLOWING HEMATOPOIETIC STEMCELL TRANSPLANTATION.

27 / 160


Poster Presenter: Marek Ussowicz, PL

P372 09:50 - 09:50SEVERE GI REGIMEN RELATED TOXICITIES INCREASE WITHAGE IN PATIENTS RECEIVING AUTOLOGOUS TRANSPLANTFOR LYMPHOMA

Poster Presenter: Geoffrey Shouse, US

P373 09:50 - 09:50LECTIN PATHWAY INHIBITOR FOR TRANSPLANT-ASSOCIATED THROMBOTIC MICROAGANGIOPATHY

Poster Presenter: Parth J Ganatra, IN

P374 09:50 - 09:50EXTRACELLULAR DNA IN CHILDREN WITH VENOOCCLUSIVEDISEASE AFTER HEMATOPOIETIC STEM CELLTRANSPLANTATION TREATED WITH DEFIBROTIDE

Poster Presenter: Peter Svec, SK

P375 09:50 - 09:50WEIGHT LOSS POST ALLOGENEIC STEM CELL TRANSPLANTIS ASSOCIATED WITH INCREASED TRANSPLANT RELATEDMORTALITY

Poster Presenter: Kayla Madsen, CA

P377 09:50 - 09:50COMPASSIONATE USE NARSOPLIMAB TO TREATTRANSPLANT ASSOCIATED THROMBOTICMICROANGIOPATHY IN A PEDIATRIC PATIENT WITH MULTI-ORGAN FAILURE

Poster Presenter: Michelle Schoettler, US

P378 09:50 - 09:50INCIDENCE AND IMPACT ON SURVIVAL OF SINUSOIDALOBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE INADULT PATIENTS AFTER ALLOHCT - RETROSPECTIVE PALGANALYSIS. VALIDATION OF EBMT SEVERITY SCORINGSYSTEM

Poster Presenter: Patrycja Mensah-Glanowska, PL

P379 09:50 - 09:50EASIX AND ENDOTHELIAL CELL DYSFUNCTION INALLOGENEIC STEM CELL TRANSPLANTATION

Poster Presenter: Laura Pardo Gambarte, ES

P380 09:50 - 09:50VENO-OCCLUSIVE DISEASE AFTER HIGH-DOSEBUSULFAN–MELPHALAN IN NEUROBLASTOMA – A 10 YEARSINGLE CENTRE EXPERIENCE (2011-2021)

Poster Presenter: Yashashree Gupta, GB

P381 09:50 - 09:50A REAL-WORLD EVIDENCE SYSTEMATIC LITERATUREREVIEW (SLR) OF THE METRICS USED TO DETECT VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME(VOD/SOS) AFTER HAEMATOPOIETIC CELLTRANSPLANTATION (HCT)

Poster Presenter: James Angus, GB

P382 09:50 - 09:50LOW RATES OF TESTING AND HIGH PREVALENCE OFVITAMIN D DEFICIENCY BEFORE AND AFTERTRANSPLANTATION AT AN AUSTRALIAN TRANSPLANTCENTRE

Poster Presenter: Jacinta Perram, AU

28 / 160


P383 09:50 - 09:50SYSTEMATIC LITERATURE REVIEW OF THE NATURALHISTORY OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN ADULTS

Poster Presenter: Steve Whitaker, US

P384 09:50 - 09:50A CASE SERIES OF POSTERIOR REVERSIBLEENCEPHALOPATHY SYNDROME (PRES SYNDROME) INPEDIATRIC TRANSPLANTATION RECEPIENTS AFTERALLOGENEIC BONE MARROW TRANSPLANTATION: SINGLECENTER EXPERIENCE

Poster Presenter: Hatice Ilgen Sasmaz, TR

P385 09:50 - 09:50EFFICACY OF ORAL CRYOTHERAPY IN PREVENTINGMUCOSITIS AND REDUCING MORBIDITY WHENADMINISTERED DURING CONDITIONING REGIMEN FOR STEMCELL TRANSPLANTATION

Poster Presenter: Munira Moosajee, PK

P386 09:50 - 09:50OUTCOMES RELATED TO PEDIATRIC INTENSIVE CARE UNITADMISSION IN THE FIRST 100 DAYS POST HEMATOPOIETICCELL TRANSPLANTATION

Poster Presenter: Hasan Hashem, JO

P387 09:50 - 09:50THE RECIPIENT-SPECIFIC ANTIBODIES (RSA) IN MISMATCHEDRELATED DONORS MAY AFFECT TRANSPLANT-RELATEDCOMPLICATIONS.

Poster Presenter: Alicja Sadowska-Klasa, PL

P388 09:50 - 09:50CLINICAL FACTORS ASSOCIATED WITH RED BLOOD CELLAND PLATELET TRANSFUSION AFTER HEMATOPOIETIC STEMCELL TRANSPLANTATION

Poster Presenter: Laura Pardo Gambarte, ES

P389 09:50 - 09:50ROLE OF N. ACETYL CYSTEINE IN REDUCING THE MUCOSITISIN BONE MARROW TRANSPLANTATION

Poster Presenter: Chatada Srivaishnava Ranjit Kumar, IN

P390 09:50 - 09:50HEPATIC VENOOCCLUSIVE DISEASE AS MAIN COMPLICATIONOF AUTOLOGOUS STEM CELL TRANSPLANTATION

Poster Presenter: MARÍA AMPARO PIMENTEL VILLAR, ES


Haematopoietic Stem Cells

P001 09:50 - 09:50A COMPREHENSIVE MODEL TO PREDICT SEVERE ACUTEGRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICALHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Meng zhu Shen, CN

P002 09:50 - 09:50ANTIBODY RESPONSE TO SARS-COV-2 VACCINATION INPATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION

Poster Presenter: Alice Huang, CH

29 / 160


P003 09:50 - 09:50POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ACUTELEUKEMIA PATIENTS RECEIVING MORE THAN 5/10 HLA-MISMATCHED ALLOGENEIC STEM CELL TRANSPLANTATION:A STUDY ON BEHALF OF THE ALWP OF THE EBMT

Poster Presenter: Michele Wieczorek, FR

P004 09:50 - 09:50INFLUENCE OF C-KIT MUTATIONS ON PROGNOSISFOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PEDIATRIC PATIENTS WITH COREBINDING FACTOR AML WITH RUNX1-RUNX1T1 FUSION GENE

Poster Presenter: Hai He, CN

P005 09:50 - 09:50A PREDICTED MODEL FOR REFRACTORY/RECURRENTCYTOMEGALOVIRUS INFECTION AFTER HAPLOIDENTICALHEMATOPOIETIC STEM CELL TRANSPLANTATION.

Poster Presenter: Shuang Fan, CN

P006 09:50 - 09:50VALIDATION OF THE REVISED PRETRANSPLANTASSESSMENT OF MORTALITY SCORE AFTER ALLOGENEICHEMATOPOIETIC TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE

Poster Presenter: Annalisa Ruggeri, IT

P007 09:50 - 09:50EXCELLENT RESULTS OF ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION FORRELAPSED/REFRACTORY PH-POSITIVE B-CELL ACUTELYMPHOBLASTIC LEUKEMIA

Poster Presenter: Yanzhi Song, CN

P009 09:50 - 09:50A COMPARISON BETWEEN ATG AND PT-CY GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS IN PATIENTS WITH LYMPHOMAUNDERGOING REDUCED INTENSITY CONDITIONING REGIMENHSCT FROM 1 ANTIGEN MMUD

Poster Presenter: Annalisa Paviglianiti, ES

P010 09:50 - 09:50PRECEDING PROTEINURIA AS A RISK AND PROGNOSTICFACTOR FOR TRANSPLANT-ASSOCIATED THROMBOTICMICROANGIOPATHY IN ADULT ACUTE MYELOID LEUKEMIACOHORTS

Poster Presenter: Gi June Min, KR

P011 09:50 - 09:50COVID19 VACCINE RESPONSES IN PATIENTS POST STEMCELL TRANSPLANT

Poster Presenter: Fayhan Alroqi, SA

P012 09:50 - 09:50MULTIPLE MYELOMA: HOME TREATMENT IS POSSIBLE IN ATERTIARY HOSPITAL. FROM AUTOLOGOUS STEM CELLTRANSPLANTATION TO ORAL THERAPY.

Poster Presenter: Laura Solán, ES

P014 09:50 - 09:50HAPLOIDENTICAL TRANSPLANT FROM PBSC WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE ANDCONTROLLED NUMBER OF T LYMPHOCYTES

Speaker: Fulvio Porta, IT

30 / 160


P015 09:50 - 09:50PREDICTORS OF OUTCOMES IN HEMATOPOIETIC CELLTRANSPLANTATION FOR FANCONI ANEMIA: A MULTICENTERANALYSIS

Poster Presenter: Maria Cancio, US

P016 09:50 - 09:50ADVERSE EVENTS OF MRNA-1273 SARS-COV-2 VACCINE INRECENT ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANT RECIPIENTS

Poster Presenter: Nil Albiol, ES

P017 09:50 - 09:50QUALITY OF LIFE RELATED-FACTORS IN LONG-TERMSURVIVORS FOLLOWING ALLOGENIC STEM CELLTRANSPLANTATION

Poster Presenter: Juan José Domínguez-García, ES

P018 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)INTERNATIONAL COOPERATIVE PROJECT IN IRAQIKURDISTAN: A 3 YEAR FOLLOW UP ON THALASSEMIAPATIENTS AND IMPACT OF SARSCOV2 INFECTION

Poster Presenter: Marta Verna, IT

P019 09:50 - 09:50USE OF ABATACEPT AS GVHD PROPHYLAXIS IN PEDIATRICPATIENTS UNDERGOING HSCT FROM MATCHED ORMISMATCHED UNRELATED DONOR


P020 09:50 - 09:50EARLY ABSOLUTE LYMPHOCYTE RECOVERY PREDICTSBETTER SURVIVAL AFTER AUTOLOGOUS STEM CELLTRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMAAND NON-HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY

Poster Presenter: Carles Tolosa, ES

P021 09:50 - 09:50EFFICACY AND SAFETY OF VENETOCLAX IN THE TREATMENTOF RECRUDESCENCE AFTER ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION


P022 09:50 - 09:50EFFICACY OF HEMATOPOIETIC STEM CELL BOOST FORPATIENTS PRESENTING POOR GRAFT FUNCTION (PGF)AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION(HSCT) : A MULTICENTER RETROSPECTIVE STUDY

Poster Presenter: Maude Gaffet, FR

P023 09:50 - 09:50ADVERSE REACTIONS DURING INFUSION OF ALLOGENEICHAEMATOPOIETIC STEM CELLS GRAFTS

Poster Presenter: Nikolina Friš?i?, HR

P024 09:50 - 09:50TOTAL BODY IRRADIATION BASED CONDITIONING REGIMENIMPROVE THE SURVIVAL OF PATIENTS WITH T-CELLLYMPHOBLASTIC LYMPHOMA AFTER ALLOGENEICPERIPHERAL BLOOD STEM CELL TRANSPLANTATION

Poster Presenter: Jiahua Niu, CN

P025 09:50 - 09:50SURVIVAL EFFICACY OF MDS/AML PATIENTS WITH TP53

31 / 160


GENE ALTERATION RECEIVED ALLO-GENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION


P026 09:50 - 09:50?????OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA,ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TOAUTOLOGOUS STEM CELL TRANSPLANTATION FORHODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRICEXPERIENCE

Poster Presenter: Fabrizio Pane, IT

P027 09:50 - 09:50OUTCOMES OF ALLO-HSCT FOR ADULTS WITH PRIMARYMEDIASTINAL B CELLS LYMPHOMA: A RETROSPECTIVESTUDY ON BEHALF OF THE SFGM-TC AND THE LYSA GROUP.

Poster Presenter: Baptiste Le Calvez, FR

P029 09:50 - 09:50DEGREE OF CELL PACKING OF CRYOPRESERVED AT -80ºCHEMATOPOIETIC STEM CELLS DOES NOT AFFECT THEIRVIABILITY AND HEMATOLOGIC RECOVERY OFTRANSPLANTED MYELOMA PATIENTS

Poster Presenter: Ivan Tonev, BG

P030 09:50 - 09:50LYMPHOCYTE DOSE IN GRAFT, CLONOGENIC EFFICIENCYAND MALE SEX AS PREDICTIVE FACTORS OF EARLYLYMPHOCYTE RECOVERY FOLLOWING AUTOLOGOUS STEMCELL TRANSPLANTATION

Poster Presenter: Jesus Fernandez-Sojo, ES

P032 09:50 - 09:50IMPROVEMENT IN ACUTE NEUROLOGICAL COMPLICATIONSRELATED TO STEM CELL TRANSPLANT IN SICKLE CELLDISEASE: LESSONS FROM OUR EXPERIENCE

Poster Presenter: José Manuel Marco Sánchez, ES

P033 09:50 - 09:50THIOTEPA-TREOSULFAN-FLUDARABINE (TTF) ASCONDITIONING REGIMEN IN PATIENTS UNDERGOINGALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION (ALLOHSCT) FOR MYELOFIBROSIS ORMYELODYSPLASTIC SYNDROME: A SINGLE CENTEREXPERIENCE

Poster Presenter: Filippo Antonio Canale, IT

P034 09:50 - 09:50NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELLGRAFT FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLTRANSPLANTATION IN MULTIPLE MYELOMA AND LYMPHOMA

Poster Presenter: Panarat Noiperm, TH

P036 09:50 - 09:50FEASIBILITY OF DARATUMUMAB FOR ADULT PATIENTS WITHCD38 POSITIVE ACUTE MYELOID LEUKEMIA RELAPSEDAFTER ALLOGENIC STEM CELL TRANSPLANTATION


P037 09:50 - 09:50THE EFFECT OF DELAYED CORD CLAMPING ON THE QUALITYOF COLLECTED CORD BLOOD UNITS FOR BANKING

Poster Presenter: AHMAD DARWISH, EG

32 / 160


P038 09:50 - 09:50COVID-19 RISK PERCEPTION IN ALLOGENEICHEMATOPOIETIC CELL TRANSPLANT RECEPTORSFOLLOWING MRNA-1273 SARS-COV-2 VACCINATION

Poster Presenter: Nil Albiol, ES

P039 09:50 - 09:50ACUTE GRAFT VERSUS HOST DISEASE IS COMMON INPATIENTS WHO DEVELOP ENGRAFTMENT SYNDROME AFTERALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN CHILDREN

Poster Presenter: Mariah Wright, US

P040 09:50 - 09:50REVIEW OF OCCURRENCES AT A HAEMATOPOETIC STEMCELL TRANSPLANT COLLECTION AND PROCESSING FACILITYIN SOUTH AFRICA

Poster Presenter: Laurel Anderson, ZA

P041 09:50 - 09:50CARDIOTOXICITY IN HEMATOPOIETIC STEM CELLTRANSPLANTATION: ARE THERE DIFFERENCES BETWEENAUTOLOGOUS AND ALLOGENEIC?

Poster Presenter: Asuncion Borrero Borrego, ES

P042 09:50 - 09:50ALLOGENEIC TRANSPLANTATION (ALLOHCT) IN ACUTEMYELOID LEUKEMIA (AML) WITH FLT3 MUTATIONS: STUDY OFOUTCOME AT THE ERA OF TARGETED THERAPY

Poster Presenter: Natassa - Eleni Loutsidi, GR

P043 09:50 - 09:50UNRELATED DONOR TRANSPLANTATION IN APLASTICANEMIA WITH A QUADRUPLE GVHD PROPHYLAXIS

Poster Presenter: Sabrina Giammarco, IT

P044 09:50 - 09:50EVALUATION OF DISEASE PROGRESSION/RELAPSE INPATIENTS WITH MULTIPLE MYELOMA WAITING FORAUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT INBRAZIL

Poster Presenter: GIANCARLO FATOBENE, BR

P045 09:50 - 09:50GASTROINTESTINAL MICROBIOME CHANGES DURINGAUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA

Poster Presenter: Vitalii Chebotkevich, RU

P046 09:50 - 09:50FEASIBILITY OF TRANSPLANTATION FOR MYELOMA INRESOURCE CONSTRAINED STETTING; REAL-WORLD DATAON SURVIVAL AND COST OF TREATMENT FROM THE FIRSTHAEMATO-ONCOLOGY CENTRE IN SRI LANKA.

Poster Presenter: Saman Hewamana, LK

P047 09:50 - 09:50RESULTS OF ALLOGENEIC STEM CELL TRANSPLANTATION INBONE MARROW FAILURES: A SINGLE-CENTER EXPERIENCE

Poster Presenter: Vildan Özkocaman, TR

P048 09:50 - 09:50STRATEGIC COST ANALYSIS OF HEMATOPOIETIC STEM CELLBANKING FROM CORD BLOOD: AN EGYPTIAN MODEL

Poster Presenter: AHMAD DARWISH, EG

P049 09:50 - 09:50CLADRIBINE ADDED TO MODIFIED

33 / 160


BUSULFAN/CYCLOPHOSPHAMIDE CONDITIONING FORAUTOLOGOUS HEMATOPOIETIC STEM CELLTRANSPLANTATION IN ACUTE MYELOID LEUKEMIA


P050 09:50 - 09:50TRYPAN BLUE AND FLOW CYTOMETRY CELL VIABILITYTESTING OF PACKED OR DILUTED CRYOPRESERVED AT-80ºC HEMATOPOIETIC STEM CELLS SHOW SIMILAR RESULTS

Poster Presenter: Ivan Tonev, BG

P051 09:50 - 09:50ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONIN IRANIAN PATIENTS WITH CONGENITAL SIDEROBLASTICANEMIA: A SINGLE-CENTER EXPERIENCE

Poster Presenter: Bibi Shahin Shamsian, IR


Stem Cell Mobilization, Collection and Engineering

P052 09:50 - 09:50NO ADDED BENEFIT FROM HIGH-DOSE CYCLOPHOSPHAMIDESTEM CELL MOBILIZATION IN MULTIPLE MYELOMA IN FIRSTCOMPLETE REMISSION AFTER BORTEZOMIB-BASEDINDUCTION THERAPY

Poster Presenter: Pedro Baptista, PT

P053 09:50 - 09:50EFFECT OF CD34+ CELL DOSE ON CLINICAL OUTCOMESAFTER ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION WITH POST-TRANSPLANTCYCLOPHOSPHAMIDE

Poster Presenter: Alexandra Pedraza, ES

P055 09:50 - 09:50PROLONGED INFUSION TIME OF CYCLOPHOSPHAMIDE ISMORE EFFECTIVE AS A STEM CELL MOBILIZATION REGIMENIN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS?ARETROSPECTIVE MONOCENTRIC REPORT

Poster Presenter: Yanjuan Li, CN

P056 09:50 - 09:50UPREGULATED EXPRESSION OF SIRT5, SIRT6 AND SIRT7 ISASSOCIATED WITH HIGHER NUMBER OF CD34+ CELLSCOLLECTED AT FIRST APHERESIS.

Poster Presenter: Anna Szmigielska-Kap?on, PL

P057 09:50 - 09:50STEM CELL APHERESIS: ACCURACY OF THE PREDICTION OFTHE STEM CELL YIELD USING PRE-APHERESIS CD34+ CELLCOUNT

Poster Presenter: Maximilian Hornung, DE

P058 09:50 - 09:50HANDLING OF ALLOGENEIC RELATED AND UNRELATED HPCGRAFTS DURING THE COVID-19 PANDEMIC – A SURVEY FROMTHE INFECTIOUS DISEASES AND CELLULAR THERAPY &IMMUNOBIOLOGY WORKING PARTY

Poster Presenter: Nina Worel, AT

P059 09:50 - 09:50CRYOPRESERVATION OF ALLOGENEIC STEM CELLS MAY BEASSOCIATED WITH INCREASED EARLY RELAPSE COMPARED

34 / 160


WITH FRESH PRODUCT: A COHORT STUDY OF IRISHPATIENTS

Poster Presenter: Chris Armstrong, IE

P061 09:50 - 09:50EXTRACORPOREAL PHOTOPHERESIS - COMPARISON OF THEIN-LINE AND OFF-LINE SYSTEM

Poster Presenter: Miriam Lanska, CZ

P062 09:50 - 09:50PREDICTION OF COST-EFFECTIVE CALCULATION OFAPHERESIS BLOOD VOLUME ACHIEVING TARGET CD3+ CELLNUMBER FOR THE MANUFACTURING OF CAR-T CELLS – ASINGLE CENTER COHORT STUDY

Poster Presenter: Efrat Rosenbaum, IL

P063 09:50 - 09:50MODIFICATIONS OF A STANDARD ARA-C MOBILIZATIONPROTOCOL FOR AMBULATORY CONDITIONS

Poster Presenter: Magdalena Dutka, PL

P064 09:50 - 09:50PLERIXAFOR. A FIXED DOSE OF 12 MG FOR RESCUING POORMOBILIZER PATIENTS WITH MYELOMA OR LYMPHOMA.

Poster Presenter: Amado Karduss-Urueta, CO

P065 09:50 - 09:50ADOPTING PLERIXAFOR IN A LIMITED RESOURCE SCENARIO:CLINICAL AND PHARMACOECONOMIC COMPARISON OFHEMATOPOIETIC STEM CELL MOBILIZATION STRATEGIES.

Poster Presenter: Livia Mariano, BR

P066 09:50 - 09:50THE IMPACT OF CRYOPRESERVATION OF PERIPHERALBLOOD STEM CELLS (PBSC) ON EARLY CLINICAL OUTCOMEAFTER ALLO-HSCT

Poster Presenter: Iwona Mitrus, PL

P067 09:50 - 09:50HEMATOPOIETIC RECOVERY WITH MANAGEABLECOMPLICATIONS AFTER STEM CELL BOOST WITHIMMUNOMAGNETIC SELECTION IN THE THERAPY OFALLOGENEIC POOR GRAFT FUNCTION

Poster Presenter: Jowita Fraczkiewicz, PL

P068 09:50 - 09:50A COMPARISON OF MOBILIZATION REGIMENS INAUTOLOGOUS STEM CELL TRANSPLANTATION FORMULTIPLE MYELOMA

Poster Presenter: Thea Chandler, GB

P069 09:50 - 09:50CLINICO-LABORATORISTIC ASPECTS OFCRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS(PBSC) IN MATCH UNRELATED TRANSPLANT

Poster Presenter: Gabriele Facchin, IT

P070 09:50 - 09:50AUTOLOGOUS STEM CELL TRANSPLANTATION IN A PATIENTWITH RED CELLS AGGLUTINATION IN LOW TEMPERATURE

Poster Presenter: Iwona Mitrus, PL

P071 09:50 - 09:50FACTORS LIMITING THE ACCESS TO PERFORMING ANAUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT INCANDIDATES. A SINGLE CENTER EXPERIENCE IN MEXICO.

35 / 160


Poster Presenter: Mario Alberto Tapia Bravo, MX

P072 09:50 - 09:50MOBILIZATION OF HEMATOPOIETIC STEM CELLS WITHLENOGRASTIM IN MULTIPLE MYELOMA PATIENTS WITHMINIMAL RESIDUAL DISEASE

Poster Presenter: Ja Min Byun, KR

P073 09:50 - 09:50SAFETY OF BONE MARROW HEMATOPOIETIC STEM CELLCOLLECTION FROM A SARS-COV-2 POSITIVE DONOR: ASINGLE EXPERIENCE DURING THE ITALIAN PANDEMIC

Poster Presenter: Gabriele Magliano, IT

P074 09:50 - 09:50THE IMPACT OF DARA-VRD ON STEM CELL MOBILISATIONAND SUCCESSFUL ENGRAFTMENT; A REAL WORLD CASESERIES

Poster Presenter: Janki Patel, GB

P075 09:50 - 09:50EFFICACY OF PLERIXAFOR PLUS G-CSF IN PATIENTS WITHMULTIPLE MYELOMA AND LYMPHOMA WHO HAVE HADMOBILIZATION FAILURE WITH AT LEAST TWO REGIMENS. ARETROSPECTIVE STUDY

Speaker: Vildan Özkocaman, TR

P076 09:50 - 09:50HAEMATOPOETIC STEM CELL TRANSPLANT COLLECTIONSDURING THE COVID-19 PANDEMIC IN SOUTH AFRICA

Poster Presenter: Tanya Nadia Glatt, ZA

P077 09:50 - 09:50PREDICTIVE FACTORS OF POOR MOBILIZATION IN MULTIPLEMYELOMA PATIENTS

Poster Presenter: Nur Soyer, TR

P078 09:50 - 09:50PREDICTING THE SUCCESS OF PERIPHERAL BLOODPROGENITOR CELLS COLLECTION WITH CVC

Speaker: Ana Salselas, PT


Stem Cell Donor

P169 09:50 - 09:50DONOR KLRC2 DELETION GENOTYPE IS ASSOCIATED WITHUPREGULATION OF ALLOREACTIVITY PATHWAYS WITHINCREASED GVHD AND NRM FOLLOWING T-REPLETEHAPLOIDENTICAL HCT

Poster Presenter: Sarita Rani Jaiswal, IN

P170 09:50 - 09:50HLA-MISMATCHED UNRELATED DONOR TRANSPLANTATIONWITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HLA-HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITHACTIVE ACUTE MYELOID LEUKEMIA

Poster Presenter: Frédéric Baron, BE

P171 09:50 - 09:50EXCELLENT 3-YEAR SURVIVAL IN RECIPIENTS OFMISMATCHED UNRELATED DONOR TRANSPLANTS USINGPOST-TRANSPLANT CYCLOPHOSPHAMIDE: LONGER TERMOUTCOMES OF A NATIONAL MARROW DONOR PROGRAM-

36 / 160


SPONSORED PROSPECTIVE CLINICAL TRIAL.

Poster Presenter: Bronwen Shaw, US

P172 09:50 - 09:50ANALYSIS OF UNRELATED ALLOGENEIC HSC DONORS WHOTESTED POSITIVE FOR SARS-COV-2 AT DIFFERENTDONATION STAGES, AND THE EFFECT ON DONATIONOUTCOMES: A DONOR REGISTRY EXPERIENCE

Poster Presenter: Ruta Maniusyte, GB

P173 09:50 - 09:50MYELOABLATIVE CONDITIONING AND PERIPHERAL BLOODSTEM CELLS FROM HAPLOIDENTICAL DONORS OFFERSCOMPARABLE OUTCOMES TO MATCHED DONORS INALLOGENEIC TRANSPLANTATION FOR HAEMATOLOGICALMALIGNANCIES

Poster Presenter: Kristjan Paulson, CA

P174 09:50 - 09:50PERSONALIZED STRATEGY FOR ALLOGENEIC STEM CELLTRANSPLANTATION GUIDED BY MACHINE LEARNING: A REAL-WORLD DATA ANALYSIS OF THE JAPANESE TRANSPLANTREGISTRY UNIFIED MANAGEMENT PROGRAM

Poster Presenter: Hiroshi Okamura, JP

P175 09:50 - 09:50DONOR SPECIFIC ANTI-HLA (DSA) ANTIBODIES IN HSCT ANDDESENSITIZATION STRATEGIES

Poster Presenter: Ursula La Rocca, IT

P176 09:50 - 09:50RETROSPECTIVE ANALYSIS OF THE IMPACT OF RECIPIENT-DONOR HLA-DISPARITY ON VIRAL REACTIVATION AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

Poster Presenter: Anke Habermehl, AT

P177 09:50 - 09:50THE CLINICAL OUTCOMES OF B-CELL ACUTELYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITHHAPLOIDENTICAL STEM CELLS COMBINED WITH UMBILICALCORD BLOOD TRANSPLANTATION

Poster Presenter: Biqi Zhou, CN

P178 09:50 - 09:50CHRONIC GVHD AFTER MISMATCH UNRELATED DONOR STEMCELL TRANSPLANTATION (9/10) MAY BE ASSOCIATED WITHPIRCHE (PREDICTED INDIRECTLY RECOGNIZABLE HLAEPITOPES) CALCULATED FROM SIX LOCI HLA.

Poster Presenter: Marcelina Grabowska, PL

P179 09:50 - 09:50HIGHER DONOR AGE WITH A CUT-OFF OF 50 YEARS ISASSOCIATED WITH INCREASED NON-RELAPSE MORTALITYAFTER ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA.

Poster Presenter: Yasmine Kadri, CA

P180 09:50 - 09:50RESEARCH ON THE EFFECTS OF TRANSPLANTATION OFCLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIALON RECIPIENTS


P181 09:50 - 09:50ALLOGENEIC STEM CELLS AND LYMPHOCYTE DONATIONS:

37 / 160


RESPONDING TO THE SARS-COV-2 CHALLENGE

Poster Presenter: Cristina Tassi, IT

P182 09:50 - 09:50IMPACT OF GRAFT CD3 LYMPHOCYTE CELL DOSE ONCLINICAL OUTCOMES IN PEDIATRIC PATIENTS UNDERGOINGHAPLOIDENTICAL PERIPHERAL BLOOD STEM CELLTRANSPLANTATION WITH POST TRANSPLANTATIONCYCLOPHOSPHAMIDE

Poster Presenter: Upasana Karthik, IN

P183 09:50 - 09:50UNRELATED HEMATOPOIETIC PERIPHERAL BLOOD STEMCELL DONORS' EXPERIENCE; RESULTS ON 880 DONORS OFTHE EZER MIZION ISRAELI NATIONAL BONE MARROW DONORREGISTRY

Poster Presenter: Roni Zisser (Diamant), IL

P184 09:50 - 09:50TRANSPLANT ACTIVITY IN MEXICO DURING THE COVID19PANDEMIC: ON THE WAY TO RECOVERY

Poster Presenter: Andres Gomez-De Leon, MX

P185 09:50 - 09:50NO IMPACT OF DONOR TYPE ON ALLOGENEICTRANSPLANTATION (ALOHCT) OUTCOMES IN PATIENTS WITHMYELOID MALIGNITY ?60 YEARS OLD

Poster Presenter: Veronika Schneiderová, CZ

P186 09:50 - 09:50A REPORT ON UNMANIPULATED HAPLOIDENTICALHEMATOPOIETIC STEM CELL TRANSPLANTATION FORPEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AT THELARGEST CHILDREN’S MEDICAL HOSPITAL IN IRAN

P187 09:50 - 09:50COMPARISON OF THE LONG-TERM OUTCOMES OF HLA-MISMATCHED UNRELATED DONOR TRANSPLANTATION ANDSINGLE UNRELATED CORD BLOOD TRANSPLANTATIONAFTER REDUCED INTENSITY/TOXICITY CONDITIONING

Poster Presenter: Masatomo Kuno, JP

P188 09:50 - 09:50IMPACT OF ABO INCOMPATIBILITY ON HAPLOIDENTICALHEMATOPOIETIC STEM CELL TRANSPLANT. A SINGLECENTER RETROSPECTIVE STUDY.

Poster Presenter: Beatriz Astibia Mahillo, ES

P189 09:50 - 09:50IMPACT OF ABO MISMATCH ON SURVIVAL ANDENGRAFTMENT IN HAPLOIDENTICAL HEMATOPOIETIC STEMCELL TRANSPLANTATION

Poster Presenter: Benjamin J. McCormick, US

P191 09:50 - 09:50HAPLOIDENTICAL HEMATOPOIETIC STEM CELLTRANSPLANTATION: A SINGLE CENTER EXPERIENCE

Poster Presenter: Isabel Iturrate, ES

P192 09:50 - 09:50PROPOSAL OF THE DIAGNOSTIC WORKUP OF PLASMODIUMSPP. SEROPOSITIVE ALLOGENEIC STEM CELL DONORS

Poster Presenter: Rafal Machowicz, PL

P193 09:50 - 09:50A SINGLE CENTER EXPERIENCE OF HAPLOIDENTICAL STEM

38 / 160


CELL TRANSPLANTATION WITH UNMANIPULATED GRAFT -CASE SERIES OF ELEVEN PATIENTS

Poster Presenter: Ilina Micheva, BG


Graft-versus-host Disease – Clinical

P202 09:50 - 09:50REAL-WORLD DATA ON RUXOLITINIB IN STEROID-REFRACTORY ACUTE INTESTINAL GRAFT-VERSUS-HOST-DISEASE

Poster Presenter: Francesca Biavasco, DE

P203 09:50 - 09:50BORTEZOMIB MAINTENANCE AFTER UPFRONT ALLOGENEICTRANSPLANTATION IN MYELOMA PATIENTS: LESS CHRONICGVHD AND IMMUNOSUPPRESSION BUT STILL NO IMPACT ONSURVIVAL

Poster Presenter: Jean-Sebastien Claveau, US

P204 09:50 - 09:50BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASEAFTER 2 OR MORE PRIOR LINES OF SYSTEMIC THERAPY:LONG-TERM SAFETY FOLLOW-UP OF THE PIVOTAL PHASE 2ROCKSTAR STUDY (KD025-213)

Poster Presenter: Corey Cutler, US

P205 09:50 - 09:50INTERLEUKIN-1 GENE SINGLE NUCLEOTIDEPOLYMORPHISMS: IMPACT ON OUTCOME AFTERALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN CHILDREN

Poster Presenter: Bernd Gruhn, DE

P206 09:50 - 09:50FECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENTOF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOSTDISEASE: A RETROSPECTIVE SURVEY OF THE TRANSPLANTCOMPLICATIONS WORKING PARTY OF EBMT

Poster Presenter: Grzegorz Basak, PL

P207 09:50 - 09:50PROSPECTIVE MULTICENTER NON INTERVENTIONALOBSERVATIONAL STUDY ON THE USE OF ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN (ATLG) IN UNRELATEDDONOR TRANSPLANTATION IN ADULTS WITHHAEMATOLOGICAL MALIGNANCIES (ATOS STUDY)

Poster Presenter: Jürgen Finke, DE

P208 09:50 - 09:50GRAFT VERSUS HOST DISEASE RELATED EOSINOPHILICFASCIITIS

Speaker: Lucía López-Corral, ES

P209 09:50 - 09:50METHOTREXATE OR MYCOPHENOLATE MOFETIL WITHCYCLOSPORINE AND ANTITHYMOCYTE GLOBULIN INMATCHED UNRELATED DONOR TRANSPLANTATION FORACUTE MYELOID LEUKEMIA WITH BUSULFAN-FLUDARABINEREDUCED-INTENSITY CONDITIONING: AN ALWP STUDY

Poster Presenter: Jacques-Emmanuel Galimard, FR

39 / 160


P210 09:50 - 09:50TRIPLE AGENTS GVHD PROPHYLAXIS FOR HLA MATCHEDDONOR: POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUSTHYMOGLOBULINES AND METHOTREXATE


P211 09:50 - 09:50TEN YEARS OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION: WHATHAVE WE LEARNED?

Poster Presenter: Anne B Verbeek, NL

P212 09:50 - 09:50RUXOLITINIB AS AN EFFECTIVE AND STEROID-SPARINGFIRST-LINE TREATMENT IN NEWLY-DIAGNOSED BOSPATIENTS AFTER HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Xiaoyu Zhang, CN

P213 09:50 - 09:50IMPACT OF TIMING OF CYCLOSPORINE-A ADMINISTRATION INGRAFT-VERSUS-HOST-DISEASE AND PATIENT OUTCOMES INHAPLOIDENTICAL HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Anne Banet, FR

P214 09:50 - 09:50EARLY RESULTS OF PHASE I STUDY OF SHR0302, ASELECTIVE JAK1 INHIBITOR, COMBINED WITH PREDNISONEIN FIRST-LINE TREATMENT OF CGVHD AFTER ALLO-HSCT

Poster Presenter: Xianmin Song, CN

P215 09:50 - 09:50ANTIBIOTIC USE AND ILEOCOLONIC IMMUNE CELLSCOMPOSITION IN PATIENTS RECEIVING FECAL MICROBIOTATRANSPLANTATION FOR REFRACTORY ACUTE INTESTINALGVHD

Poster Presenter: Peter Neumeister, AT

P216 09:50 - 09:50CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITHGRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWINGALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION(ALLO-HSCT) IN FRANCE

Poster Presenter: David Michonneau, FR

P217 09:50 - 09:50POST-TRANSPLANT-CYCLOPHOSPHAMIDE AND SHORT-TERMEVEROLIMUS AS GRAFT-VERSUS-HOST-PROPHYLAXIS INPATIENTS WITH HIGH-RISK LYMPHOMA AND MYELOMA –FINAL RESULTS OF THE PHASE II OCTET-EVER TRIAL.

Poster Presenter: Udo Holtick, DE

P218 09:50 - 09:50INCIDENCE AND RISK FACTORS FOR HYPONATREMIAINDUCED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE INALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Poster Presenter: Marta Gómez Hernando, ES

P219 09:50 - 09:50HOST VERSUS GRAFT HLA-DPB1 MISMATCHES PROMOTECLINICAL GRAFT VERSUS HOST DISEASE

Poster Presenter: Callum Wright, GB

40 / 160


P220 09:50 - 09:50VARIABLE IMPACT OF GRAFT CD3+ CELLS ON GRAFTVERSUS HOST DISEASE IN HEMATOPOIETIC STEM CELLTRANSPLANT RECIPIENTS: IS THE ROLE OF DONOR CD3+

CELLS OVERESTIMATED?

Poster Presenter: Zeynep Arzu Yegin, TR

P221 09:50 - 09:50THE USE OF VEDOLIZUMAB AS SECOND-LINE THERAPY FORSTEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS HOST DISEASE IN CHILDREN

Poster Presenter: Gleb Bronin, RU

P222 09:50 - 09:50PREDICTIVE VALUE OF ST2, REG3A AND MAGIC ALGORITHMIN SURVIVAL AND COMPLICATIONS RELATED TOHAPLOIDENTICAL TRANSPLANTATION WITH POST-TRASPLANT CYCLOPHOSPHAMIDE: SINGLE CENTEREXPERIENCE

Poster Presenter: Marta Fonseca Santos, ES

P223 09:50 - 09:50PANCREATIC ATROPHY AND RECOVERY AFTER ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION: PREDICTIVEFACTORS AND PROGNOSIS

Poster Presenter: Yosuke Okada, JP

P224 09:50 - 09:50SAFETY OF HOME CARE IN PATIENTS WITH PREVIOUSAUTOLOGOUS STEM CELL TRANSPLANT PURSUINGALLOGENEIC STEM CELL TRANSPLANTATION

Poster Presenter: Marta Garcia-Recio, ES

P225 09:50 - 09:50MODULAATE, A 2-PART, DOSE-FINDING, EFFICACY ANDSAFETY TRIAL WITH ALPHA-1 ANTITRYPSIN FORPREVENTION OF ACUTE GRAFT VS. HOST DISEASE: PART 1SAFETY AND PHARMACOKINETIC RESULTS

Poster Presenter: John Mallee, US

P226 09:50 - 09:50THE ATG DOSE AND TLC DON'T IMPACT ON THEDEVELOPMENT OF GVHD AND VIRAL REACTIVATIONS INPATIENTS UNDERGOING CD34+ SELECTED ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION.

Poster Presenter: Ángela Sánchez Cayuela, ES

P228 09:50 - 09:50HLA MOLECULAR MISMATCH AND ITS IMPLICATION IN THEALLORESPONSE AND OUTCOMES AFTER HEMATOPOIETICSTEM CELL TRANSPLANTATION

Poster Presenter: Marta Gómez Hernando, ES

P229 09:50 - 09:50POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT, ANDSHORT COURSE OF TACROLIMUS (CAST) FOR GRAFT-VERSUS-HOST DISEASE PREVENTION FOLLOWINGHAPLOIDENTICAL HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: A Samer Al-Homsi, US

P230 09:50 - 09:50POST TRANSPLANTATION CYCLOPHOSPHAMIDE BASEDGVHD PROPHYLAXIS ACROSS DONOR TYPES – A SINGLECENTER EXPERIENCE

41 / 160


Poster Presenter: Jan Vydra, CZ

P231 09:50 - 09:50HIGH EXPRESSION OF CD62L AS A SIGNATURE OF STEROID-REFRACTORY/RESISTANT GVHD REVEALED BY IMMUNEPROFILING AND MACHINE LEARNING

Poster Presenter: Yuntian Ding, DE

P232 09:50 - 09:50CYTOKINE TRAJECTORIES AND RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION

Poster Presenter: Lars Klingen Gjærde, DK

P233 09:50 - 09:50SIMILAR OUTCOMES OF PTCY AND ATG BASED GVHDPROPHYLAXIS IN HEMATOPOIETIC CELL TRANSPLANTATIONFROM MATCHED UNRELATED DONORS

Poster Presenter: Jan Vydra, CZ

P234 09:50 - 09:50ANTI-THYMOCYTE GLOBULIN (ATG) EQUALIZE THEINCIDENCE OF GRAFT-VERSUS-HOST DISEASE (GVHD)AMONG UNRELATED AND IDENTICAL SIBLING DONORTRANSPLANTATION.

Poster Presenter: Agustina Cia, AR

P235 09:50 - 09:50FIRST-LINE STEROID-FREE SYSTEMIC TREATMENT OF ACUTEAND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER NOVELPROPHYLAXIS REGIMENS IN ADULTS


P236 09:50 - 09:50PEMBROLIZUMAB AND ALLOTRANSPLANTS FOR RELAPSEDREFRACTORY CLASSICAL HODGKIN LYMPHOMA

Poster Presenter: Khalid Halahleh, JO

P237 09:50 - 09:50CLINICAL ANALYSIS OF AIR-LEAK SYNDROME FOLLOWINGALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PEDIATRIC PATIENTS

Poster Presenter: Wei Zhao, CN

P238 09:50 - 09:50COMPARISON OF REGULATORY T CELL SUBPOPULATIONBETWEEN ANTITHYMOCYTIC GLOBULIN AND POST-TRANSPLANTCYCLOPHOSPHAMIDE FOR PREVENTION OFTHE GVHD IN PATIENTS UNDERGOING ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Ik-Chan Holtick, KR

P239 09:50 - 09:50CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITHACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) FOLLOWINGALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION(ALLO-HSCT) IN GERMANY

Poster Presenter: Udo Holtick, DE

P240 09:50 - 09:50TREATMENT PATTERN CHARACTERIZATION AND OUTCOMESIN CHRONIC GRAFT VERSUS HOST DISEASE PATIENTSTREATED WITH EXTRACORPOREAL PHOTOPHERESIS INCLINICAL PRACTISE IN SWEDEN

Poster Presenter: Gösta Berlin, SE

42 / 160


P241 09:50 - 09:50LONG-TERM FOLLOW-UP OF RUXOLITINIB FOR THERAPY INCORTICOSTEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: A SINGLE CENTER-EXPERIENCE


P242 09:50 - 09:50PHARMACOKINETICS OF DIFFERENT TACROLIMUSFORMULATIONS FOR GVHD PREVENTION AFTERALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION.

Poster Presenter: Carmen Martínez, ES

P243 09:50 - 09:50PROPHYLACTIC DEFIBROTIDE IS EFFECTIVE FOR ACUTEGRAFT VERSUS HOST DISEASE AS WELL AS SINUSOIDALOBSTRUCTIVE SYNDROME

Poster Presenter: Selami Kocak Toprak, TR

P244 09:50 - 09:50PROSPECTIVE ANALYSIS OF THE INCIDENCE AND OUTCOMEOF LATE ACUTE AND CHRONIC GRAFT-VERSUS-HOSTDISEASE FROM MULTIPLE TRANSPLANT CENTERS

Poster Presenter: Ronja Langer, DE

P245 09:50 - 09:50MYELOID-DERIVED SUPPRESSOR CELLS PREDICTRESPONSE TO RUXOLITINIB-CORTICOSTEROIDS THERAPYFOR ACUTE GRAFT VERSUS HOST DISEASE

Poster Presenter: Bo Peng, CN

P247 09:50 - 09:50RELATIONSHIP WITHIN ANAEROBICIDAL ANTIBIOTICS,CLOSTRIDIUM DIFFICILE INFECTION AND THE DEVELOPMENTAND DEGREE OF DIGESTIVE GRAFT VERSUS HOST DISEASE.

Poster Presenter: Asuncion Borrero Borrego, ES

P248 09:50 - 09:50LOW-DOSE ANTITHYMOCYTE GLOBULIN PLUS LOW-DOSEPOSTTRANSPLANT CYCLOPHOSPHAMIDE COULD MITIGATETHE RISK OF GRAFT VERSUS HOST DISEASE AFTERHAPLOIDENTICAL TRANSPLANTATION FROMMATERNAL/COLLATERAL DONORS


P249 09:50 - 09:50GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS BASED ONEVEROLIMUS AND TACROLIMUS IN CHILDREN WITH ACUTELEUKEMIA AND JMML AFTER HAPLO-HSCT

Poster Presenter: Ludmila Zubarovskaya, RU

P250 09:50 - 09:50EXOCRINE PANCREATIC INSUFFICIENCY AS AN ATYPICALMANIFESTATION OF CHRONIC GRAFT VERSUS HOSTDISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION

Poster Presenter: Ana Puchol Crespo, ES

P251 09:50 - 09:50ASSESSMENT OF EFFICACY AND TOXICITY OFMETHOTREXATE IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

Poster Presenter: Isabella Gonçalves Ramos, BR

P252 09:50 - 09:50TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH

43 / 160


EXTRACORPOREAL PHOTOPHERESIS. EXPERIENCE IN ACENTER

Poster Presenter: Paula López de Ugarriza, ES

P253 09:50 - 09:50APOPTOSIS AND CYTOKINE SECRETION OF T CELLS DURINGECP TREATMENT FOR CGVHD USING THE AMICUS™ BLUE™ONLINE ECP SYSTEM

Poster Presenter: Yendry Ventura-Carmenate, AE

P254 09:50 - 09:50ROUTINE USE OF ANTI-THYMOCYTE GLOBULIN (ATG)RESULTS IN LOW INCIDENCE OF SEVERE GRAFT-VERSUS-HOST DISEASE: A SINGLE CENTER EXPERIENCE

Poster Presenter: Flóra Kovácsová, CZ

P255 09:50 - 09:50JAK 1/2 INHIBITOR (RUXOLITINIB) MIGHT HAVE A POSITIVEEFFECT ON MDSCS

Poster Presenter: Jingjing Yang, CN

P256 09:50 - 09:50LONG-TERM OUTCOME ?N PATIENTS RECEIVING ?MATINIBFOR STEROID-REFRACTORY CHRONIC GVHD/ FORREFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASEWITH FIBROTIC FEATURES: A SINGLE-CENTER EXPERIENCE


P258 09:50 - 09:50ESCALATING COMBINATORY FIRST-LINE TREATMENT FORSEVERE ACUTE GVHD AFTER HEMATOPOIETIC STEM CELLTRANSPLANT

Poster Presenter: Francesco Saraceni, IT

P259 09:50 - 09:50RETROSPECTIVE SINGLE CENTER ANALYSIS OF ALPHA 1ANTITRYPSIN FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE GUT AFTER MULTIPLE LINESOF PRETREATMENT

Poster Presenter: Katharina Nickel, DE

P260 09:50 - 09:50MESENCHYMAL STROMAL CELLS IN PATIENTS WITH III-IVGRADE STEROID-REFRACTORY ACUTE GRAFT VERSUS HOSTDISEASE: 8 YEARS OF EXPERIENCE

Poster Presenter: Adomas Bukauskas, LT

P261 09:50 - 09:50A SINGLE CENTRE EXPERIENCE OF RUXOLITINIB FORTREATMENT OF STEROID REFRACTORY CHRONIC GRAFTVERSUS HOST DISEASE

Poster Presenter: Zoe Kirkham, GB

P262 09:50 - 09:50A PROSPECTIVE ANALYSIS OF THE CHANGES IN THE IMMUNEPROFILE OF SR-CGVHD PATIENTS UNDERGOING ECPTREATMENT WITH THE AMICUS BLUE™ ONLINE ECP SYSTEM


P263 09:50 - 09:50ASSOCIATION BETWEEN VITAMIN D AND GVHD BIOMARKERSWITH RESPONSE TO IMMUNOSUPPRESSION AND SURVIVALIN ACUTE GVHD: AN EXPLORATORY STUDY

Poster Presenter: Jose Ros-Soto, GB

44 / 160


P264 09:50 - 09:50ANTI-THYMOCYTE GLOBULIN TO PREVENT GRAFT VERSUSHOST DISEASE AFTER HLA MATCHED RELATED ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION IN ACUTELEUKEMIA PATIENTS

Poster Presenter: Nabil YAFOUR, DZ

P265 09:50 - 09:50SAFETY AND EFFECTIVENESS OF THE AMICUS BLUE™ONLINE ECP SYSTEM IN SR-CGVHD PATIENTS DURING A6-MONTH TREATMENT REGIMEN


P266 09:50 - 09:50A RANDOMIZED, OPEN LABEL, MULTICENTRE, PHASE 3 TRIALOF FIRST LINE TREATMENT WITH MSC VERSUS BAT INPATIENTS WITH STEROID REFRACTORY ACUTE GVHD (IDUNNTRIAL)

Poster Presenter: Robert Zeiser, DE

P267 09:50 - 09:50EXTRACORPOREAL PHOTOPHERESIS- A CASE BASED NEWEXPERIENCE IN TREATING CHRONIC GVHD

Poster Presenter: Lazar Chadievski, MK


Infectious Complications

P268 09:50 - 09:50RECONSTITUTION OF BACTEROIDES FRAGILIS AND FAECALIBACTERIUM PRAUSNITZII ASSOCIATED WITHCLINICAL RESPONSE IN ACUTE INTESTINAL GVHD


P269 09:50 - 09:50THE MANAGEMENT OF CYTOMEGALOVIRUS INFECTIONAMONG EBMT CENTERS: A SURVEY FROM INFECTIOUSDISEASES WORKING PARTY OF EBMT

Poster Presenter: Simone Cesaro, IT

P270 09:50 - 09:50ENDOTHELIAL COMPLICATIONS AFTER ALLOGENEIC STEMCELL TRANSPLANTATION (HSCT) IN PATIENTS WITHRESOLVED COVID 19 DISEASE

Poster Presenter: Christian Niederwieser, DE

P272 09:50 - 09:50SAFETY AND IMMUNOGENICITY OF A MENINGOCOCCALRECOMBINANT VACCINE IN ALLOGENEIC HEMATOPOIETICCELL TRANSPLANTATION: A PROSPECTIVE STUDY WITH A 12MONTHS FOLLOW-UP

Poster Presenter: Christine Robin, FR

P273 09:50 - 09:50IMPACT OF FLUOROQUINOLONE PROPHYLAXIS ONBLOODSTREAM INFECTION INCIDENCE IN THE FIRST 30 DAYSAFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Poster Presenter: Chiara Maria Dellacasa, IT

P274 09:50 - 09:50BK POLYOMAVIRUS-LOADS REFLECT NAKED DNAFRAGMENTS AFFECTING QUANTIFICATION ANDIDENTIFICATION OF VARIANT IMMUNODOMINANT LTAG ANDVP1 EPITOPES IN HCT PATIENTS WITH BKPYV-ASSOCIATED

45 / 160


HEMORRHAGIC CYSTITIS (BKPYV-HC)

Poster Presenter: Karoline Leuzinger, CH

P275 09:50 - 09:50ANTI-SARS-COV-2 MONOCLONAL ANTIBODY THERAPY ISEFFECTIVE AT PREVENTING SEVERE DISEASE IN STEM CELLTRANSPLANT AND CELLULAR IMMUNOTHERAPY RECIPIENTSDIAGNOSED WITH SARS-COV-2

Poster Presenter: Eloho Ajayi, US

P276 09:50 - 09:50ANTIBODY RESPONSE AFTER VACCINATION WITH BNT162B2MRNA VACCINE AGAINST SARS-COV-2 IN PATIENTS WITHHEMATOLOGIC MALIGNANCIES POST HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A SINGLE-CENTER PROSPECTIVESTUDY

Poster Presenter: John V. Asimakopoulos, GR

P277 09:50 - 09:50INCIDENCES OF INFECTIONS AND VIRAL REACTIVATIONSMORE FREQUENT WITH ATG THAN WITH POST-TRANSPLANTION CYCLOPHOSPHAMIDE AS GVHDPROPHYLAXIS IN MATCHED UNRELATED DONORHEMATOPOIETIC STEM CELL TRANSPLANTATIONS

Poster Presenter: Mesire Aydin, NL

P278 09:50 - 09:50CLINICAL COURSE AND OUTCOMES OF COVID-19 INPEDIATRIC PATIENTS AFTER CHEMOTHERAPY,IMMUNOSUPPRESSIVE THERAPY AND HEMATOPOIETIC CELLTRANSPLANTATION

Poster Presenter: Tatiana Bykova, RU

P279 09:50 - 09:50EFFICACY AND SAFETY OF MRNA SARS-COV-2 VACCINATIONIN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)RECIPIENTS: SINGLE CENTRE EXPERIENCE.

Poster Presenter: Maria Huguet, ES

P280 09:50 - 09:50THE EFFECT OF HLA MATCHING ON EARLY POST-TRANSPLANT INFECTIONS IN PATIENTS RECEIVING TRIPLEPTCY-BASED GVHD PROPHYLAXIS

Poster Presenter: John Marra, IT

P281 09:50 - 09:50IMPACT OF LEVOFLOXACIN PROPHYLAXIS WITHDRAWAL ONPRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTERALLOGENEIC STEM CELL TRANSPLANT

Poster Presenter: Daniela Clerici, IT

P282 09:50 - 09:50OUTCOME OF POST-VACCINATION COVID-19 INHEMATOPOIETIC STEM CELL TRANSPLANT AND CAR T CELLTREATMENT RECIPIENTS; RESULTS FROM AN IDWPPROSPECTIVE SURVEY.

Poster Presenter: Per Ljungman, SE

P283 09:50 - 09:50INCREASED RISK OF BLOODSTREAM INFECTIONS IN ADULTSUNDERGOING ALLOGENENEIC HEMATOPOIETIC CELLTRANSPLANTATION COMBINED WITH POST-TRANSPLANTCYCLOPHOSPHAMIDE

Poster Presenter: Maria Queralt Salas, ES

46 / 160


P284 09:50 - 09:50THE TIMING OF CLINICALLY SIGNIFICANT CMV INFECTIONFOLLOWING ALLOGENEIC HAEMATOPOIETIC CELLTRANSPLANTATION (ALLOHCT) IS ASSOCIATED WITH POORSURVIVAL; A NATIONAL MULTI-CENTRE COHORT STUDY

Poster Presenter: Michelle Yong, AU

P285 09:50 - 09:50HUMORAL RESPONSE TO ANTI-SARS-COV2 VACCINES INRECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTS INCLUDING CYTOMETRIC ANALYSIS OFPERIPHERAL BLOOD LYMPHOCYTES

Poster Presenter: Agnieszka Tomaszewska, PL

P286 09:50 - 09:50THE VALUE OF BASELINE CHEST CT SCAN FOR THEDIAGNOSIS OF IPA IN PATIENTS WITH AML TREATED WITHINTENSIVE CHEMOTHERAPY: A RETROSPECTIVE SINGLE-CENTRE COHORT STUDY

Poster Presenter: Alexander Schauwvlieghe, BE

P287 09:50 - 09:50EFFECTIVE RAPID DIAGNOSIS OF BACTERIAL BLOODSTREAMINFECTIONS BY T2 MAGNETIC RESONANCE TECHNOLOGY INPEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Federica Galaverna, IT

P288 09:50 - 09:50DEVELOPMENT OF A RISK PREDICTION MODEL OFSUBSEQUENT BLOODSTREAM INFECTION AFTERCARBAPENEM-RESISTANT ENTEROBACTERIACEAEISOLATED FROM PERIANAL SWABS SAMPLES IN PATIENTSWITH HEMATOLOGICAL DISEASES


P289 09:50 - 09:50PHASE 3 TRIAL OF TRANSPLANT RECIPIENTS WITHREFRACTORY CYTOMEGALOVIRUS WITH/WITHOUTRESISTANCE RECEIVING MARIBAVIR OR INVESTIGATOR-ASSIGNED THERAPIES: SUBGROUP ANALYSES OF EFFICACYAND SAFETY BY RENAL IMPAIRMENT

Poster Presenter: Sanjeet Dadwall, US

P290 09:50 - 09:50PERSISTENCE OF THE IMMUNE RESPONSE AFTERVACCINATION AGAINST SARS-COV-2 IN PATIENTS WITHONCOHEMATOLOGICAL DISEASES WHO UNDERWENTAUTOLOGOUS OR ALLOGENIC STEM CELLTRANSPLANTATION

Poster Presenter: Lucía Pérez-Lamas, ES

P291 09:50 - 09:50ADENOVIRUS INFECTION IN GI BIOPSIES OFIMMUNOCOMPROMISED PATIENTS WHO UNDERWENTALLOGENEIC STEM CELL TRANSPLANTATION

Poster Presenter: Batia Avni, IL

P292 09:50 - 09:50THE IMPACT OF INTESTINAL MICROBIOTA IN ATG-BASEDMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC-CELLTRANSPLANTATION

Poster Presenter: Zhenyang Gu, CN

P293 09:50 - 09:50CLINICAL OUTCOMES OF PATIENTS WITH EPSTEIN–BARR

47 / 160


VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVEDISEASE FOLLOWING HEMATOPOIETIC STEM CELLTRANSPLANTATION WHO FAIL RITUXIMAB: AMULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

Poster Presenter: Jaime Sanz Caballer, ES

P294 09:50 - 09:50IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANTGRAM-NEGATIVE BACTERIA ON BLOODSTREAM INFECTIONSIN EARLY PHASE OF HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Yuliya Rogacheva, RU

P295 09:50 - 09:50REAL-WORLD EXPERIENCE WITH ISAVUCONAZOLE INALLOGENEIC STEM CELL TRANSPLANTATION

Poster Presenter: Gillen Oarbeascoa, ES

P296 09:50 - 09:50IMPACT OF SOCIETAL AND HEALTHCARE INFECTIONCONTROL MEASURES ON INCIDENCE OF NON-SARS-2-COVRESPIRATORY VIRAL INFECTIONS IN HSCT IN-PATIENTADMISSIONS; A SINGLE UK CENTRE EXPERIENCE

Poster Presenter: Jack Murrell, GB

P297 09:50 - 09:50INFECTIVE COMPLICATIONS FOLLOWING ALLOGENEIC STEMCELL TRANSPLANTATION FOR HEMATOLOGICALMALIGNANCIES: RESULTS OF AN INNOVATIVE PROGRAMFOR SURVEILLANCE, PROPHYLAXIS AND TREATMENT(BATMO PROTOCOL)

Poster Presenter: Michele Malagola, IT

P298 09:50 - 09:50BEYOND THE RESPIRATORY TRACT – THE IMPACT OF ARESPIRATORY VIRAL OUTBREAK IN A HSCT UNIT IN INDIA

Poster Presenter: Revathi Raj, IN

P299 09:50 - 09:50THE HUMORAL RESPONSE TO SARS-COV2 VACCINATION ISINFLUENCED BY VACCINATION SCHEME,IMMUNOSUPPRESSION, LYMPHOCYTE COUNTS AND TIMEAFTER ALLOHCT

Poster Presenter: Claudia Wehr, DE

P300 09:50 - 09:50LETERMOVIR PROPHYLAXIS REDUCES PEAK CMV TITRESAND NEED FOR ADDITIONAL ANTIVIRAL TREATMENT INALLOGENEIC HAEMATOPOIETIC STEM CELLTRANSPLANTATION.

Poster Presenter: Michael Buckton, GB

P301 09:50 - 09:50INCIDENCE AND OUTCOME OF CMV REACTIVATION IN NON-MALIGNANT PEDIATRIC HSCT RECIPIENTS

Poster Presenter: Zofia Szmit, PL

P302 09:50 - 09:50LOW RATE OF DOCUMENTED INFECTIONS AS THE CAUSE OFENTEROCOLITIS IN ALLOGENEIC STEM CELL TRANSPLANTRECIPIENTS: PROSPECTIVE STUDY BY THE GETH.


P303 09:50 - 09:50OPEN-LABEL RANDOMIZED CONTROLLED STUDY OF

48 / 160


CIPROFLOXACIN VERSUS RIFAXIMIN AS NEUTROPENIAPROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION: SURVIVAL BENEFIT FORCIPROFLOXACIN


P304 09:50 - 09:50CHANGES IN RESPIRATORY VIRAL INFECTIONS LANDSCAPEAMONG ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTSDURING SARS-COV 2 PANDEMIA: SINGLE CENTRE REAL LIFEEXPERIENCE


P305 09:50 - 09:50FECAL COLONIZATION IN PATIENTS FOLLOWINGHEMATOPOIETIC STEM-CELL TRANSPLANTATION BYMULTIDRUG-RESISTANT BACTERIA: A SINGLE CENTERSTUDY ON MICROBIAL SPECTRUM AND RESISTANCEPROFILE

Poster Presenter: Denis Niyazi, BG

P306 09:50 - 09:50PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTERFIRST AND SECOND ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION: INCIDENCE, ETIOLOGY, RISK FACTORSAND OUTCOMES

Poster Presenter: Mobil Akhmedov, RU

P307 09:50 - 09:50THE PATIENT’S CMV SEROLOGICAL STATUS IS ANINDEPENDENT FACTOR FOR CMV INFECTION (CMVI) IN THEPOST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHDPROPHYLAXIS ERA

Poster Presenter: Beatriz Herruzo, ES

P308 09:50 - 09:50THIRD-DOSE BNT162B2 VACCINE IS HIGHLY EFFICIENT ATINCREASING ANTI-RBD SARS-COV-2 IGG TITERS IN ALLO-HCTRECIPIENTS


P309 09:50 - 09:50POSOLEUCEL FOR THE PREVENTION OF CLINICALLYSIGNIFICANT INFECTIONS IN HIGH-RISK ALLOGENEICHEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: DESIGNOF A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Poster Presenter: Simona Sica, IT

P310 09:50 - 09:50BLOODSTREAM INFECTIONS IN HEMATOPOIETIC STEM CELLTRANSPLANT RECIPIENTS COLONIZED BY MULTIDRUG-RESISTANT BACTERIA

Poster Presenter: Ana Pilar Gonzalez-Rodriguez, ES

P311 09:50 - 09:50COVID-19 IN ALLOGENEIC STEM CELL TRANSPLANTPATIENTS: A LONGITUDINAL STUDY TROUGH EIGHTEENMONTHS OF PANDEMIC

Poster Presenter: Monica Cabrero, ES

P312 09:50 - 09:50ANALYSIS OF THE EXPRESSION OF CYTOMEGALOVIRUSDRUG RESISTANCE GENE MUTATIONS IN PATIENTS HAVING

49 / 160


CYTOMEGALOVIRUS INFECTION WITH POOR EFFICACYAFTER TRANSPLANTATION

Poster Presenter: Donglin Yang, CN

P313 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PATIENTS WITH PRIOR INFECTIONCAUSED BY THE SARS-COV-2 (COVID-19)

Poster Presenter: Aleksandr Siniaev, RU

P314 09:50 - 09:50RITUXIMAB THERAPY AFTER PEDIATRIC HEMATOPOETICSTEM CELL TRANSPLANTATION CAN CAUSE PROLONGED BCELL DAMAGE AND INCREASES THE RISK FOR INFECTIONS

Poster Presenter: Michael Launspach, DE

P315 09:50 - 09:50CIDOFOVIR TREATMENT FOR BK-ASSOCIATEDHEMORRHAGIC CYSTITIS AFTER ALLOGENIC STEAM CELLTRANSPLANTATION WITH POST-TRANSPLANTCYCLOPHOSPHAMIDE: A RETROSPECTIVE ANALYSIS AT ASINGLE INSTITUTION

Poster Presenter: Mario Andres Sanchez-Salinas, ES

P316 09:50 - 09:50BLOODSTREAM INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN HEMATOLOGICALPATIENTS: A RETROSPECTIVE SINGLE-CENTER STUDY

Poster Presenter: Lining Zhang, CN

P317 09:50 - 09:50THE ANTIBODY RESPONSE TO BNT162B2 OR MRNA-1273VACCINES IN ALLOTRANSPLANT RECIPIENTS DEPENDS ONTHE EXISTING RESPONSE TO ENDEMIC HUMANCORONAVIRUSES AND PREVIOUS ATG THERAPY

Poster Presenter: Tor Henrik Anderson Tvedt, NO

P318 09:50 - 09:50ANTIBODY RESPONSES TO SARS-COV-2VACCINATION/INFECTION IN HEMATOLOGICALMALIGNANCES AND ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION PATIENTS – A SINGLE-CENTEREXPERIENCE

Poster Presenter: Jaroslaw Dybko, PL

P319 09:50 - 09:50EPIDEMIOLOGY OF INVASIVE ASPERGILLOSIS CAUSED BY ASPERGILLUS NON-FUMIGATUS VS ASPERGILLUSFUMIGATUS IN ADULTS AFTER ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION

Poster Presenter: Yuliya Rogacheva, RU

P320 09:50 - 09:50PREVENTION OF CPE BLOODSTREAM INFECTION AND DEATHIN A PAEDIATRIC ALLOGENIC HSCT POPULATION : THEMANCHESTER STORY

Poster Presenter: Annalie Shears, GB

P321 09:50 - 09:50PROSPECTIVE TRIAL ON UROLOGICAL COMPLICATIONS INLONG-TERM SURVIVORS OF ALLOGENEIC STEM CELLTRANSPLANTATION (ASCT) – ANALYSIS FOCUSED ON VIRALUROLOGICAL INFECTIONS

Poster Presenter: Thomas Neumann, DE

50 / 160


P322 09:50 - 09:50CYTOMEGALOVIRUS REACTIVATION UNDER PRE-EMPTIVETHERAPY DURING ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANT: THE PATTERN, SURVIVAL, AND RISK FACTORSIN SOUTH KOREA

Poster Presenter: Ka-Won Kang, KR

P323 09:50 - 09:50CMV REACTIVATION AFTER ALLOHCT IN TWO GROUPS OFRECIPIENTS: FROM HAPLOIDENTICAL AND MISMATCHEDUNRELATED DONOR – A PRELIMINARY ANALYSIS ON BEHALFOF POLISH ADULT LEUKEMIA GROUP

Poster Presenter: Jaroslaw Dybko, PL

P324 09:50 - 09:50ANTIBODY RESPONSES AND SAFETY OF THECOMMERCIALLY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLDDATA FROM A SINGLE CENTER

Poster Presenter: Panayotis Kaloyannidis, SA

P325 09:50 - 09:50LETERMOVIR IS EFFECTIVE AS PRIMARY PROPHYLAXISAGAINST CYTOMEGALOVIRUS IN HEMATOPOIETIC STEMCELL TRANSPLANT RECIPIENTS, BUT LATE INFECTIONSOCCUR FOLLOWING DISCONTINUATION WHEN CELLULARIMMUNITY IS IMPAIRED

Poster Presenter: Ifigeneia Tzannou, GR

P326 09:50 - 09:50SARS COV-2 INFECTION AND COVID-19 IN HEALTH CAREWORKERS FROM A HEMATOPOIETIC STEM CELLTRANSPLANT (HSCT) UNIT BEFORE AND AFTERVACCINATION: A PROSPECTIVE COHORT STUDY

Poster Presenter: Clarisse Machado, BR

P328 09:50 - 09:50OFF-LABEL USE OF LETERMOVIR IN A PEDIATRIC COHORTOF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION


P329 09:50 - 09:50MONITORING AND MANAGEMENT OF CYTOMEGALOVIRUSREACTIVATION IN AUTOLOGOUS STEM CELL TRANSPLANTRECIPIENTS: RESULTS OF MORE THAN A DECADE OFEXPERIENCE

Poster Presenter: Vildan Özkocaman, TR

P330 09:50 - 09:50COVID-19 IN HEMATOPOIETIC STEM-CELLTRANSPLANTATION RECIPIENTS: SINGLE CENTEREXPERIENCE

Poster Presenter: Zeynep Tugba Guven, TR

P331 09:50 - 09:50INFECTIOUS COMPLICATIONS AFTER HEMATOPOIETICALLOGENEIC TRANSPLANTATION IN THE ERA OF FLT3INHIBITORS

Poster Presenter: Ilaria Cutini, IT

P332 09:50 - 09:50QTC PROLONGATION DURING LEVOFLOXACIN AND TRIAZOLECOMBINATION CHEMOPROPHYLAXIS: PREVALENCE ANDPREDISPOSING RISK FACTORS IN A COHORT OF

51 / 160


HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS


P333 09:50 - 09:50ANTIBODY RESPONSES TO SARS-COV-2 VACCINATION INALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTRECIPIENTS

Poster Presenter: Maria Liga, GR

P335 09:50 - 09:50A STUDY FOR THE RELATIONSHIP BETWEEN FEVER INNEUTROPENIC PATIENTS AND BACTERIA-DERIVEDMICROVESICLES.

Poster Presenter: Sungnam Lim, KR

P336 09:50 - 09:50SAFETY AND IMMUNOGENICITY OF BNT162B2 MRNACOVID-19 VACCINE IN JAPANESE PATIENTS AFTERALLOGENEIC STEM CELL TRANSPLANTATION.

Poster Presenter: Marika Watanabe, JP

P337 09:50 - 09:50EFFICACY OF CYTOMEGALOVIRUS SPECIFICIMMUNOGLOBULINS (CMV-IG) IN REDUCING CMVREACTIVATION IN PAEDIATRIC HAEMATOPOIETIC STEM CELLTRANSPLANT

Poster Presenter: Claire Geurten, BE

P338 09:50 - 09:50OUTCOMES OF COVID-19 IN PATIENTS AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION ORCELLULAR THERAPY: A SINGLE CENTER EXPERIENCE

Poster Presenter: Flóra Kovácsová, CZ

P339 09:50 - 09:50POSOLEUCEL FOR ADENOVIRUS INFECTION IN PEDIATRICAND ADULT ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANT RECIPIENTS: DESIGN OF A PHASE 3,RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLEDTRIAL

Poster Presenter: Kanchan Rao, GB

P340 09:50 - 09:50OVERVIEW OF CYTOMEGALOVIRUS VIREMIA IN ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS:EXPERIENCE OF A POPULATION WITH HIGHSEROPREVALENCE

Poster Presenter: Ana Karen Toledo Riquelme, MX

P342 09:50 - 09:50CYTOMEGALOVIRUS VIREMIA RATE AND HEALTHCAREBURDEN OF DISEASE IN ADULT ALLOGENIC HEMATOPOIETICSTEM CELL TRANSPLANTATION PATIENTS

Poster Presenter: Riku Korhonen, FI

P343 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR HUMAN T-LYMPHOTROPIC VIRUSTYPE 1 (HTLV-1) LEUKEMIA-LYMPHOMA: TWO CASESREPORT.

Poster Presenter: Sofia Diaz-Lopez, ES

P344 09:50 - 09:50HIGH DOSE CIDOFOVIR, CIPRO, AND IVIG COMBINATIONTREATMENT FOR BK VIRUS HEMORRHAGIC CYSTITIS

52 / 160


Poster Presenter: Sami Brake, US

P345 09:50 - 09:50ACTIVE SARS-COV-2 INFECTION ON THE DAY BEFOREAUTOLOGOUS STEM CELL TRANSPLANT IN A PATIENT WITHMULTIPLE MYELOMA

Poster Presenter: Marta Henriques, PT

P346 09:50 - 09:50COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASESAFTER SCT : SINGLE CENTER OBSERVATION FROMBULGARIA , SOFIA, 859 BMT UNIT

Poster Presenter: Penka Ganeva, BG

P347 09:50 - 09:50MYCOBACTERIUM ABSCESSUS CATHETER RELATEDINFECTION BLOODSTREAM IN AUTOLOGOUSHEMATOPOEITIC STEM CELL TRANSPLANTATION

Poster Presenter: Miriam López, ES

P348 09:50 - 09:50HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AFTERALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION: EASY DIAGNOSIS AND MANAGEMENT?A CASE REPORT



Conditioning Regimens

P409 09:50 - 09:50AUTOLOGOUS STEM CELL TRANSPLANTATION IN AL-AMYLOIDOSIS FOLLOWING YTTRIUM-90 LABELLED ANTI-CD66 (BESILESOMAB) MONOCLONAL ANTIBODY AS SOLECONDITIONING IS ASSOCIATED WITH LOW TOXICITY ANDDEMONSTRABLE DISEASE RESPONSES

Poster Presenter: Kim Orchard, GB

P410 09:50 - 09:50IS 8- INSTEAD OF 12-GRAY TOTAL BODY IRRADIATIONSUFFICIENT FOR ACUTE LYMPHOBLASTIC LEUKEMIAPATIENTS TRANSPLANTED IN FIRST COMPLETE REMISSION?

Poster Presenter: Alexandros Spyridonidis, GR

P412 09:50 - 09:50THIOTEPA-BASED REDUCED-INTENSITY CONDITIONING AREA VALID ALTERNATIVE TO TOTAL-BODY IRRADIATION-BASEDREGIMENS IN PATIENTS WITH ACUTE LYMPHOBLASTICLEUKEMIA: A STUDY OF THE ALWP OF THE EBMT

Poster Presenter: Annalisa Ruggeri, IT

P413 09:50 - 09:50EXCELLENT OUTCOME WITH FB4 REGIMEN IN PATIENTS WITHMYELOID MALIGNANCIES OLDER THAN 55 AND WITH HCT-CISCORE

Poster Presenter: Daniele Avenoso, GB

P414 09:50 - 09:50SHOULD ATG BE ADDED IN PTCY-BASED HLA-MATCHEDUNRELATED PERIPHERAL-BLOOD STEM CELLTRANSPLANTATION? A STUDY ON BEHALF OF THE ACUTELEUKEMIA WORKING PARTY OF THE EBMT

Poster Presenter: Alexandros Spyridonidis, GR

53 / 160


P415 09:50 - 09:50COMPARISON OF FLUDARABINE/MELPHALAN(FLUMEL) WITHFLUDARABINE/MELPHALAN/BCNU OR THIOTEPA(FBM/FTM) INPATIENTS WITH AML UNDERGOING ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION – A REGISTRYSTUDY ON BEHALF OF THE EBMT ALWP

Poster Presenter: Jesus Duque-Afonso, DE

P416 09:50 - 09:50FLUDARABINE AND MELPHALAN CONDITIONING WITHTHIOTEPA VERSUS TOTAL BODY IRRADIATION FORHAPLOIDENTICAL HEMATOPOIETIC STEM CELLTRANSPLANTATION (HAPLO-SCT)

Poster Presenter: Supawee Saengboon, US

P417 09:50 - 09:50EFFICACY OF TREOSULFAN IN COMBINATION WITHFLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEICTRANSPLANTATION AS COMPARED WITH A MYELOABLATIVECONDITIONING USING BUSULFAN AND FLUDARABINE.

Poster Presenter: José Álvaro Calvo Sánchez, ES

P418 09:50 - 09:50HIGH DOSE INTRAVENOUS BUSULFAN INCREASES RISK FORHEMORRHAGIC CYSTITIS IN ALLOGENIC HEMATOPOIETICSTEM CELL TRANSPLANT PATIENTS

Poster Presenter: Abel Santos Carreira, CA

P420 09:50 - 09:50AUC TARGETED BUSULFAN ADMINISTRATION CANOVERCOME THE NEGATIVE IMPACT OF PRE-TRANSPLANTMRD POSITIVITY IN INTERMEDIATE RISK AML PATIENTS.

P421 09:50 - 09:50OPTIMISING IN VIVO ALEMTUZUMAB LEVELS IN MATCHEDUNRELATED HAEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Maymoon Madkhali, GB

P423 09:50 - 09:50TOTAL BODY IRRADIATION-BASED CONDITIONING VERSUSCHEMOTHERAPY BEFORE ALLOGENEIC STEM CELLTRANSPLANTATION FOR ADULTS WITH ACUTELYMPHOBLASTIC LEUKEMIA

Poster Presenter: Nour Ben Abdeljelil, TN

P424 09:50 - 09:50COMPARISON OF PORCINE ALG AND RABBIT ATG ONOUTCOMES OF HLA-HAPLOIDENTICAL HEMATOPOIETIC STEMCELL TRANSPLANTATION FOR PATIENTS WITH ACQUIREDAPLASTIC ANEMIA

Poster Presenter: Juan Chen, CN

P425 09:50 - 09:50LOW DOSE ANTI T-LYMPHOCYTE GLOBULIN IN HIGH T-CELLCONTENT PBSC GRAFT: IMPROVING TRANSPLANTOUTCOMES IN POST-TRANSPLANT CYCLOPHOSPHAMIDEPLATFORM

Poster Presenter: Raffaella Greco, IT

P426 09:50 - 09:50FULL DONOR CHIMERISM IN PATIENTS UNDERGOING HSCTWITH A REDUCED CONDITIONING REGIMEN AFTER ONE ORTWO ALKYLATING AGENTS: A SINGLE CENTER EXPERIENCE

Poster Presenter: Carolina Arevalo, ES

54 / 160


P427 09:50 - 09:50OVERALL SURVIVAL IN ADVANCED STAGE MANTLE CELLLYMPHOMA AFTER EARLY AUTOLOGOUS STEM CELLTRANSPLANTATION WITH CISPLATIN, ETOPOSIDE,CYTARABINE AND MELPHALAN (PEAM) AS A CONDITIONINGREGIMEN.

Poster Presenter: Daniel Franco-Saenz, MX

P428 09:50 - 09:50HIGH-INTENSITY TREOSULFAN-ETOPOSIDE-FLUDARABINECONDITIONING CAN BE SAFELY USED IN COMBINATION WITHMAJOR GVHD PREVENTION PLATFORMS IN CHILDREN WITHLEUKEMIA

Poster Presenter: Evgeniy Zhuravel, RU

P430 09:50 - 09:50CHEMOKINE RECEPTOR 4 DIRECTED ENDORADIOTHERAPYWITH [177LU]-PENTIXATHER IN ADDITION TO TOTAL BODYIRRADIATION AS CONDITIONING REGIMEN FORRELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA - ARETROSPECTIVE ANALYSIS

Poster Presenter: Krischan Braitsch, DE

P431 09:50 - 09:50POTENTIAL PHARMACOKINETICS INTERACTIONS BETWEENBUSULFAN AND IRON CHELATION IN CHILDREN GIVEN HSCTFOR NON-MALIGNANT DISEASES

Poster Presenter: Francesca Compagno, IT

P432 09:50 - 09:50GVHD PROPHYLAXIS WITH POST TRANSPLANTCYCLOPHOSPHAMIDE AFTER ALLO-HSCT WITH MISMATCHEDUNRELATED AND HAPLOIDENTICAL DONORS: RISK OF CMVREACTIVATION AT LETERMOVIR DISCONTINUATION

Poster Presenter: Maria Caterina Mico', IT

P434 09:50 - 09:50DECREASED GLOMERULAR FILTRATION RATE IS RELATEDTO INCREASED MUCOSITIS IN AUTOLOGOUS STEM CELLTRANSPLANTATION CONDITIONED WITH HIGH DOSEMELPHALAN

Poster Presenter: Javier Arzuaga-Méndez, ES

P435 09:50 - 09:50AUTOLOGOUS STEM CELL TRANSPLANTATION USINGCYCLOPHOSPHAMIDE AND TOTAL BODY IRRADIATION FOR T-CELL LYMPHOMAS

Poster Presenter: U?ur ?ahin, TR

P436 09:50 - 09:50COMPARISON OF GIT TOXICITY OF THE BEAM VS TEAMCONDITIONING BEFORE AUTOLOGOUS TRANSPLANTATIONIN PATIENTS WITH LYMPHOMAS

Poster Presenter: Barbara B?ízová, CZ

P437 09:50 - 09:50CLINICAL OUTCOMES OF REDUCED INTENSITY TBFCONDITIONING REGIMEN IN ADULT PATIENTS UNDERGOINGALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOIDMALIGNANCIES

Poster Presenter: Marta Peña Domingo, ES

P438 09:50 - 09:50UPDATE ON A PILOT STUDY: FLUMELTBI PERIPHERALBLOOD HLA-HAPLOIDENTICAL STEM CELL

55 / 160


TRANSPLANTATION WITH POST-TRANSPLANTCYCLOPHOSPHAMIDE AND BORTEZOMIB (CY2BOR3)

Poster Presenter: Sowjanya Vuyyala, US

P439 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FORHODGKIN LYMPHOMA POST ANTI-PD1 INHIBITORS:INCORPORATION OF POST-TRANSPLANTCYCLOPHOSPHAMIDE IN THE CONDITIONING REGIMEN


P440 09:50 - 09:50TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HSCTIN CHILDREN: A CASE SERIES OF SINGLE CENTEREXPERIENCE

Poster Presenter: Ali Bülent Antmen, TR

P441 09:50 - 09:50CLOFARABINE FOLLOWED BY REDUCED INTENSITYCONDITIONING AS A SEQUENTIAL CONCEPT PRIOR TOALLOGENEIC HSCT IN THREE PATIENTS WITH ADVANCEDSTAGED CUTANEOUS T CELL LYMPHOMA

Poster Presenter: Elena Stauffer, DE

P442 09:50 - 09:50TEAM VERSUS BEAM CONDITIONING REGIMEN FORAUTOLOGOUS STEM CELL TRANSPLANTATION INMALIGNANT LYMPHOMAS. RETROSPECTIVE COMPARISON OFTOXICITY

Poster Presenter: Jana Stevkova, CZ

P443 09:50 - 09:50HAPLO-IDENTICAL HEMATOPOIETIC STEM CELLTRANSPLANTATION USING A COMBINATION OF G-CSFMOBILIZED BONE MARROW AND PERIPHERAL BLOOD CELLSIN HIGH-RISK HEMATOLOGICAL MALIGNANCIES


P444 09:50 - 09:50SINGLE CENTRE EXPERIENCE OF EFFICACY AND TOXICITYOF REDUCED-DOSE MELPHALAN CONDITIONING (140 MG/M2OR 110 MG/M2) IN AUTOLOGOUS STEM CELLTRANSPLANTATION FOR MULTIPLE MYELOMA.

Poster Presenter: Dario Melotti, GB

P445 09:50 - 09:50LONG-TERM FOLLOW-UP OF AUTO-HCT WITH TBI-BASEDCONDITIONING REGIMEN IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS: A SINGLE-CENTER ANALYSIS

Poster Presenter: Tomasz Czerw, PL

P446 09:50 - 09:50REDUCED INTENSITY CONDITIONING REGIMEN WITHTREOSULFAN FOR SECOND ALLOGENEIC STEM CELLTRANSPLANTATION IN PATIENTS WITH ACUTE MYELOIDLEUKEMIA OR MYELODYSPLASTIC SYNDROME. A SINGLE-CENTRE EXPERIENCE.

Poster Presenter: Jana Stevkova, CZ

P447 09:50 - 09:50LOW DOSE ANTI-THYMOCYTE GLOBULIN WITHPOSTTRANSPLANT CYCLOPHOSPHAMIDE HAPLOIDENTICALSTEM CELL TRANSPLANTATION FOR HIGH RISKHEMATOLOGIC MALIGNANCIES – UMC LJUBLJANA,

56 / 160


SLOVENIA EXPERIENCE

Poster Presenter: Polona Novak, SI

P448 09:50 - 09:50DETERMINATION OF TRANSPLANT CONDITIONING INTENSITY:A REAL-LIFE DATA

Poster Presenter: ?rfan Yava?o?lu, TR


Non-infectious Late Effects, Quality of Life and Fertility

P391 09:50 - 09:50SECONDARY NEOPLASMS AFTER UMBILICAL CORD BLOODTRANSPLANTATION. ON BEHALF OF EUROCORD AND THEEUROPEAN GROUP FOR BLOOD AND MARROWTRANSPLANTATION

Poster Presenter: Fernanda Volt, FR

P392 09:50 - 09:50???HOW TO IMPROVE QUALITY OF LIFE IN ALLOGENEICTRANSPLANT PATIENTS WITH A TELEMEDICINE-BASEDPROTOCOL: MANDATORY DURING COVID-19 CRISIS, ANOPPORTUNITY FOR THE FUTURE.???

Poster Presenter: Monica Cabrero, ES

P393 09:50 - 09:50LATE EFFECTS: PATIENT-REPORTED AND PROXY-REPORTEDOUTCOMES AMONG PEDIATRIC ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISEASES – WHAT DOESN’T KILL YOU, MAKESYOU STRONGER

Poster Presenter: Joëll Esmée Bense, NL

P394 09:50 - 09:50A MOBILE PHONE APPLICATION AND PHYSICIANDASHBOARD FOR REAL TIME REMOTE MONITORING OFSYMPTOMS, VITAL SIGN AND ACTIVITY IN PATIENTS AFTERALLOGENEIC STEM CELL TRANSPLANTATION.

Poster Presenter: Eshrak Al-Shaibani, CA

P395 09:50 - 09:50ARE CARDIO-METABOLIC LATE-EFFECTS MODIFIABLETHROUGH A LOW-FAT DIET IN LONG-TERM SURVIVORS OFPEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION?

Poster Presenter: Louise Pedersen, DK

P396 09:50 - 09:50SECONDARY NON-HEMATOLOGIC MALIGNANCIES INCREASEAFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ANATIONWIDE CASE-CONTROL COHORT STUDY

Poster Presenter: Ka Young Kim, KR

P397 09:50 - 09:50PULMONARY FUNCTION IS A STRONG PREDICTOR OF 2-YEAROVERALL SURVIVAL AND NON-RELAPSE MORTALITY AFTERALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION

Poster Presenter: Frederikke Schierbeck, DK

P398 09:50 - 09:50RELAPSE AND SEVERE GRAFT-VERSUS-HOST-DISEASE HAVEA NEGATIVE IMPACT ON LONG-TERM SYMPTOMS ANDQUALITY OF LIFE OF PATIENTS THREE YEARS AFTERALLOGENEIC HAEMATOPOIETIC STEM CELL

57 / 160


TRANSPLANTATION

Poster Presenter: Simone Oerlemans, NL

P399 09:50 - 09:50THE TIMING OF RATG MATTERS: MSD-PBSCT PATIENTSRECEIVING 2D-ATG REGIMEN HAVE LOWER CUMULATIVEINCIDENCE OF RELAPSE AND BETTER DFS THAN THOSERECEIVING 4D-ATG REGIMEN.

Poster Presenter: Nan Wang, CN

P400 09:50 - 09:50EMERGENCY DEPARTMENT CONSULTATION IN ALLOGENEICHSCT RECIPIENTS - DATA FROM THE VIENNA HSCTPROGRAM

Poster Presenter: Clara Katharina Baumann, AT

P401 09:50 - 09:50LONG-TERM PSYCHOSOCIAL IMPACT OF PEDIATRICHEMATOLOGICAL STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISEASES: A QUALITATIVE STUDY

Poster Presenter: Joëll Esmée Bense, NL

P402 09:50 - 09:50ENDOCRINOPATHIES IN LONG-TERM FOLLOW-UP AFTERAUTOLOGOUS HEMATOPOIETIC STEM CELLTRANSPLANTATION.

Poster Presenter: Mario Alberto Tapia Bravo, MX

P403 09:50 - 09:50MEN´S HEALTH AND UROLOGICAL OUTCOMES IN LONG-TERM SURVIVORS OF ALLOGENEIC STEM CELLTRANSPLANTATION – RESULTS OF A PROSPECTIVECLINICAL TRIAL

Poster Presenter: Thomas Neumann, DE

P404 09:50 - 09:50THE IMPACT OF THROMBOPOIETIN RECEPTOR AGONISTS ONBONE MARROW FIBROSIS IN ALLOGENEIC STEM CELLTRANSPLANT RECIPIENTS

Poster Presenter: Zeynep Arzu Yegin, TR

P405 09:50 - 09:50ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTSSURVIVING AT LEAST 2 YEARS WITHOUT RELAPSE.OUTCOME AND RISK-FACTORS.

Poster Presenter: Bjørn Linder Grønvold, NO

P406 09:50 - 09:50CUMULATIVE INCIDENCE OF THYROID DISORDERS INPATIENTS UNDERGOING HSCT AT THE FOSCAL CLINIC IN THEPERIOD 2009 – 2019

Poster Presenter: Claudia Sossa-Melo, CO

P407 09:50 - 09:50INCIDENCE OF MALE HYPOGONADISM AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION:EXPERIENCE OF A REFERRAL CENTER


P408 09:50 - 09:50INCIDENCE OF PRIMARY OVARIAN INSUFFICIENCY AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION:EXPERIENCE OF A REFERENCE CENTER


58 / 160



Paediatric Issues

P472 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANTATION FORINHERITED IMMUNE DISORDERS : 30-YEAR ITALIAN SINGLE-CENTER EXPERIENCE.

Poster Presenter: Gianluca Dell'Orso, IT

P473 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ANEFFECTIVE THERAPEUTIC MODALITY FOR THE INFANTS WITHHIGH-RISK ACUTE LEUKEMIA.

Poster Presenter: Michael Maschan, RU

P474 09:50 - 09:50PLASMA LEVELS OF MRP-8/14 ASSOCIATE WITH NEUTROPHILRECOVERY, ENGRAFTMENT SYNDROME AND BACTERIALBLOOD STREAM INFECTIONS FOLLOWING PEDIATRICALLOGENEIC HSCT[

Poster Presenter: Katrine Kielsen, DK

P475 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION FROM MATCHED RELATED ANDUNRELATED DONORS IN CHILDREN WITH HEMATOLOGICMALIGNANCIES USING “NAÏVE” (CD45RA+) T-CELL-DEPLETEDGRAFTS.

Poster Presenter: Blanca Molina Angulo, ES

P476 09:50 - 09:50MATCHED SIBLING DONOR TRANSPLANT WITH REDUCEDINTENSITY CONDITIONING HAS EXCELLENT RESULTS INPEDIATRIC BONE MARROW FAILURE SYNDROMES

Poster Presenter: Joseph Oved, US

P477 09:50 - 09:50UPFRONT STEM CELL TRANSPLANT FROM MATCHEDUNRELATED DONORS IN NEWLY DIAGNOSED IDIOPATHICSEVERE APLASTIC ANAEMIA AND REFRACTORY CYTOPENIAOF CHILDHOOD. THE SPANISH EXPERIENCE.

Poster Presenter: Victor Quintero, ES

P478 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR PEDIATRIC HIGH-RISK T-CELLACUTE LYMPHOBLASTIC LEUKEMIA


P479 09:50 - 09:50INCIDENCE OF INVASIVE FUNGAL DISEASE AND RISKFACTORS IN 368 CHILDREN RECEIVING ALLOGENEICHAEMATOPOIETIC CELL TRANSPLANTATION: A UK MULTI-CENTRE, PROSPECTIVE AUDIT ON NATIONAL ANTI-FUNGALGUIDELINES

Poster Presenter: Giorgio Ottaviano, GB

P480 09:50 - 09:50LEVOFLOXACIN PROPHYLAXIS AND PARENTERAL NUTRITIONHAVE A DETRIMENTAL EFFECT ON INTESTINAL MICROBIALNETWORKS IN PEDIATRIC PATIENTS UNDERGOING ALLO-HSCT

Poster Presenter: Daniele Zama, IT

59 / 160


P481 09:50 - 09:50SPORTS MEDICINE PHYSICIANS AND EXERCISE SCIENTISTSIN A TRANSPLANT UNIT: PRECISION EXERCISE AND BEYOND

Poster Presenter: Adriana Balduzzi, IT

P482 09:50 - 09:50DEVELOPING A PEDIATRIC HEMATOPOIETIC CELLTRANSPLANTATION-COMPOSITE RISK SCORE TO PREDICTOUTCOMES IN CHILDREN WITH ACUTE LEUKEMIAUNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION

Poster Presenter: Madhavi Lakkaraja, US

P483 09:50 - 09:50TREOSULFAN-BASED CONDITIONING REGIMEN INHEMATOPOIETIC STEM CELL TRANSPLANTATION INCHILDREN AND ADOLESCENTS: AN ANALYSIS OF SPANISHGROUP OF HEMATOPOIETIC STEM CELL TRANSPLANTATION(GETH)

Poster Presenter: Antonio Perez-Martínez, ES

P484 09:50 - 09:50PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE(HRQOL) FOLLOWING ALLOGENEIC STEM CELLTRANSPLANTATION (SCT) PERFORMED EARLY AFTERDIAGNOSIS OF PEDIATRIC CHRONIC MYELOID LEUKEMIA(CML)

Poster Presenter: Meinolf Suttorp*, DE

P485 09:50 - 09:50PLASMA ST2 LEVELS ARE ASSOCIATED WITH AGVHDSEVERITY AND TREATMENT RESPONSE IN PEDIATRIC HSCT

Poster Presenter: Nakisa Gadanehzadeh, DK

P486 09:50 - 09:50PRELIMINARY DATA FROM AN EARLY PHASE TRIAL INCHILDREN USING POOLED GRANULOCYTES TO GENERATETRANSIENT T-CELL EXPANSION AFTER CORD BLOODTRANSPLANT IN HIGH-RISK LEUKAEMIA

Poster Presenter: Roisin Borrill, GB

P487 09:50 - 09:50UPFRONT ALTERNATIVE DONOR HSCT FOR PEDIATRICPATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA

Poster Presenter: Ho Joon Im, KR

P488 09:50 - 09:50RELAPSE AFTER TRANSPLANTATION IN CHILDREN WITHACUTE LYMPHOBLASTIC LEUKEMIA IN CELLULARTHERAPIES ERA. A RETROSPECTIVE ANALYSIS OF GRUPOESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH)PEDIATRIC COMMITTEE

Poster Presenter: MARTA GONZALEZ VICENT, ES

P489 09:50 - 09:50NON-OSTEOPENIC BONE PATHOLOGY POST-HEMATOPOIETICSTEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH INBORNERRORS OF IMMUNITY (IEI)

Poster Presenter: Zainab Golwala, GB

P490 09:50 - 09:50IMPACT OF LEVOFLOXACIN-BASED PROPHYLAXIS DURINGTHE PRE-ENGRAFTMENT PHASE IN ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANT PEDIATRICRECIPIENTS: A SINGLE-CENTER RETROSPECTIVE MATCHEDANALYSIS.

60 / 160


Poster Presenter: Alessia G Servidio, IT

P491 09:50 - 09:50ENDOTHELIAL INJURY IMPACT ON THE RESULTS OF EX VIVOT-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELLTRANSPLANTATION IN PEDIATRIC PATIENTS WITHMALIGNANT HEMOPATHIES

Poster Presenter: Iván López Torija, ES

P492 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANTATION FORCHILDREN IN JORDAN 2003-2021: ACTIVITY AND TRENDS

Poster Presenter: Rawad Rihani, JO

P493 09:50 - 09:50RE-VISIT OF THE APPLICATIONS OF GRANULOCYTE COLONY-STIMULATING FACTOR IN PEDIATRIC PATIENTS UNDERGOINGAUTOLOGOUS HIGH DOSE CHEMOTHERAPY WITH STEM CELLRESCUE – SINGLE CENTER EXPERIENCE

Poster Presenter: Parmeet Manku, CA

P494 09:50 - 09:50ANALYSIS OF ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION IN THE TYROSINE KINASE INHIBITORERA: A MULTICENTER, PROSPECTIVE STUDY ON PEDIATRICCHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (JPLSGCML-08)

Poster Presenter: CHIKAKO TONO, JP

P495 09:50 - 09:50REDUCED INTENSITY CONDITIONING REGIMEN IN CHILDRENWITH NON-MALIGNANT DISEASES: HIGH INCIDENCE OFMIXED CHIMERISM WITHOUT IMPACT ON OVERALL SURVIVALAND DISEASE FREE SURVIVAL

Poster Presenter: Maria Isabel Benitez Carabante, ES

P496 09:50 - 09:50PRIMARY IMMUNODEFICIENCIES: HSCT EXPERIENCES OF ASINGLE PEDIATRIC CENTER IN ARGENTINA.

Poster Presenter: Maria Daniela Iglesias, AR

P497 09:50 - 09:50SUCCESSFUL HAPLOIDENTICAL STEM CELL TRANSPLANTWITH POST TRANSPLANT DECITABINE FOR 3 PATIENTS WITHHIGH RISK JUVENILE MYELOMONOCYTIC LEUKAEMIA

Poster Presenter: Frances Yeap, SG

P499 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN CHILDREN WITH LYMPHOBLASTICLYMPHOMA NOT ACHIEVING REMISSION


P500 09:50 - 09:50HAPLOIDENTICAL T CELL DEPLETED HSCT REPRESENTS ASAFE THERAPEUTIC ALTERNATIVE TO MSDTRANSPLANTATION IN PATIENTS WITH TRANSFUSIONDEPENDENT THALASSEMIA

Poster Presenter: Katharina Kleinschmidt, DE

P501 09:50 - 09:50IRON OVERLOAD AFTER PEDIATRIC ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATIONS: VARIESBY DISEASE TYPE, IMPROVES OVER TIME. A SINGLE CENTEREXPERIENCE

61 / 160


Poster Presenter: Aharon Gefen, IL

P502 09:50 - 09:50HAPLOIDENTICAL STEM CELL TRANSPLANT IN PAEDIATRICPATIENTS WITH RECURRENT OR TREATMENT-REFRACTORYSEVERE APLASTIC ANAEMIA AND REFRACTORY CYTOPENIAOF CHILDHOOD.

Poster Presenter: Victor Quintero, ES

P503 09:50 - 09:50VERY LOW DAY-100 AND 1-YEAR TRANSPLANT-RELATEDMORTALITY (TRM) IN THE PEDIATRIC HEMATOPOIETIC CELLTRANSPLANTATION PROGRAM AT KING HUSSEIN CANCERCENTER

Poster Presenter: Hasan Hashem, JO

P504 09:50 - 09:50FAVOURABLE EVOLUTION OF A HEMATOPOIETIC STEM CELLTRANSPLANT IN A CBL SYNDROME PATIENT AFTERSPLENECTOMY AND IMMUNOSUPPRESSION SUSPENSION


P505 09:50 - 09:50NONTUBERCULOUS MYCOBACTERIAL INFECTION AMONGPAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTRECIPIENTS

Poster Presenter: Yasmina Mozo, ES

P506 09:50 - 09:50DONOR LYMPHOCYTE INFUSION POST HAEMATOPOIETICSTEM CELL TRANSPLANTATION – FUNDENI CLINICALINSTITUTE EXPERIENCE

Poster Presenter: Cristina Jercan, RO

P507 09:50 - 09:50MODIFIED JOHNS HOPKINS CONDITIONING PROTOCOL FORNON-MALIGNANT HAPLOIDENTICAL STEM CELLTRANSPLANTATION IN CHILDREN

Poster Presenter: Chatada Srivaishnava Ranjit Kumar, IN


Acute Leukaemia

P509 09:50 - 09:50HLA-HAPLOIDENTICAL TRANSPLANTATION WITH PTCY INAML PATIENTS WITH ACTIVE DISEASE ATTRANSPLANTATION: BETTER SURVIVAL WITH BM THAN WITHPBSC IN PATIENTS &GT; 55 YEARS


P510 09:50 - 09:50TCR??+/CD19+-DEPLETION IN SECOND ALLOGENIC HSCT INCHILDREN ACUTE LEUKEMIA.

Speaker: Michael Maschan, RU

P511 09:50 - 09:50POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED ANTI-GVHD PROPHYLAXIS IN PATIENTS WITH ALL TREATED IN CRWITH ALLO-HCT FROM HAPLOIDENTICAL VS HLA-MISMATCHED UNRELATED DONORS: AN ALWP EBMTANALYSIS

Poster Presenter: Arnon Nagler, IL

62 / 160


P512 09:50 - 09:50PROPHYLACTIC OR PRE-EMPTIVE USE OF TYROSINE KINASEINHIBITORS POST-ALLOGENEIC STEM CELLTRANSPLANTATION IN BCR-ABL POSITIVE ACUTELYMPHOBLASTIC LEUKEMIA. A SUB-ANALYSIS OF GITMO ALLSTUDY

Poster Presenter: Anna Candoni, IT

P513 09:50 - 09:50AUTOLOGOUS VERSUS HAPLOIDENTICAL STEM CELLTRANSPLANTATION IN ADULT PATIENTS WITH ACUTEMYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSIONWITH UNDETECTABLE MINIMAL RESIDUAL DISEASE:CHINESE DATA

Poster Presenter: Yiyang Ding, CN

P514 09:50 - 09:50SEQUENTIAL CONDITIONING WITH HIGH DOSE MELPHALANFOLLOWED BY BUSULFAN AND FLUDARABINE IN ELDERYPATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTEMYELOID LEUKEMIA (AML)

Poster Presenter: Matthias Stelljes, DE

P515 09:50 - 09:50IMPACT OF DONOR AND PATIENT TGFB1 ?1347C&GT;TVARIANT IN ACUTE MYELOID LEUKEMIA AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: IVAN MARTIN, ES

P516 09:50 - 09:50POST-TRANSPLANT CYCLOPHOSPHAMIDE SEPARATESGRAFT-VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUSLEUKEMIA (GVL) EFFECTS AFTER HLA- MATCHED STEM-CELLTRANSPLANTATION (SCT) FOR AML.

Poster Presenter: Avichai Shimoni, IL

P517 09:50 - 09:50COMPARISON OF HAPLOIDENTICAL AND MATCHEDUNRELATED DONOR HSCT WITH UNIFORMPOSTTRANSPLANTATION CYCLOPHOSPHAMIDE GVHDPROPHYLAXIS IN DE NOVO AML

Poster Presenter: Dmitrii Zhogolev, RU

P518 09:50 - 09:50ALLOGENEIC TRANSPLANTATION FOR ADULTS WITH ACUTEMEGAKARYOBLASTIC LEUKEMIA, A STUDY FROM ACUTELEUKEMIA WORKING PARTY OF THE EUROPEAN SOCIETYFOR BLOOD AND MARROW TRANSPLANTATION (EBMT).

Poster Presenter: Enrico Maffini, IT

P520 09:50 - 09:50AUTOLOGOUS VERSUS HAPLOIDENTICAL STEM CELLTRANSPLANTATION IN ADULT PATIENTS WITH ACUTEMYELOGENOUS LEUKEMIA IN FIRST REMISSION WITHUNDETECTABLE MINIMAL RESIDUAL DISEASE: A EUROPEANPRELIMINARY ANALYSIS:

Poster Presenter: Norbert-Claude Gorin, FR

P521 09:50 - 09:50INFLUENCE OF THE EXPRESSION OF GENESCHARACTERISTIC OF LEUKEMIC STEM CELLS ON THERESULTS OF ALLOGENEIC HSCT IN CHILDREN WITH ACUTEMYELOID LEUKEMIA


63 / 160


P522 09:50 - 09:50THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF AYAAND OLDER ADULT EARLY T-CELL PRECURSORLEUKEMIA/LYMPHOMA: A REAL-WORLD MULTICENTERSTUDY IN CHINA

Poster Presenter: Jinyan Xiao, CN

P523 09:50 - 09:50OUTCOME PREDICTION BY THE KNOWLEDGE BANKAPPROACH IN AML PATIENTS UNDERGOING ALLOGENEICSTEM CELL TRANSPLANTATION

Poster Presenter: Lara Bischof, DE

P524 09:50 - 09:50MIDOSTAURIN MAINTENANCE VS ALLO SCT VS W&AMP;W INFLT3 MUTATED AML. A "REAL LIFE" MULTICENTER STUDY

Poster Presenter: Adolfo de la Fuente, ES

P525 09:50 - 09:50THE EBMT DISEASE RISK STRATIFICATION SYSTEM (DRSS)ALLOWS PREDICTION OF RELAPSE AFTER ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTEMYELOID LEUKEMIA.

Poster Presenter: Yasmine Kadri, CA

P526 09:50 - 09:50STRUCTURAL ANALYSIS OF LEUKEMIA-ASSOCIATEDPROTEIN TYROSINE PHOSPHATASE PTPN21 AND PROTEININTERACTION NETWORK ANALYSIS OF ITS WILD TYPE ANDMUTANTS

Poster Presenter: Zijun Qian, CN

P527 09:50 - 09:50THIOTEPA, BUSULFAN AND FLUDARABINE: A CONDITIONING-REGIMEN FOR ADULT PATIENTS WITH ACUTELYMPHOBLASTIC LEUKEMIA

Poster Presenter: Anne Banet, FR

P528 09:50 - 09:50MOLECULAR GENETIC CHANGES AND MRD AFTER FIRSTINDUCTION CHEMOTHERAPY WERE RELATED WITHPROGNOSIS IN ACUTE LYMPHOBLASTIC LKUKEMIA

Poster Presenter: Xue Sun, CN

P529 09:50 - 09:50PATTERNS OF RELAPSE AND OUTCOMES IN PATIENTS WITHACUTE LEUKEMIA POST ALLOGENIC TRANSPLANTATION

Poster Presenter: Megha Saroha, IN

P530 09:50 - 09:50PREEMPTIVE IMMUNOTHERAPY FOR MINIMAL RESIDUALDISEASE IN PATIENTS WITH T(8;21) ACUTE MYELOIDLEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION.

Poster Presenter: Shuang Fan, CN

P531 09:50 - 09:50SIMILAR OS AND DFS AFTER ATG OR POST-TRANSPLANTCYCLOPHOSPHAMIDE (PT-CY) AS GVHD PROPHYLAXIS INPATIENTS WITH ALL IN CR 1 AFTER ALLOGENEIC STEM CELLTRANSPLANTATION

Poster Presenter: Christian Niederwieser, DE

P532 09:50 - 09:50INTEGRATED GENOMIC AND SINGLE-CELL MOLECULARANALYSES OF DONOR CELL LEUKEMIA AFTER

64 / 160


HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Huiqiao Chen, CN

P533 09:50 - 09:50CAN ALLOGENEIC STEM CELL HEMATOPOIETIC TRANSPLANTWITH ANY TYPE OF DONOR BE THE STANDARD POST-REMISSION TREATMENT IN INTERMEDIATE-RISK ACUTEMYELOID LEUKEMIA IN FIRST COMPLETE REMISSION?

Poster Presenter: Juan Manuel Cerezo Martín, ES

P534 09:50 - 09:50RISK FACTORS FOR CENTRAL NERVOUS SYSTEM RELAPSEAFTER ALLOGENEIC H-SCT IN FLT3-MUTATED AML

Poster Presenter: Khouloud Kouidri, DE

P535 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTICLEUKEMIA: A MULTICENTER RETROSPECTIVE STUDY.

Poster Presenter: Daniel Alzetta, IT

P536 09:50 - 09:50THE OUTCOME OF AML AND MDS PATIENTS RELAPSEDAFTER ALLOGENEIC TRANSPLANTATION, SINGLE CENTREEXPERIENCE

Poster Presenter: Markéta Š?astná Marková, CZ

P537 09:50 - 09:50CONTROL LEUKEMIA BY INDUCING ANTI-CANCER IMMUNEREACTIVITY IN VIVO? POTENTIAL OF A DC-TRIGGEREDMECHANISM

Poster Presenter: Helga Schmetzer, DE

P538 09:50 - 09:50SECOND ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION IN RELAPSED ACUTE MYELOIDLEUKEMIA – RETROSPECTIVE ANALYSIS OF THE OUTCOME

Poster Presenter: Anna Lojko-Dankowska, PL

P539 09:50 - 09:50PRE-CONDITIONING ENDOTHELIAL ACTIVATION AND STRESSINDEX (EASIX) PREDICTS ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION OUTCOMES

Poster Presenter: Ka Young Kim, KR

P542 09:50 - 09:50ALLOGENIC STEM CELL TRANSPLANTATION AND PERITRANSPLANT STRATEGIES IN PATIENTS WITHRELAPSED/REFRACTORY OR INTERMEDIATE/HIGH RISKNPM1 MUTATED ACUTE MYELOID LEUKEMIA – A SINGLECENTER EXPERIENCE

Poster Presenter: Paul Jäger, DE

P543 09:50 - 09:50VIALE-T: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OFVENETOCLAX IN COMBINATION WITH AZACITIDINE AFTERALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTSWITH ACUTE MYELOID LEUKEMIA

Poster Presenter: Charles Craddock, GB

P544 09:50 - 09:50OPTIMIZATION OF FLUDARABINE-PHARMACOKINCETICS TOREDUCE THE RI IN AML PATIENTS AFTER ALLOGENEIC STEMCELL TRANSPLANTATION

65 / 160


Poster Presenter: Tharshika Thavayogarajah, CH

P545 09:50 - 09:50RELEVANCE OF VITAMIN D IN PATIENTS UNDERGOING HLAMATCHED ALLOGENIC STEM CELL TRANSPLANT FOR ACUTELEUKAEMIA

Poster Presenter: Nishant Jindal, IN

P546 09:50 - 09:50EVALUATION OF DIFFERENT MAINTENANCE TREATMENTSTRATEGIES AFTER ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION IN FLT3 POSITIVE AML PATIENTS

Poster Presenter: Elena Stauffer, DE

P547 09:50 - 09:50OUTCOME OF ACUTE LEUKEMIA IN INFANTS: A REPORTFROM A SINGLE THIRD LEVEL CENTER IN MADRID, SPAIN.

Poster Presenter: Bárbara Ochoa Fernández, ES

P548 09:50 - 09:50POST-TRANSPLANT TREATMENT IN HIGH-RISK ACUTEMYELOID LEUKAEMIA: A SINGLE CENTER REAL-LIFEEXPERIENCE

Poster Presenter: Gianluca Cavallaro, IT

P549 09:50 - 09:50OFF-LABEL VENETOCLAX IN COMBINATION WITHHYMPOMETHYLATING AGENTS FOR POST-ALLOGENEIC HSCTAML RELAPSE

Poster Presenter: Fabio Serpenti, IT

P550 09:50 - 09:50ALLOGENEIC BONE MARROW TRANSPLANT IN INFANT WITHACUTE LEUKEMIA

Poster Presenter: Monia Ben Khaled, TN

P551 09:50 - 09:50PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTICLEUKEMIA: FIRST EXPERIENCE OF DIAGNOSTICS ANDDESCRIPTION OF CLINICAL CASES

Poster Presenter: Kseniia Afanaseva, RU

P552 09:50 - 09:50REAL-LIFE VALIDATION OF PROGNOSTIC RISKSTRATIFICATION ACCORDING TO ELN 2017 IN PATIENTS WITHAML AND ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION.

Poster Presenter: Clara Aparicio Pérez, ES

P553 09:50 - 09:50TREATMENT OF CHILDREN WITH ACUTE LYMPHOBLASTICLEUKEMIA AND HISTORY OF HIGH-RISK RELAPSE WITH BONEMARROW TRANSPLANTATION AT THE NATIONAL INSTITUTEOF PEDIATRICS, MEXICO.

Poster Presenter: Alberto Olaya-Vargas, MX

P554 09:50 - 09:50FEASIBILITY OF MYELOABLATIVE ALLO-SCT FROMHAPLOIDENTICAL DONOR IN AML PATIENTS OLDER THAN 70YEARS: A SINGLE-CENTRE EXPERIENCE

Poster Presenter: Kordelia Barbullushi, IT

P555 09:50 - 09:50ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTEMYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE

66 / 160


Poster Presenter: Osman Ilhan, TR

P556 09:50 - 09:50LONG TERM FOLLOW-UP AFTER ALLOGENEIC STEM CELLTRANSPLANTATION IN PEDIATRIC ACUTE MYELOIDLEUKEMIA PATIENTS



Aplastic Anaemia

P557 09:50 - 09:50COMPARISON&AMP;NBSP;OF&AMP;NBSP;HEMATOPOIETICSTEM CELL TRANSPLANTATION FROMMATCHED&AMP;NBSP;SIBLING&AMP;NBSP;DONOR,HAPLOIDENTICAL DONOR, AND IMMUNOSUPPRESSIVETHERAPY FOR PATIENTS WITH ACQUIRED APLASTIC ANEMIA

Poster Presenter: Yuanfeng Zhang, CN

P559 09:50 - 09:50COVID-19 IN ADULT PATIENTS WITH BONE MARROW FAILURESYNDROMES

Poster Presenter: Darya A. Chebykina, RU

P560 09:50 - 09:50CORRELATION OF DONOR CHIMERISM AND OUTCOMES INCHILDREN WITH SEVERE APLASTIC ANEMIA AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Rajinder Bajwa, US

P561 09:50 - 09:50LONG-TERM OUTCOME IN FANCONI ANEMIA PATIENTS FROMTHE ITALIAN NATIONAL DATABASE

Poster Presenter: Maura Faraci, IT

P562 09:50 - 09:50HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITHPOST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITHAPLASTIC ANEMIA: A GATMO-TC EXPERIENCE

Poster Presenter: Ana Lisa Basquiera, AR

P564 09:50 - 09:50HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) TOTREAT PURE RED CELL APLASIA (PRCA)

Poster Presenter: shengnan zhou, CN


Autoimmune Diseases

P566 09:50 - 09:50NT-PROBNP MEASUREMENTS DURING CYCLOPHOSPHAMIDECONDITIONING IN PATIENTS UNDERGOING AUTOLOGOUSHAEMOPOIETIC STEM CELL TRANSPLANTATION FORSYSTEMIC SCLEROSIS SUGGEST INCREASED CARDIACSTRAIN

Poster Presenter: Ross Penglase, AU

P567 09:50 - 09:50RESIDUAL RECIPIENT T-CELLS ARE RESPONSIBLE FORSEVERE LUPUS NEPHRITIS IN RALS-ASSOCIATED LUPUSNEPHRITIS PERSISTENCE AFTER ALLOGENEIC, MATCHEDSIBLING DONOR TRANSPLANT.

67 / 160


Poster Presenter: Srividhya Senthil, GB

P568 09:50 - 09:50ENCEPHALITIS AND THROMBOTIC MICROANGIOPATHYAFTER MRNA SARS-COV2 VACCINE IN A PATIENT WITHCHRONIC GVHD: A CASE REPORT.

Poster Presenter: Carlota Mayor Bastida, ES


Inborn Errors, Granulocyte and Osteoclast Disorders

P583 09:50 - 09:50NEUROLOGICAL OUTCOME AFTER HAEMATOPOIETIC STEMCELL TRANSPLANTATION IN PATIENTS WITH MALIGNANTINFANTILE OSTEOPETROSIS

Poster Presenter: Simin Amin-Salehi, DE

P585 09:50 - 09:50EARLY ALLOGENEIC HSCT FOR MITOCHONDRIALNEUROGASTROINTESTINAL ENCEPHALOMYOPATHY

Poster Presenter: Anders Eivind Myhre, NO


Multiple Myeloma

P616 09:50 - 09:50BEST TREATMENT STRATEGY BEFORE AUTOLOGOUSPERIPHERAL BLOOD STEM CELL TRANSPLANTATION INPOEMS PATIENTS

Poster Presenter: Simona Sica, IT

P618 09:50 - 09:50TREATMENT COMPARISON OF CILTACABTAGENEAUTOLEUCEL VERSUS PHYSICIAN’S CHOICE IN PATIENTSWITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: AMETA-ANALYSIS

Poster Presenter: Maria-Victoria Mateos, ES

P619 09:50 - 09:50IMPACT OF DOUBLE-HIT GENETICS ON REAL-WORLDOUTCOMES OF MULTIPLE MYELOMA PATIENTS UNDERGOINGAUTOLOGOUS STEM CELL TRANPLANTATION (ASCT) – A UKASCT CENTRE EXPERIENCE

Poster Presenter: Aikaterini Panopoulou, GB

P620 09:50 - 09:50LONG-TERM FOLLOW-UP OF TANDEM AUTOLOGOUS PLUSNON-MYELOABLATIVE ALLOGENEIC-SCT PROGRAM INRELAPSED MYELOMA: AN AUSTRALIAN REPORT FROM THEALFRED &AMP; THE MYELOMA AND RELATED DISEASESREGISTRY

Poster Presenter: Aditya Tedjaseputra, AU

P621 09:50 - 09:50TANDEM AUTO-ALLO-HCT WITH USE OF HDM AND TOTALMARROW IRRADIATION WITH BENDAMUSTINE AS REDUCED-TOXICITY MYELOABLATIVE CONDITIONING FOR YOUNGERPATIENTS WITH MULTIPLE MYELOMA

Poster Presenter: Sebastian Giebel, PL

P622 09:50 - 09:50CUMULATIVE EFFECT OF CYTOGENETIC HITS ON MULTIPLE

68 / 160


MYELOMA RELAPSE AFTER FRONT-LINE AUTOLOGOUS STEMCELL TRANSPLANT

Poster Presenter: Pedro Baptista, PT

P623 09:50 - 09:50LOSS OF 13P AS AN INDEPENDENT PROGNOSTIC FACTORFOR EARLY RELAPSE AFTER FIRST LINE AUTOLOGOUS STEMCELL TRANSPLANT IN MULTIPLE MYELOMA

Poster Presenter: Marta Henriques, PT

P624 09:50 - 09:50IMPACT OF TIMING OF STEM CELL RETURN FOLLOWING HIGH-DOSE MELPHALAN IN MYELOMA PATIENTS WITH RENALIMPAIRMENT

Poster Presenter: George Nesr, GB

P625 09:50 - 09:50AUTOLOGOUS STEM CELL TRANSPLANTATION IN 540MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER,REAL- WORLD STUDY

Poster Presenter: Song-Yau Wang, DE

P626 09:50 - 09:50PROGNOSTIC FACTORS FOR OVERALL SURVIVAL AFTERALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION INMULTIPLE MYELOMA PATIENTS

Poster Presenter: Lucia Rita Morais Bras, ES

P627 09:50 - 09:50TREATMENT LANDSCAPE IN RELAPSED/REFRACTORYMULTIPLE MYELOMA (RRMM): REAL-WORLD OUTCOMES FORSTANDARD-OF-CARE

Poster Presenter: Michel Delforge, BE

P628 09:50 - 09:50NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELLSAUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA:ABOUT 81 CASES.

Poster Presenter: Selim Jennane, MA

P629 09:50 - 09:50OUTCOME OF PATIENTS WITH MULTIPLE MYELOMARECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION IN THE PRE-CAR T CELL ERA

Poster Presenter: Carmen de Ramon Ortiz, CH

P630 09:50 - 09:50RESPONSE TO LENALIDOMIDE MAINTENANCE IN PATIENTSDIAGNOSED WITH MULTIPLE MYELOMA AFTER AUTOLOGOUSTRANSPLANTATION. MODIFICATIONS DURING TREATMENTPLAN DUE TO ITS TOXICITY

Poster Presenter: Eduard Fort Casamartina, ES

P632 09:50 - 09:50TREATMENT OUTCOME AND PROGNOSTIC FACTORS OFNEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVINGBORTEZOMIB-BASED INDUCTION IN HONG KONG: ANANALYSIS OF 448 PATIENTS

Poster Presenter: Hoi Ki Karen Tang, HK

P634 09:50 - 09:50EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH MULTIPLEMYELOMA WHO DEVELOPED PULMONARY COMPLICATIONSAFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION


69 / 160


P635 09:50 - 09:50MULTIPLE MYELOMA CHARACTERISTICS CORRELATED TOSERUM FREE LIGHT CHAIN RATIO AT DIAGNOSIS ANDASSOCIATION WITH EARLY RENAL DAMAGE

Poster Presenter: Danilo De Novellis, IT

P636 09:50 - 09:50TANDEM ASCT OR AMYELOABLATIVE ALLO-SCT IN PATIENTSHIGH RISK WITH MULTIPLE MYELOMA: A PHASE 3BIOLOGICAL ASSIGNMENT TRIAL

Poster Presenter: Beihui Huang, CN

P637 09:50 - 09:50ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION INPATIENTS WITH MYELOMA – UNICENTRIC STUDY

Poster Presenter: Tomas Kriz, CZ

P638 09:50 - 09:50SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IS ACOST-EFFECTIVE TREATMENT OPTION FOR MULTIPLEMYELOMA RELAPSING AFTER PRIOR ASCT: A SINGLE-CENTER EXPERIENCE IN CHINA

Poster Presenter: Lifen Kuang, CN

P639 09:50 - 09:50AUTOLOGOUS STEM CELL TRANSPLANTATION IN ALAMYLOIDOSIS: A SINGLE CENTRE EXPERIENCE

Poster Presenter: Ines Santos Marques, PT


Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution

P449 09:50 - 09:50FOCUSING ATG TOWARDS HOST T-CELL DEPLETIONELIMINATES GRADE III-IV ACUTE GVHD AND IS ASSOCIATEDWITH EARLY GRAFT VERSUS LEUKEMIA (GVL) IMMUNERESPONSES

Poster Presenter: Zaid Al-Kadhimi, US

P450 09:50 - 09:50COMBINATION OF RUXOLITINIB AND INTERFERON ?-2B ISEFFECTIVE FOR TREATMENT OF RELAPSE OR MINIMALRESIDUAL DISEASE AFTER ALLO-SCT: PHASE I/II STUDY OFNCT02185261 AND NCT02568241

Poster Presenter: Meng Lv, CN

P451 09:50 - 09:50ASSESSMENT OF SARS-COV-2 SPECIFIC T-CELL RESPONSEIN IMMUNOCOMPROMISED PATIENTS FAILING TOSEROCONVERT IN RESPONSE TO SARS-COV-2 VACCINE

Poster Presenter: Gesine Bug, DE

P452 09:50 - 09:50HIGHLY-SENSITIVE CHIMERISM ANALYSIS IN BLOOD AFTERALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION INCHILDHOOD LEUKEMIA: RESULTS FROM THE NORDICMICROCHIMERISM STUDY

Poster Presenter: Anna Karen Haugaard, DK

P453 09:50 - 09:50NGS-BASED VERIFICATION OF LOW MRD POSITIVITY ISHIGHLY SPECIFIC IN PREDICTION OF RELAPSE IN POST-TRANSPLANT ALL PATIENTS

Poster Presenter: Krystof Seferna, CZ

70 / 160


P454 09:50 - 09:50IMMUNE RECONSTITUTION FOLLOWING BASILIXIMABTREATMENT FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICALHEMATOPOIETIC STEM CELL TRANSPLANTATION

Poster Presenter: Dao-Xing Deng, CN

P455 09:50 - 09:50POST-TRANSPLANT DAY +100 MRD DETECTION RATHERTHAN MIXED CHIMERISM PREDICTS RELAPSES AFTER ALLO-SCT FOR INTERMEDIATE RISK AML PATIENTSTRANSPLANTED IN CR.

P456 09:50 - 09:50CLINICAL CHARACTERISTICS AND OUTCOME ANALYSIS FORHLA LOSS PATIENTS BETWEEN MYELOID AND LYMPHOIDMALIGNANCIES BY NEXT-GENERATION SEQUENCING


P458 09:50 - 09:50SEQUENTIAL CONDITIONING IN NPM1 POSITIVE AML WITHMEASURABLE RESIDUAL DISEASE PRE-TRANSPLANT MIGHTOVERCOME NEGATIVE IMPACT OF RESIDUAL LEUKEMIA

Poster Presenter: Alessia Fraccaroli, DE

P459 09:50 - 09:50THE PATTERN OF IMMUNE RECONSTITUTION DETERMINESTHE SURVIVAL AT THREE MONTHS AND THE DEVELOPMENTOF CHRONIC GRAFT-VERSUS HOST DISEASE IN ALLO-HSCT

Poster Presenter: Valle Gómez García de Soria, ES

P460 09:50 - 09:50GVHD IS ASSOCIATED WITH COMPROMISEDRECONSTITUTION OF B-CELL PRECURSORS IN THE BONEMARROW FOLLOWING ALLOGENEIC HSCT

Poster Presenter: Elisa Christine Peen, DK

P461 09:50 - 09:50IDENTIFICATION OF RELATIONSHIP BETWEEN QUANTITATIVECHIMERISM AND NPM1 POSITIVITY CUT OFF, AS PREDICTIVEFOR HAEMATOLOGICAL RELAPSE IN AML-NPM1+ ADULTPATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANT

Poster Presenter: Simona Maria Muggianu, IT

P462 09:50 - 09:50IMMUNE-MONITORING FOR VIRUS-SPECIFIC T-CELLRESPONSES IN ALLOGENEIC HSCT RECIPIENTS: A SURVEYFROM THE EBMT CELLULAR THERAPY &AMP;IMMUNOBIOLOGY WORKING PARTY

Poster Presenter: Raffaella Greco, IT

P463 09:50 - 09:50HIGH-SENSITIVE INDEL-QPCR CHIMERISM TO INDIVIDUALIZEDPOST-HSCT FOLLOW-UP IN MYELOID NEOPLASMS

Poster Presenter: Candela Ceballos, ES

P464 09:50 - 09:50OXIDATIVE BURST FLOW CYTOMETRY ASSAY FORCHIMERISM IN PATIENTS WITH CHRONIC GRANULOMATOUSDISEASE AFTER HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Dmitry Pershin, RU

P465 09:50 - 09:50THE APPLICATION OF DIGITAL POLYMERASE CHAINREACTION FOR CHIMAERISM ENGRAFTMENT MONITORING IN

71 / 160


SELECTED HAEMATOLOGICAL MALIGNANCIES: A SINGLECENTRE EXPERIENCE

Poster Presenter: Kimberley Robinson, GB

P466 09:50 - 09:50CIRCULATING MICRO-RNA PROFILING IN PATIENTSRELAPSING AFTER ALLOGENEIC HEMATOPOIETICTRANSPLANTATION.

Poster Presenter: Jesus Duque-Afonso, DE

P467 09:50 - 09:50LATE RECOVERY OF DONOR STEM CELL CHIMERISM AFTERAPPARENT GRAFT FAILURE WITH AUTOLOGOUSRECONSTITUTION: IMPLICATIONS FOR PLANNING SECONDTRANSPLANTS

Poster Presenter: Dafydd Stonehewer, GB

P468 09:50 - 09:50DAY +21 ABSOLUTE LYMPHOCYTE COUNT COULD BE ANINDEPENDENT PREDICTOR FOR THE OUTCOME OFALOGENEIC TRANSPLATION OF HEMOPOETIC STEM CELLS INPATIENTS WITH ACUTE LEUKAEMIA.

Poster Presenter: Kameliya Milcheva, BG

P469 09:50 - 09:50NEXT GENERATION SEQUENCING (NGS) FOR CHIMERISMMONITORING FOLLOWING HAEMATOPOEITIC STEM CELLTRANSPLANT (HSCT)- A SERVICE DEVELOPMENT PROPOSAL.

Poster Presenter: Laura Kusyk, GB

P470 09:50 - 09:50QUANTIFERON-MONITOR - A PREDICTIVE TOOL OFINFECTIOUS COMPLICATIONS IN PATIENTS AFTERALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION

Poster Presenter: Kate?ina Žib?idová, CZ

P471 09:50 - 09:50PERSISTENCE OF FIRST DONOR NATURAL KILLER CELLSAFTER A SECOND TRANSPLANT FOR INFANT ACUTELYMPHOBLASTIC LEUKEMA

Speaker: Francesco Paolo Tambaro, IT


Chronic Leukaemia and Other Myeloproliferative Disorders

P646 09:50 - 09:50THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR PATIENTS WITH PRIMARYMYELOFIBROSIS

Poster Presenter: KuoJui Sun, TW

P647 09:50 - 09:50RESULTS OF THERAPY FOR PATIENTS WITH ADVANCEDPHASES OF CHRONIC MYELOID LEUKEMIA

Poster Presenter: Elena Morozova, RU

P648 09:50 - 09:50WHAT CAN WE DO TO IMPROVE THE MANAGEMENT OF HSCTELIGIBLE PATIENTS WITH CMML IN LATIN AMERICA?


72 / 160


Special Session09:50 - 18:00 On-demand Library

SS3 - HLA - Beyond the simple allele counting

Chair: Frantisek Mrázek, CZChair: Neema Mayor, GB

SS3-01 -Introduction

Speaker: Frantisek Mrázek, CZ

SS3-02 -HLA and mechanism of relapse

Speaker: Luca Vago, IT

SS3-03 -New concepts in the HLA barrier in transplantation

Speaker: Effie Petersdorf, US

SS3-04 -HLA-DP matching and expression as tool for donor selectionrefinement

Speaker: Esteban Arrieta-Bolaños, DE

SS3-05 -Conclusions

Speaker: Neema Mayor, GB

On Demand Library09:50 - 18:00 On-demand Library

On-demand Library


SS4 - Sickle Cell Anaemia

Chair: Selim Corbacioglu, DEChair: Françoise Bernaudin, FR

SS4-01 09:50 - 09:55Introduction

Speaker: Françoise Bernaudin, FR

SS4-02 09:55 - 10:10Sickle Cell Disease in adults: An orphan disease

Speaker: Erfan Nur, NL

SS4-03 10:10 - 10:25Gene correction: The next generation of gene therapy for SickleCell Disease

Speaker: Matthew Porteus, US

SS4-04 10:25 - 10:40Clonal evolution in Sickle Cell Disease

Speaker: Courtney Fitzhugh, US

SS4-05 10:40 - 10:50Conclusions

Speaker: Selim Corbacioglu, DE


SS5 - Global Committee Session - Global perspective for cellular immune therapy


Speaker: Norbert-Claude Gorin, FR

73 / 160


SS5-02 09:53 - 10:08Global evolution: The future of allogeneic stem celltransplantation: the next decade

Speaker: Huang Xiao-Jun, CN

SS5-03 10:08 - 10:23Global evolution of CAR T cells: Acute T lymphoblasticleukemia as a model

Speaker: He Huang, CN

SS5-04 10:23 - 10:38Remodeling clinical care for stem cell transplantation in a postpandemic world

Speaker: Shinichiro Okamoto, JP

SS5-05 10:38 - 10:54Navigating the road ahead for the implementation of novel Cell-based Therapies worldwide: Balancing safety with equitableaccess

Speaker: Mickey Koh, GB

SS5-06 10:54 - 11:09Global evolution: The future of fecal microbiotometransplantation

Speaker: Florent Malard, FR


Speaker: Nicolaus Kröger, DE

Nurses Group09:50 - 18:00 On-demand Library

NG22 - What nurses need to know about essential transplant medications

NG22-01 09:50 - 10:10Prophylactic medication

Speaker: Sandra Schoenfeld, CH

NG22-02 10:10 - 10:24Management of bacterial infection

Speaker: Marta Canesi, IT

NG22-03 10:24 - 10:45Anti-viral medication

Speaker: Claudia Langebrake, DE

NG22-04 10:45 - 11:05Immunosuppression

Speaker: Jens Neefs, BE

NG22-05 11:05 - 11:25Anti-fungal medication

Speaker: Estela Moreno, ES

NG22-06 11:25 - 11:45Steroids

Speaker: Nick Duncan, GB

Joint Session09:50 - 18:00 On-demand Library

JS03 - Joint session EBMT-KSBMT: Optimal Unrelated donor selection regarding HLA and beyond

Chair: Nicolaus Kröger, DEChair: Hee-Je Kim, KR

JS03-01 09:50 - 10:15European perspective

Speaker: Alejandro Madrigal, GB

74 / 160


JS03-02 10:15 - 10:40Optimal selection of Unrelated donor and Cord blood units:Korean perspective

Speaker: Jae-ho Yoon, KR

JS03-03 10:40 - 10:55Panel Discussion


JS05 - Joint Session EBMT-HARMONY | Big Data innovations for bone marrow transplantprofessionals: Learn about the new ‘tools’ to rapidly select the most promising treatment for bloodcancer patients.

Chair: Anna Sureda, ESChair: Jesús María Hernández, ES

09:50 - 09:50Introducing the HARMONY Alliance and EBMT as Partner of theHARMONY Alliance

JS05-01 09:50 - 09:56What value can Big Data technology add in the daily practice ofbone marrow transplant professionals

Speaker: Anna Sureda, ES

JS05-02 09:56 - 10:02Introducing the HARMONY Alliance [HARMONY and HARMONYPLUS] - Mission, Activities and Achievements so far

Speaker: Jesús María Hernández, ES

10:02 - 10:02Collaboration plans opportunities between EBMT and theHARMONY Alliance

JS05-03 10:02 - 10:10Doing research within the HARMONY Alliance in AML: results,projects ahead, and core outcome sets development

Speaker: Lars Bullinger, DE

JS05-04 10:10 - 10:18The HARMONY Machine Learning Researching Tool to predictthe risk of relapse after 1st Remission in AML Patients treatedwithout Allogeneic Haematopoietic Stem Cell Transplantation

Speaker: Marta Sobas, PL

JS05-06 10:26 - 10:34The HARMONY unique data anonymization concept, OMOPcommon data model for harmonizing and using data, and howHARMONY could help the EBMT to amplify its relevance andenvision

Speaker: Laura Tur, ES

JS05-07 10:34 - 10:42The building of a new EBMT platform: Coping with the needs ofwidening and easing collaboration with other internationalregistries/organisations


JS05-09 10:50 - 10:55Expectancies of the pharmaceutical industry in a successfulEBMT | HARMONY collaboration

Speaker: Frederico Calado, PT

JS05-10 10:55 - 11:04Closing message of the HARMONY Patient Cluster incollaboration with the EBMT Patient Committee

75 / 160


How do I… ?09:50 - 18:00 On-demand Library

HDI6 - How Do I... improve SCT outcome in elderly or comorbid patients with malignant diseases? -Supported through an unrestricted educational grant by Medac

Chair: Alessandro Rambaldi, IT

HDI6-1 -HSCT in the Eighth Decade

Speaker: Andrew Artz, US

HDI6-2 -QoL after allogeneic SCT in elderly patients

Speaker: Angela Scherwath, DE

HDI6-3 -How I select conditioning regimen in elderly patients

Speaker: Nico Gagelmann, DE

HDI6-4 -Q&A


NG18 - GVHD practical tips

NG18-01 -GVHD and the eye: update on diagnosis and management ofocular GVHD

Speaker: Dimitri Roels, BE

NG18-02 -Mouth

Speaker: Nathaniel Triester, US

NG18-03 -Skin

Speaker: Rubeta Matin, GB


NG19 - GVHD treatment and supportive care

NG19-01 -Physiotherapy guidelines for managing patients undergoinghematopoietic stem cell transplantation

Speaker: Jaleel Mohammed, GB

NG19-02 -Supportive care in GVHD

Speaker: Zinaida Peric, HR

NG19-03 -Eating well with GVHD

Speaker: Marek Hanza, CZ


NG17 - COVID

NG17-01 -Vaccination in transplant population


NG17-02 -Transplant care in the post pandemic era

Speaker: Julia Ruiz Pato, ES

76 / 160


NG17-03 -Workforce wellbeing

Speaker: Regina De Jesus, GB


NG16 - Apheresis

NG16-01 -Mobilization in stem cell donors: the basics and points ofattention

Speaker: Charlotte Mestdagh, BE

NG16-02 -Access challenges

Speaker: Petra Vodi?ková, CZ

NG16-03 -Management of side effects

Speaker: Jennifer Rose, GB

Quality Management09:50 - 18:00 On-demand Library

QM5 - Quality Management Abstracts session

QM5-01 09:50 - 10:05DEVELOPMENT OF A NURSING EDUCATION PATHWAY FORTHE INTRODUCTION OF CHIMERIC ANTIGEN RECEPTOR TCELL (CAR T) THERAPY.

Oral Presenter: Maria Gillespie, IE

QM5-02 10:05 - 10:20IMPLEMENTATION OF A STANDARDIZED THERAPEUTICEDUCATION PROGRAM FOR PATIENTS WHO RECEIVE ANALLO-HSCT

Oral Presenter: Carolina Bonilla, ES

QM5-03 10:20 - 10:35IMPACT ON DAYS TO TAKE BY CHANGING FROM FRESH TOCRYOPRESERVED PERIPHERAL BLOOD STEM CELLS DURINGTHE COVID-19 PANDEMIC – A SINGLE CENTER STUDY

Oral Presenter: Ann-Mari Berthelsen, DK

QM5-04 10:35 - 10:50CAN REGULATORY-DRIVEN PROCESS INNOVATION OPENTHE DOOR FOR CELLULAR THERAPIES TO EMERGINGMARKETS?

Oral Presenter: Gabriela Valentová, US


SS6 - How to get published

SS6-01 -BMT: Official journal of the EBMT

Speaker: Hillard Lazarus, US

SS6-02 -How to get published

Speaker: Mohamad Mohty, FR

77 / 160



NG21 - JACIE

NG21-01 -JACIE: What's new for nurses?

Speaker: Tuula Rintala, GB

NG21-02 -Nursing considerations and perspective

Speaker: Marie Waller, GB

NG21-03 -Inspector's perspective

Speaker: Anne Emmett, GB


NG23 - Paediatrics Session - Challenges in peadiatric HSCT nursing

NG23-01 09:50 - 10:10The experiences of pain in children during Haematopoietic StemCell Transplantation

Speaker: Karin Plummer, AU

NG23-02 10:10 - 10:30Virtual reality on CVC management

Speaker: Elisa Piccinelli, IT

NG23-03 10:30 - 10:50Pediatric nurses' perception of factors affecting negotiation ofcare in a pediatric stem cell transplant unit

Speaker: Simona Calza, IT


SS2 - COVID-19

Chair: Catherine Cordonnier, FRChair: Ondrej Susol, CZ


Speaker: Ondrej Susol, CZ

SS2-02 09:55 - 10:10Prevention policies, measures and testing in the setting ofallogeneic HCT

Speaker: Adriana Balduzzi, IT

SS2-03 10:10 - 10:23SARS-COV-2 vaccines for HCT recipients

Speaker: Rafael de la Cámara, ES

SS2-04 10:23 - 10:38Treatment of COVID19 after HCT

Speaker: Jan Styczynski, PL


Speaker: Catherine Cordonnier, FR


NG20 - Research session 2: Keep Calm and Keep Researching - Examples of differentmethodologies in HSCT nursing research

78 / 160


NG20-01 -Variation in hydration use after reinfusion of autologous stemcells: a survey of EBMT centres

Speaker: Jantina Kortleve-Kadijk, NL

NG20-02 -The exploration of the dysgeusia in patients with allogeneichaematopoietic cell transplantation: a qualitative study

Speaker: Davide Bomben, ITSpeaker: Valentina Bressan, IT

NG20-03 -Dressings for the central venous catheter to prevent infection inpatients undergoing hematopoietic stem cell transplantation: asystematic review and meta-analysis

Speaker: Renata Cristina de Campos Pereira Silveira, BR


JS04 - Joint session EBMT-WBMT: Maintaining safe access to stem cell transplantation during thepandemic

JS04-01 09:50 - 10:10Adapting inpatient and outpatient clinical care: comparingexperiences from transplant centres worldwide

Speaker: Adriana Seber, BR

JS04-02 10:10 - 10:30Challenges in donor selection and stem cell collection

Speaker: Nina Worel, AT

JS04-03 10:30 - 10:50Global perspective on achieving quality for cellular therapy

Speaker: Yossi Schwartz, US


NG15 - Cellular Therapy beyond CAR T and HSCT

NG15-01 -DLI – Donor Lymphocyte Infusion: How it works and indications

Speaker: Lud?k Raida, CZ

NG15-02 -NK cells and dendritic cells as tool for immunotherapy

Speaker: Karolina Dostálová Weberová, CZ

NG15-03 -Treatment of viral infection with T-Cell (Adoptiveimmunotherapies)

Speaker: Robert Pytlík, CZ

Trainee Day10:00 - 11:15 South Hall 2A+B / Virtual Hall 5

TD1 - Trainees' Day - EBMT for Trainees

Chair: Francesca Bonifazi, ITChair: Nico Gagelmann, DE

TD1-01 10:00 - 10:25The EBMT Trainee Survey

Speaker: Nico Gagelmann, DESpeaker: Claire Horgan, GB

TD1-02 10:25 - 10:40Choosing wisely: Fellowship in Transplantation and Cellular

79 / 160


Therapy the Path for Success

Speaker: Silvy Lachance, CA

TD1-03 10:40 - 11:15Roundtable: Career development in SCT/cellular therapy

Speaker: Alexandra Gómez Arteaga, USSpeaker: Valentín Ortiz-Maldonado, ESSpeaker: Mizuki Watanabe, JPSpeaker: Rafaella Muratori, BR

Breaks11:15 - 11:45 VH1

Break, Virtual ePoster Viewing, Visit Virtual Exhibition


Psy2 - Difficult conversations around blood and marrow transplantation

Chair: Martin Lou?ka, CZ

Psy2-01 11:45 - 12:05How to share bad news with paediatric patients and theirparents

Speaker: Bryan Sisk, US

Psy2-02 12:05 - 12:25Shared decision making for HSCT: Reality or wish?

Speaker: Hilda Mekelenkamp, NL

Psy2-03 12:25 - 12:45Patient preferences for allogeneic HSCT: How much benefit isworthwhile from the patient’s perspective?

Speaker: Alix Stern, CH



TSCD2 - EBMT-WMDA Transplant and Search Coordinators Day - A unique phenotype - what do Ido?

Chair: Irina Evseeva, GBChair: Sergio Querol, ES

TSCD2-01 11:45 - 12:05Unique HLA phenotypes: Perspectives on the difficult search

Speaker: Valerie Stewart, US

TSCD2-02 12:05 - 12:25Why be hesitant about cord blood options?

Speaker: Dunia Jawdat, SA

TSCD2-03 12:25 - 12:45How TCs can help in ethnic minorities recruitment: Patientappeals

Speaker: Sabine Hildebrand, DE

TSCD2-04 12:45 - 13:00QA

80 / 160



Pharm2 - Panel discussion: Antiinfective prophylaxis

Chair: Estela Moreno, ESChair: Agnès Bonnin, FR

Pharm2-01 11:45 - 12:05Antimicrobial prophylaxis in HSCT

Speaker: Sofia Jorge, PT

Pharm2-02 12:05 - 12:25Antifungal prophylaxis in HSCT

Speaker: Garbiñe Lizeaga, ES

Pharm2-03 12:25 - 12:45Antiviral prophylaxis in HSCT


Pharm2-04 12:45 - 13:00QA


DM2 - Data Management Session 2: CT Discussion Forum

Chair: Annelot van Amerongen, NL

DM2-01 11:45 - 12:15Allo CAR Ts

Speaker: Jurgen Kuball, NL

DM2-02 12:15 - 12:41Treating hematological malignancies with academic CARTs

Speaker: Alvaro Urbano-Ispizua, ES

DM2-03 12:41 - 13:00Q&A

Trainee Day11:45 - 13:00 South Hall 2A+B / Virtual Hall 5

TD2 - Trainees' Day - Transplant for Trainees

Chair: Zinaida Peric, HRChair: Tiene Bauters, BE

TD2-01 11:45 - 12:05A difficult diagnosis of endothelial syndromes

Speaker: Ivan Moiseev, RU

TD2-02 12:05 - 12:25Drugs in transplant: Pharmacy group collaboration -Therapeutic Drug Monitoring

Speaker: Rick Admiraal, NLSpeaker: Vera Domingos, PT

TD2-03 12:25 - 12:40CAR-T toxicity management for Trainees

Speaker: Claire Roddie, GB

TD2-04 12:40 - 12:50The nurse-doctor team in transplant

Speaker: Nico Gagelmann, DESpeaker: John Murray, GB

TD2-05 12:50 - 13:00QA

81 / 160



PFD2 - Patient, Family and Donor Day: Living Beyond Bone Marrow Transplantation

Chair: Andrea Linke, DEChair: Sarah Hutton, GB


PFD2-02 11:50 - 12:05After the stem cell transplant – dealing with fatigue

Speaker: Kirsten Wittke, DE

PFD2-03 12:05 - 12:20"After care plan" for transplant surviors?

Speaker: Francis Ayuk, DE

PFD2-04 12:20 - 12:35Return to work: Best practices from Finland

Speaker: Emma Andersson, FI

PFD2-05 12:35 - 12:50Life After Transplant – Adjusting to your ‘New Normal’

Speaker: Philip Alexander, GB

PFD2-06 12:50 - 13:00QA

Breaks13:00 - 14:00 VH1



PFD3 - Patient, Family and Donor Day: Lunch with Prof. Buchanan & Kate Washington - SpecialLecture

Chair: Guy Bouguet, FR

PFD3-01 13:10 - 13:45Nonfiction in Progress: LIVING WITH GRAFT-VERSUS-HOSTDISEASE and the Family Caregiver Burnout

Speaker: Brad Buchanan, USSpeaker: Kate Washington, US

PFD3-02 13:45 - 13:55Q&A


Psy3 - How to support caregivers of HSCT patients?

Chair: Marie Chardon, US

Psy3-01 14:00 - 14:20Longitudinal study of family caregivers’ support needs duringallo-HSCT

Speaker: Annika Kisch, SE

Psy3-02 14:20 - 14:40How to prepare for the role of caregiver for HSCT patients?

Speaker: Jeanette Winterling, SE

Psy3-03 14:40 - 15:00What is the role of religious coping in caregivers of paediatricHSCT?

Speaker: Marie Chardon, US

82 / 160




TSCD3 - EBMT-WMDA Transplant and Search Coordinators Day - Panel discussion: Improvingcollaboration between Registry and Clinical Teams

Chair: Annette Rasche, DEChair: Keith Wilson, GB

TSCD3-01 14:00 - 15:00Panel discussion: How do you achieve efficient and goodcollaboration between the registry and clinical partners? Bestpractices: what works in different environments and what canthe audience learn from them?

Speaker: Marisa Jack, USSpeaker: Jennifer McAtee, USSpeaker: Ann O'Leary, GBSpeaker: Juliette Lethier, GBSpeaker: Shari Denovan, GBSpeaker: Josefine Teeler, NLSpeaker: Marianne Lucassen, NL

TSCD3-02 15:00 - 15:15QA


Pharm3 - Best abstract awards

Chair: Vera Domingos, PTChair: Vera Pires, PT

Pharm3-01 14:00 - 14:20WEIGHT-BASED DOSING OF CICLOSPORIN A IN OBESEPATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLTRANSPLANTATION: SERUM LEVELS AND CLINICALOUTCOMES

Oral Presenter: Midori Nakagaki, AU

Pharm3-02 14:20 - 14:40POPULATION PHARMACOKINETICS OF BUSULFAN AND ITSMETABOLITE SULFOLANE IN PATIENTS WITHMYELOFIBROSIS UNDERGOING HEMATOPOIETIC STEM CELLTRANSPLANTATION

Oral Presenter: Adrin Dadkhah, DE

Pharm3-03 14:40 - 15:00THE SAFETY, FEASIBILITY, AND EFFICACY OF GANCICLOVIRPROPHYLAXIS THROUGH DAY +100 IN PEDIATRIC ALLOSCTRECIPIENTS: BONE MARROW SUPPRESSION SECONDARY TOGANCICLOVIR MAY LIMIT EFFECTIVENESS

Oral Presenter: Liana Klejmont, US

Pharm3-04 15:00 - 15:15Q&A



Chair: Paula Busto, NL

83 / 160


DM3-01 14:00 - 14:40Update of the EBMT and JACIE project on Benchmarking ofsurvival outcomes

Speaker: Riccardo Saccardi, ITSpeaker: John Snowden, GB

DM3-02 14:40 - 14:50Q&A - part I

DM3-03 14:50 - 15:13Data Protection

Speaker: Iris Bargalló, ES

DM3-04 15:13 - 15:15Q&A - part II

Lab Technicians14:00 - 15:15 South Hall 2A+B / Virtual Hall 5

LT1 - Lab Technicians Day - Specialised cell processing

Chair: Britta Eiz-Vesper, DE

LT1-01 14:00 - 14:20CART manufacturing in academic setting: technical aspects andperformance

Speaker: Marta Español Rego, ES

LT1-02 14:20 - 14:40GMP-compliant manufacturing TEGs (abT cells Engineered toexpress a gdTCR)

Speaker: Trudy Straetemans, NL

LT1-03 14:40 - 15:00Gene corrected autologous CD34-stem cell productmanufacturing

Speaker: Karin Pike-Overzet, NL

LT1-04 15:00 - 15:15QA


PFD4 - Patient, Family and Donor Day: New therapies - New Hopes?

Chair: Ellen Kramer, NLChair: Hans Scheurer, NL


PFD4-02 14:05 - 14:25GVHD new approaches: Current status and future directions


PFD4-03 14:25 - 14:40Latest CAR T cell therapy developments: new indications andprogress in previous indications

Speaker: Andreas Mackensen, DE

PFD4-04 14:40 - 14:55Improving the CAR-T therapy patient and carer experience

Speaker: Lorna Warwick, CA

PFD4-05 14:55 - 15:15QA

Breaks15:15 - 15:45 VH1


84 / 160



Psy4 - Panel discussion: How to integrate palliative care and blood and marrow transplantationmedicine?

Chair: Martin Lou?ka, CZ

Psy4-01 15:45 - 17:00Panel discussion

Speaker: Areej Al-Jawahri, USSpeaker: Anne Pralong, DESpeaker: Steffen Simon, DESpeaker: Mario Luppi, IT


TSCD4 - EBMT-WMDA Transplant and Search Coordinators Day - Lessons to share

Chair: Valerie Stewart, USChair: Annika Kisch, SE

TSCD4-01 15:45 - 16:05Reporting SEAR/SPEAR - a tool to share lessons learnt

Speaker: Thilo Mengling, DE

TSCD4-02 16:05 - 16:25Search, Match & Connect - tips and tricks on your match list

Speaker: Alicia Venter, NL

TSCD4-03 16:25 - 16:44What has changed in unrelated transplants since 2020?

Speaker: Isabel Sanchez-Ortega, ES

TSCD4-04 16:44 - 17:00QA


Pharm4 - Quality and education

Chair: Katerina Nezvalova-Henriksen, NOChair: Rick Admiraal, NL

Pharm4-01 15:45 - 16:05JACIE for pharmacists: update 8th Edition

Speaker: Tiene Bauters, BE

Pharm4-02 16:05 - 16:25Results survey


Pharm4-03 16:25 - 16:45Development of the UKBMT pharmacist training passport and e-learning programmes


Pharm4-04 16:45 - 17:00QA



Chair: Carina Gross, NL

DM4-01 15:45 - 16:15Donor choice in pediatric haploidentical HSCT

Speaker: Hany Ariffin, MY

85 / 160


DM4-02 16:15 - 16:20Q&A - part I

DM4-03 16:20 - 16:41Minor sibling donors: A challenge for nurses

Speaker: Eugenia Trigoso, ES

DM4-04 16:41 - 16:46Q&A - part II

DM4-05 16:46 - 17:00Closing and farewell


Lab Technicians15:45 - 17:00 South Hall 2A+B / Virtual Hall 5

LT2 - Lab Technicians Day - Immune monitoring post cell therapy

Chair: Harry Dolstra, NL

LT2-01 15:45 - 16:05Immune monitoring post allo-transplants

Speaker: Madalena Noviello, IT

LT2-02 16:05 - 16:25Immune monitoring of patients treated with CAR T cells

Speaker: Sophie Caillat-Zucman, FR

LT2-03 16:25 - 16:45Immune monitoring of COVID immune responses in cell therapypatients

Speaker: Marcus Buggert, SE

LT2-04 16:45 - 17:00QA


PFD5 - Patient, Family and Donor Day: Registries matter

Chair: Guy Bouguet, FRChair: Natacha Bolaños, ES

PFD5-01 15:45 - 15:50Introduction by the Chairs

PFD5-02 15:50 - 16:05Do we still need a bone marrow donor registry?

Speaker: Anne-Pierre Pickaert, FR

PFD5-03 16:05 - 16:20Securing marrow registry diversity: overcoming cultural,religious and sexual orientation barriers

Speaker: Rebecca Pritchard, GB

PFD5-04 16:20 - 16:35The EBMT registry: what happens to patients medical data,challenges and opportunities

Speaker: Annelot van Amerongen, NL

PFD5-05 16:35 - 16:50QA

PFD5-06 16:50 - 17:00Closing and farewell

Speaker: Bregje Verhoeven, NLSpeaker: Mohamad Mohty, FRSpeaker: Natacha Bolaños, ES

86 / 160


Meet the Expert17:15 - 18:15 MTE

MTE-03 - Meet the Expert 3

MTE-03 17:15 - 18:15Mycobacterial infections

Speaker: Anne Bergeron, CH


Meet the Expert Sessions



MTE-02 17:15 - 18:15Therapy of fungal infections

Speaker: Dina Averbuch, IL



MTE-05 17:15 - 18:15Fertility preservation 2022: A must for all survivors below theage of 40

Speaker: Tamara Diesch, CH



MTE-04 17:15 - 18:15Allo-HCT in Myelofibrosis - Current and future trends

Speaker: Donal McLornan, GB



MTE-01 17:15 - 18:15B Cell Signaling: Pathways Toward Prevention of Chronic GVHD

Speaker: Stefanie Sarantopoulos, US

87 / 160


Sunday, 20. March 2022

Non-Profit Symposium08:30 - 10:00 Congress Hall / Virtual Hall 1

IS01 - GMMG Symposium

Chair: Katja Weisel, DEChair: Hans Salwender, DE

IS01-01 08:30 - 08:43Role of Cellular therapy in multiple myeloma

Speaker: Christof Scheid, DE

IS01-02 08:43 - 08:56Efficacy and future application strategies of antibody treatmentin multiple myeloma

Speaker: Hartmut Goldschmidt, DE

IS01-03 08:56 - 09:09Therapeutic developments for refractory multiple myeloma

Speaker: Marc Raab, DE

IS01-04 09:09 - 09:22Treatment of high risk multiple myeloma

Speaker: Katja Weisel, DE

IS01-05 09:22 - 09:35Therapy of newly-diagnosed, non-transplant eligible multiplemyeloma patients

Speaker: Maximilian Merz, DE

IS01-06 09:35 - 09:48Update in Amyloidosis

Speaker: Stefan Schönland, DE

IS01-07 09:48 - 10:00Q&A

Non-Profit Symposium08:30 - 10:00 Forum Hall / Virtual Hall 2

IS02 - Allogeneic hematopoietic stem cell transplantation for non-malignant haematological disease| SFGM-TC- Non profit Symposium

Chair: Jean-Hugues Dalle, FRChair: Charlotte Jubert, FR

IS02-01 08:30 - 09:00First line treatment of severe aplastic anemia in 2022

Speaker: Antonio Risitano, IT

IS02-02 09:00 - 09:30Sickle cell disease & allogeneic hematopoietic stem celltransplantation

Speaker: Nathalie Dhedin, FR

IS02-03 09:30 - 10:00Thalassemia & cell therapy

Speaker: Borje Andersson, US

Non-Profit Symposium08:30 - 10:00 South Hall 1A+B / Virtual Hall 4

IS03 - The latest advances in hematology and stem cell transplantation: an update | SorbonneUniversity (ATERHIT) non-profit symposium

Chair: Mohamad Mohty, FR

IS03-01 08:30 - 08:31Introduction

88 / 160



IS03-02 08:31 - 08:48MRD in AML

Speaker: Arnon Nagler, IL

IS03-03 08:48 - 09:04Modulation of the microbiota in HSCT


IS03-04 09:04 - 09:26CAR-T cells in ALL

Speaker: Eolia Brissot, FR

IS03-05 09:26 - 09:41CAR T cells versus ASCT in DLBCL

Speaker: Remy Duléry, FR

IS03-06 09:41 - 10:00CAR T cells in multiple myeloma


Nurses Group08:30 - 10:00 North Hall / Virtual Hall 6

NG01 - Nurses Education Day 1: Supporting a patient through transplant

Chair: Klara Kabatová-Maxová, CZChair: Kathy Goris, BE

NG01-01 08:30 - 08:55Pre-transplant information session: what to include

Speaker: Emma Kane, GB

NG01-02 08:55 - 09:20Preparing our paediatric patient with a non-malignant disease

Speaker: Marina Ben-Izhak, IL

NG01-03 09:20 - 09:45Preparing our adult patient with a non-malignant andchemotherapy naive disease

Speaker: Tessa Kerre, BE

NG01-04 09:45 - 10:00QA


ePoster Viewing


On-demand Library

Breaks10:00 - 10:30 North Hall / Virtual Hall 6

Break, ePoster Viewing, Visit Exhibition

Industry Symposium10:30 - 12:00 Congress Hall / Virtual Hall 1

IS04 - The evolving CAR T treatment paradigm in lymphoma - BMS Industry Symposium

Chair: Anna Sureda, ES

IS04-01 10:30 - 10:35Welcome and Introduction

89 / 160



IS04-02 10:35 - 10:55CAR T cell therapy for second line LBCL and earlier: futureperspectives

Speaker: Stephan Mielke, SE

IS04-03 10:55 - 11:15CAR T cell therapy implementation in LBCL: third line and later


IS04-04 11:15 - 11:35How to optimize CAR T cell therapy in LBCL


IS04-05 11:35 - 12:00Q&A and discussion. Closing remarks.

Industry Symposium10:30 - 12:00 Forum Hall / Virtual Hall 2

IS05 - What's new in GVHD in 2022: tackling the unmet needs from prophylaxis to treatment - SanofiIndustry Symposium

Chair: Mohamad Mohty, FRChair: Didier Blaise, FR

IS05-01 10:30 - 10:51ATG versus post-cyclophosphamide for GVHD prophylaxis


IS05-02 10:51 - 11:11Update on the pathophysiology of chronic GVHD

Speaker: Ernst Holler, DE

IS05-03 11:11 - 11:25Frontline management of chronic GVHD


IS05-04 11:25 - 11:45Management of refractory chronic GVHD

Speaker: Aleksandr Lazaryan, US

IS05-05 11:45 - 11:56Role of physical exercice in chronic GVHD management

Speaker: Bipin N Savani, US

IS05-06 11:56 - 12:00Q&A

Industry Symposium10:30 - 12:00 Panorama / Virtual Hall 3

IS07 - Role of C3 inhibition in PNH - Sobi Industry Symposium

Chair: Jens Panse, DE


Speaker: Jens Panse, DE

IS07-02 10:40 - 10:40Roundtable discussion

Speaker: Jens Panse, DESpeaker: Régis Peffault de Latour, FRSpeaker: Richard Kelly, GBSpeaker: Antonio Risitano, IT

IS07-02-01 10:40 - 11:00Charting the waters of PNH

IS07-02-02 11:00 - 11:20Where the dam is breaking

90 / 160


IS07-02-03 11:20 - 11:40Benefits of stemming the tide upstream

IS07-03 11:40 - 12:00Live Q&A with the audience

Industry Symposium10:30 - 12:00 South Hall 1A+B / Virtual Hall 4

IS06 - Looking deep into complexities of Multiple Myeloma (MM): How to decide the treatment andmeasure the outcomes? - Pfizer Industry Symposium

Chair: Roman Hájek, CZ


Speaker: Roman Hájek, CZ

IS06-02 10:35 - 10:58Current MM treatment landscape

Speaker: Hartmut Goldschmidt, DE

IS06-03 10:58 - 11:20Role of transplantation in MM treatment

Speaker: Sergio Giralt, US

IS06-04 11:20 - 11:40Emerging therapeutic landscape with novel targets

Speaker: Elena Zamagni, IT

IS06-05 11:40 - 12:00Q&A and closing remarks


IS08 - Understanding the Role of the Lectin Pathway of Complement in HSCT-TMA - OmerosIndustry Symposium

Chair: Alessandro Rambaldi, IT

IS08-01 10:30 - 10:35Welcome and Introductions

Speaker: Alessandro Rambaldi, IT

IS08-02 10:35 - 11:00Elucidating the Lectin Pathway’s Role in Endothelial InjurySyndromes and HSCT-TMA

Speaker: Eleni Gavriilaki, GR

IS08-03 11:00 - 11:25Identifying the HSCT-TMA Patient: Current Challenges andAvailable Resources

Speaker: Olaf Penack, DE

IS08-04 11:25 - 11:50Applying Real World and Clinical Trial Evidence in Support ofLectin Pathway Inhibition for the Treatment of HSCT-TMA

Speaker: Alessandro Rambaldi, IT

IS08-05 11:50 - 12:00Q&A




NG02-01 10:30 - 10:55Donor selection

91 / 160


Speaker: Katerina Steinerová, CZ

NG02-02 10:55 - 11:20Supportive care of the unrelated donor

Speaker: Rachel Miller, GB

NG02-03 11:20 - 11:45Supportive care of the minor donor

Speaker: Daphna Hutt, IL

NG02-04 11:45 - 12:00QA




IS09 - 5 years and counting: Building survival in lymphomas with CAR T | Gilead-Kite IndustrySymposium

Chair: Marek Trn?ný, CZ

IS09-01 12:30 - 12:35Introduction and CAR T overview

Speaker: Marek Trn?ný, CZ

IS09-02 12:35 - 13:10Survival in R/R DLBCL with CAR T: How long can we go?

Speaker: Jason Westin, USSpeaker: Andy Davies, GB

IS09-04 13:10 - 13:40Optimising for survival with CAR T in R/R MCL

Speaker: Tom van Meerten, NLSpeaker: Ana Marín Niebla, ES

IS09-05 13:40 - 13:58Live audience Q&A

IS09-06 13:58 - 14:00Summary and close


IS10 - Unmet needs in GvHD management: a new future within reach - Novartis Industry Symposium

Chair: Nicolaus Kröger, DE

IS10-01 12:30 - 12:33Welcome and introduction

IS10-02 12:33 - 12:43Challenges in managing acute GvHD


IS10-03 12:43 - 12:53Challenges in managing chronic GvHD

Speaker: Tsila Zuckerman, IL

IS10-04 12:53 - 13:03Panel discussion and live Q&A: challenges in managing GvHD


IS10-05 13:03 - 13:13First-line treatment in GvHD

Speaker: Robert Zeiser, DE

IS10-06 13:13 - 13:28Panel discussion and live Q&A: unmet needs in GvHD

92 / 160



IS10-07 13:28 - 13:43Interpreting GvHD trials: design and outcomes


IS10-07 13:43 - 13:58Panel discussion and live Q&A: a new future within reach?


IS10-08 13:58 - 14:00Concluding remarks


IS12 - Diagnosis and outcomes of HSCT-TMA: practical lessons from the experts - Alexion IndustrySymposium

Chair: Donald Bunjes, DE


Speaker: Donald Bunjes, DE

IS12-02 12:43 - 12:43Interactive discussion of risk factors and signs of HSCT-TMA:

IS12-02-A 12:43 - 13:18Insights from the paediatric field

Speaker: Sonata Jodele, US

IS12-02-B 13:18 - 13:28Similarities and differences in adults

Speaker: Donald Bunjes, DE

IS12-03 13:28 - 14:00Q&A


IS11 - Optimizing New Options for the Treatment of Cytomegalovirus in HSCT Recipients -Takeda/Medscape Industry Symposium

Chair: Johan Maertens, BE

IS11-01 12:30 - 12:35Welcome and Introductions

Speaker: Johan Maertens, BE

IS11-02 12:35 - 13:00The Landscape of CMV in HSCT Including Those With R/R CMV

Speaker: Johan Maertens, BESpeaker: Rafael Duarte, ES

IS11-03 13:00 - 13:15New Therapies Data Updates

Speaker: Roy F. Chemaly, US

IS11-04 13:15 - 13:35Patient Cases 1 and 2: Who Is the Refractory/Resistant Patient?

Speaker: Genovefa Papanicolaou, US

IS11-05 13:35 - 13:58Panel Discussion: Future of New Therapies and Q&A Session

IS11-06 13:58 - 14:00Concluding Remarks


93 / 160



IS13 - Cell therapy: revolutionary ideas improving todays practices - Miltenyi Biotec IndustrySymposium

Chair: Andrew Gennery, GB

IS13-01 12:30 - 12:37Welcome & introduction

Speaker: Andrew Gennery, GB

IS13-02 12:37 - 12:55CD45RA+ TN-depletion of PBSC grafts for prevention of chronicGVHD

Speaker: Marie Bleakley, US

IS13-03 12:55 - 13:09TCR??/CD19 T- and B-cell Depleted HSCT in PrimaryImmunodeficiencies


IS13-04 13:09 - 13:27Feasibility and efficacy of CD45RA depleted donor lymphocytesinfusion after haploidentical transplantation with post-transplantation cyclophosphamide

Speaker: Luca Castagna, IT

IS13-05 13:27 - 13:45The many faces of CAR-T clinical application in childhoodleukemia

Speaker: Michael Maschan, RU

IS13-06 13:45 - 14:00Questions & Answers




NG03-01 12:30 - 12:50Discharge: What you patient needs to know

Speaker: Marijke Quaghebeur, BE

NG03-02 12:50 - 13:10Psychological care of patients post-transplant (coping)

Speaker: Hannah De Messemaeker, BE

NG03-03 13:10 - 13:30Patient testimony on discharge

Speaker: Anne-Pierre Pickaert, FR

NG03-04 13:30 - 13:50Patient empowerment through recovery and beyond

Speaker: Lynn Leppla, CH

NG03-05 13:50 - 14:00QA



94 / 160



IS14 - Recent advancements in immune therapies for multiple myeloma - BMS Industry Symposium

Chair: Michel Delforge, BE


Speaker: Michel Delforge, BE

IS14-02 14:35 - 14:55Redirecting the immune system: the era of CAR T cell therapies

Speaker: Michel Delforge, BE

IS14-03 14:55 - 15:10Emerging targets and treatment modalities in RRMM

Speaker: Paula Rodríguez Otero, ES

IS14-04 15:10 - 15:30Advances in cereblon E3 ligase modulation as a therapeuticmediator for protein degradation

Speaker: Niels van de Donk, NL

IS14-05 15:30 - 15:45Emerging clinical data of CELMoD® agents

Speaker: Sagar Lonial, US

IS14-06 15:45 - 16:00Discussion and Q&A


IS15 - Optimizing antifungal treatment options in neutropenic haematology patients | GileadIndustry Symposium

Chair: Johan Maertens, BE

IS15-01 14:30 - 14:35Welcome, introduction and overview of agenda


IS15-02 14:35 - 15:00Changing epidemiology of breakthrough fungal infections

Speaker: Livio Pagano, IT

IS15-03 15:00 - 15:25Important factors to consider when initiating the early treatmentof IFIs

Speaker: Rafael Duarte, ES

IS15-04 15:25 - 15:50Managing the risk of drug-drug interactions between newhaematology treatments and antifungal agents


IS15-05 15:50 - 16:00Conclusions and Q&A


IS16 - Pursuit of hepatic VOD management excellence: A three-part report - Jazz PharmaceuticalsIndustry Symposium


IS16-00-01 14:30 - 14:37The headlines


IS16-01 14:37 - 14:37Report 1: Hepatic VOD management: the achievements so far

95 / 160


IS16-01-01 14:37 - 14:46Progress in management of paediatric hepatic VOD


IS16-01-02 14:46 - 14:57Targeting excellence: an interactive adult patient case example

Speaker: Tony Pagliuca, GB

IS16-01-03 14:57 - 15:03Expert insight


IS16-02 15:03 - 15:03Report 2: The next advance straight from the ward

IS16-02-01 15:03 - 15:13A new protocol to further advance management

Speaker: Michelle Kenyon, GBSpeaker: Daniele Avenoso, GB



IS16-03 15:19 - 15:19Report 3: Innovation in imaging

IS16-03-01 15:19 - 15:26Demonstration: liver stiffness measurement in action

Speaker: Antonio Colecchia, IT

IS16-03-02 15:26 - 15:36The future of imaging in hepatic VOD

Speaker: Francesca Bonifazi, IT


Speaker: Tony Pagliuca, GB

IS16-00-02 15:42 - 15:58Question time

IS16-00-03 15:58 - 16:00Summary and close



IS29 - mRNA technology: addressing a spectrum of unmet needs in vulnerable populations -Moderna Industry Symposium

Chair: Rafael de la Cámara, ES

IS29-01 14:30 - 14:40Welcome and Introduction

Speaker: Rafael de la Cámara, ES

IS29-02 14:40 - 15:00mRNA Science in Response to a Pandemic

Speaker: Andrea Carfi, US

IS29-03 15:00 - 15:20Immune Responses to COVID-19 mRNA Vaccines inImmunocompromised Populations

Speaker: Paul Moss, GB

IS29-04 15:20 - 15:40Challenging Infections in Immunocompromised Patients –Preventative Approaches


IS29-05 15:40 - 16:00Panel Discussion and Live Q&A

96 / 160



IS17 - Advances in the management of Hodgkin lymphoma and implications from emerging RWE inconsolidation therapy following ASCT | Takeda Industry Symposium

Chair: Martin Hutchings, DK

IS17-01 14:30 - 14:35Welcome and introductions

Speaker: Martin Hutchings, DK

IS17-02 14:35 - 15:00Perspectives in newly diagnosed advanced Hodgkin lymphoma

Speaker: Ramón García-Sanz, ES

IS17-03 15:00 - 15:10Post-ASCT consolidation strategies in Hodgkin lymphoma


IS17-04 15:10 - 15:30Real-world evidence supporting post-ASCT consolidation inHodgkin lymphoma

Speaker: Stefano Luminari, IT

IS17-05 15:30 - 15:55Panel discussion and Q&A

IS17-06 15:55 - 16:00Summary and close





NG04-01 14:30 - 14:50Isolation syndrome

Speaker: Valentina Biagioli, IT

NG04-02 14:50 - 15:10Drivers and barriers to ambulatory transplantation

Speaker: Sabine Valenta, CH

NG04-03 15:10 - 15:30Patients in ambulatory transplant

Speaker: Cristina Gallego, ES

NG04-04 15:30 - 16:00Debate: Pros and cons to ambulatory transplant care

Speaker: John Murray, GB




IS18 - Will transplant continue to be the SoC in R/R DLBCL? | Gilead-Kite Industry Symposium

Chair: John Gribben, GB


Speaker: John Gribben, GB

IS18-02 16:35 - 16:45Summary of SoC treatment paradigm in R/R DLBCL with

97 / 160


emphasis on transplant eligible (TE) vs. transplant ineligible (TI)patients


IS18-03 16:45 - 17:05Will the SoC change in R/R DLBCL?

IS18-03-01 17:05 - 17:05No, the SOC will not change in 2L

Speaker: Keith Wilson, GB

IS18-03-02 17:05 - 17:05Yes, the SOC will evolve in the upcoming years

Speaker: Jason Westin, US


IS18-05 17:20 - 17:40Is transplant eligibility the same as CAR T eligibility?

IS18-04-02 17:40 - 17:40Yes


IS18-04-01 17:40 - 17:40No

Speaker: Roberta Di Blasi, IT


IS18-07 17:55 - 18:00Summary and close – TE vs TI in the future?



IS19 - Making the most of ASCT in patients with newly-diagnosed multiple myeloma - JanssenIndustry Symposium



IS19-02 16:35 - 16:55Current treatment guidelines for managing patients withtransplant eligible MM

Speaker: Elena Zamagni, IT

IS19-03 16:55 - 17:15Optimizing induction, consolidation, and maintenance therapiesfor patients with MM receiving an ASCT?


IS19-04 17:15 - 17:35Front-line treatment of patients with high-risk MM and the roleof minimal residual disease

Speaker: Martin Kaiser, GB

IS19-05 17:35 - 17:55Panel discussion with Q&A

IS19-06 17:55 - 18:00Closing remarks

98 / 160



IS21 - CMV in HSCT: Breaking down barriers to improve patient outcomes - MSD Symposium

Chair: Per Ljungman, SEChair: Rafael de la Cámara, ES


IS21-02 16:35 - 16:55Relevance of CMV in the post-transplant setting: Evolving newevidence

Speaker: Genovefa Papanicolaou, US

IS21-03 16:55 - 17:15Progress in CMV management: Real life experiences

Speaker: Matthias Stelljes, DE

IS21-04 17:15 - 17:35CMV in HSCT: What does the future hold?

Speaker: Dionysios Neofytos, CH

IS21-05 17:35 - 17:55Panel Q&A



IS20 - Real-world data, pharmacoeconomics and treatment combination in GvHD: A focus on ECP |Therakos Industry Symposium

Chair: Hildegard Greinix, AT


Speaker: Hildegard Greinix, AT

IS20-02 16:35 - 17:00Real-world treatment patterns and outcomes in cGvHD patientstreated with ECP – a retrospective study in Sweden

Speaker: Gösta Berlin, SE

IS20-03 17:00 - 17:25ECP vs other therapies for steroid-refractory cGvHD in adultpatients: pharmacoeconomic assessment from a Spanishhospital perspective

Speaker: Rebeca Rodríguez Veiga, ES

IS20-04 17:25 - 17:50Clinical experiences and potential mechanisms of ECP alone orin combinational approaches in GvHD


IS20-05 17:50 - 18:00Q&A


IS22 - The past, present and future of haemoglobinopathy care - Vertex Industry Symposium


IS22-1 16:30 - 16:31Opening video



99 / 160


IS22-3 16:39 - 16:51Stem cell transplantation in an era of innovation: currentlimitations and future potential opportunities in transfusion-dependent ?-thalassemia

Speaker: Josu de la Fuente, GB

IS22-4 16:51 - 16:58Scientific exchange with Q&A - I

Speaker: Josu de la Fuente, GB

IS22-5 16:58 - 17:10Stem cell transplantation in an era of innovation: currentlimitations and future potential opportunities in sickle celldisease


IS22-6 17:10 - 17:17Scientific exchange with Q&A - II


IS22-7 17:17 - 17:29Patient care: the journey ahead

Speaker: Maria Domenica Cappellini, IT

IS22-8 17:29 - 17:36Scientific exchange with Q&A - III

Speaker: Maria Domenica Cappellini, IT

IS22-9 17:36 - 17:58Scientific exchange with panel discussion and Q&A

IS22-10 17:58 - 18:00Chair’s close of symposium

General18:15 - 19:30 Congress Hall / Virtual Hall 1

GS1 - Opening Ceremony

Chair: Nicolaus Kröger, DEChair: Petr Sedlá?ek, CZChair: Pavel Jindra, CZ

GS1-01 18:15 - 18:20Welcome


GS1-02 18:20 - 18:24Welcome and introduction to the conference

Speaker: Pavel Jindra, CZ

GS1-03 18:24 - 18:28Welcome from the Nurses Group

Speaker: Michelle Kenyon, GB

GS1-04 18:28 - 18:32Welcome note from the Patient Advocacy Committee

Speaker: Bregje Verhoeven, NL

GS1-05 18:32 - 18:57Honorary Member Awards and Clinical Achievement Award2022

Speaker: Judith Marsh, GBSpeaker: Fred Falkenburg, NLSpeaker: Noel Milpied, FRSpeaker: Richard Burt, US

GS1-06 18:57 - 19:02Special THANK YOU from the EBMT & Introduction of nextEBMT President


100 / 160


GS1-07 19:02 - 19:05Introduction of the Keynote speaker

Speaker: Petr Sedlá?ek, CZ

GS1-08 19:05 - 19:30Keynote Lecture: allo-HCT in Paediatric Acute LymphoblasticLeukaemia, state of art

Speaker: Christina Peters, AT

101 / 160


Monday, 21. March 2022

Meetings07:00 - 08:50 Congress Hall / Virtual Hall 1

Infectious Diseases Working Party Business Meeting

Chair: Rafael de la Cámara, ES

Meetings07:00 - 08:50 South Hall 1A+B / Virtual Hall 4

Chronic Malignancies Working Party Business Meeting

Chair: Ibrahim Yakoub-Agha, FR

Meetings07:00 - 08:50 South Hall 2A+B / Virtual Hall 5

Autoimmune Diseases Working Party Business Meeting

Chair: Raffaella Greco, IT


ePoster Viewing


On-demand Library

Working Party Session09:00 - 10:15 Congress Hall / Virtual Hall 1

IDWP - Infectious Diseases Working Party session

Chair: Rafael de la Cámara, ESChair: Dina Averbuch, IL

IDWP-01 09:00 - 09:20The most important articles on infections in HSCT recipientspublished during the last 2 years

Speaker: Malgorzata Mikulska, IT

IDWP-02 09:20 - 09:40What is new in the field of antifungals?


IDWP-03 09:40 - 10:00Is antibacterial/antifungal/antiviral prophylaxis needed in CARTtherapy?

Speaker: Lidia Gil, PL

IDWP-04 10:00 - 10:15Q&A

Cell Therapy09:00 - 10:15 Forum Hall / Virtual Hall 2

CTD1 - Cell Therapy Day 1: Immune monitoring post therapeutic intervention

Chair: Nina Worel, ATChair: Luca Vago, IT

CTD1-01 09:00 - 09:20T-cell reconstitution and clinical outcome after allogeneichematopoietic cell transplantation

102 / 160


Speaker: Marina Cavazzana, FR

CTD1-02 09:20 - 09:40Monitoring of CMV infection and disease after allogeneichematopoietic cell transplantation

Speaker: Raffaella Greco, IT

CTD1-03 09:40 - 10:00Impact of conditioning regimens on immune reconstitution

Speaker: Moniek de Witte, NL

CTD1-04 10:00 - 10:15Q&A

Nurses Group09:00 - 10:15 Panorama / Virtual Hall 3

NG05 - Nurses Programme Opening Session

Chair: Michelle Kenyon, GB

NG05-01 09:00 - 09:05Welcome and overview


NG05-02 09:05 - 09:10Welcome to Prague

Speaker: Klara Kabatová-Maxová, CZ

NG05-03 09:10 - 09:15Presentation of the NG Honorary Members 2022 and the 14thDistinguished Merit Award


NG05-04 09:15 - 09:45ICN Keynote lecture - Nurses leading and responding to theglobal health agenda

Speaker: Howard Catton, CH

NG05-05 09:45 - 10:15Worldwide evolution of CAR T: Landing in Czech Republic

Speaker: Jan Vydra, CZ

How do I… ?09:00 - 10:15 South Hall 1A+B / Virtual Hall 4

HDI1 - How Do I... treat chronic GVHD? - Supported through an unrestricted educational grant bySanofi

Chair: Nicolaus Kröger, DE

HDI1-01 09:00 - 09:20How do I prevent cGvHD?

Speaker: José Antonio Pérez Simón, ES

HDI1-02 09:20 - 09:40How I use ECP in the treatment of cGVHD

Speaker: Corey Cutler, US

HDI1-03 09:40 - 10:00How do I select drugs/treatment for second line therapy incGvHD?

Speaker: Daniel Wolff, DE

HDI1-04 10:00 - 10:15QA

103 / 160


Patient Advocacy Sessions09:00 - 10:15 South Hall 2A+B / Virtual Hall 5

PA1 - Patient Advocacy: From gaps to bridges - The future of patient advocacy in Central andEastern Europe

Chair: Natacha Bolaños, ESChair: Sarah Hutton, GB

PA1-01 09:00 - 09:05Introduction by the Chairs

PA1-02 09:05 - 09:15Facilitators and Barriers to Patient Advocacy

Speaker: Tamas Bereczky, DE

PA1-03 09:15 - 09:25CZ patient Advocacy Experience - What is needed?

Speaker: Jana Pelouchova, CZ

PA1-04 09:25 - 10:15Special round table discussion: Ukrainian crisis; coordinationof international support for lymphoma and BMT patients

Speaker: Natacha Bolaños, ESSpeaker: Irina Kriachok, UASpeaker: Anita Kienesberger, ATSpeaker: Tamas Bereczky, DESpeaker: Jana Pelouchova, CZ

Oral Session09:00 - 10:15 North Hall / Virtual Hall 6

OS01 - Oral session 1: Lymphoma, CLL, and multiple myeloma

Chair: Tomáš Jelínek, CZChair: Charalampia Kyriakou, GB

OS01-01 09:00 - 09:09CORD BLOOD TRANSPLANTATION FOR ADULT LYMPHOIDNEOPLASMS IN EUROPE AND JAPAN: A COLLABORATIVESTUDY BETWEEN EUROCORD/LWP-EBMT ANDJSTCT/JDCHCT

Oral Presenter: Mizuki Watanabe, JP

OS01-02 09:09 - 09:18QUANTIFICATION OF MRD AT 10-5 BY FLOW IN THE STEMCELL GRAFT CORRELATES WITH MARROW MRD AND PFSFOLLOWING AHCT AMONG PATIENTS DIAGNOSED WITH MM

Oral Presenter: Guldane Cengiz Seval, TR

OS01-03 09:18 - 09:27ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION (ALLO-HSCTS) FOR NON-HODGKINLYMPHOMA (NHL)S: OUTCOMES AT THE NATIONAL CANCERCENTER HOSPITAL (NCCH) OF JAPAN

Oral Presenter: Mizuki Watanabe, JP

OS01-04 09:27 - 09:36AN EARLY POST-TRANSPLANT RELAPSE PREDICTION SCOREIN MULTIPLE MYELOMA PATIENTS: A LARGE COHORT STUDYFROM CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Oral Presenter: Meral Beksac, TR

OS01-05 09:36 - 09:45INTERNATIONAL DIFFERENCES IN BASELINECHARACTERISTICS AND PRACTICE PATTERNS IN NEWLYDIAGNOSED MULTIPLE MYELOMA (MM) PATIENTSUNDERGOING UPFRONT AUTOLOGOUS STEM CELL

104 / 160


TRANSPLANTATION

Oral Presenter: Laurent Garderet, FR

OS01-06 09:45 - 09:54OUTCOMES OF AUTOLOGOUS HEMATOPOIETIC CELLTRANSPLANTATION (AHCT) IN ELDERLY PATIENTS WITHDIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Oral Presenter: Pashna Munshi, US

OS01-07 09:54 - 10:03HLA COMPATIBILITY RELEVANCE IN LYMPHOMAS USINGPOST-TRANSPLANT CYCLOPHOSPHAMIDE: MUD VSHAPLOIDENTICAL DONORS

Oral Presenter: Alberto Mussetti, ES

OS01-08 10:03 - 10:12OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION (ALLOHCT) IN ANAPLASTIC LARGE CELLLYMPHOMA (ALCL)

Oral Presenter: Mehdi Hamadani, US

Educational09:00 - 10:00 Terrace 2A

E1 - AML and allogeneic HCT: for whom, how, and when?

Chair: Jiri Mayer, CZChair: Eolia Brissot, FR

E1-01 09:00 - 09:05Introduction

Speaker: Jiri Mayer, CZ

E1-02 09:05 - 09:20Stratified use of allogeneic HCT in the initial management ofAML

Speaker: Felicitas Thol, DE

E1-03 09:20 - 09:35Allogeneic HCT in high-risk AML patients. The value ofachieving CR?

Speaker: Charles Craddock, GB

E1-04 09:35 - 09:50Prophylaxis, early intervention, and treatment of relapse afterHCT

Speaker: Martin Bornhaeuser, DE

E1-05 09:50 - 10:00Conclusions


Workshop09:00 - 10:00 Terrace 2B

W1 - How to perform alternative donor transplant in non-malignant disease

Chair: Markéta Bloomfield, CZChair: Bénédicte Neven, FR

W1-01 09:00 - 09:05Introduction

Speaker: Markéta Bloomfield, CZ

W1-02 09:05 - 09:20Haploidentical HSCT in primary immune deficiencies

Speaker: Mary Slatter, GB

W1-03 09:20 - 09:35Haploidentical HSCT in constitutional SAA

105 / 160


Speaker: Carmem Bonfim, BR

W1-04 09:35 - 09:50Cord blood HSCT in metabolic diseases

Speaker: Rob Wynn, GB

W1-05 09:50 - 10:00Conclusions

Speaker: Bénédicte Neven, FR

Breaks10:15 - 10:45 Congress Hall / Virtual Hall 1



CMWP - Chronic Malignancies Working Party session

Chair: Ibrahim Yakoub-Agha, FRChair: Patrick Hayden, IE

CMWP-01 10:45 - 11:10One year of VEXAS: what we know and where we are going

Speaker: Carmelo Gurnari, US

CMWP-02 11:10 - 11:35Blast Phase MPN – new developments

Speaker: Guillermo Ortí, ES

CMWP-03 11:35 - 12:00EBMT scoring system for early relapse after auto-HCT in MMpatients

Speaker: Meral Beksac, TR


CTD2 - Cell therapy Day 2: Clinical monitoring post therapeutic intervention

Chair: Christian Chabannon, FR

CTD2-01 10:45 - 11:00Neurological safety of CAR T-cells

Speaker: Antoine Carpentier, FR

CTD2-02 11:00 - 11:15Safety and feasibility of allogeneic bone marrow-derivedmesenchymal stromal cells (BM-MSC) in severe systemicsclerosis (SSc) refractory to conventional immunosuppressivetherapy

Speaker: Dominique Farge, FR

CTD2-03 11:15 - 11:30Assessing the risk of secondary malignancies after genetherapy for globin disorders

Speaker: Emanuele Angelucci, IT

CTD2-04 11:30 - 11:45Q&A


NG06 - Infections

Chair: Sophie Van Lancker, BEChair: Monika Marxova, CZ

106 / 160


NG06-01 10:45 - 11:05Viral infections post allogeneic stem cell transplantation

Speaker: Laura Ricketts, GB

NG06-02 11:05 - 11:25Invasive fungal infections

Speaker: Milan Navrátil, CZ

NG06-03 11:25 - 11:45Rare infections

Speaker: Tomas Kabut, CZ

NG06-04 11:45 - 12:00QA


HDI2 - How Do I... manage multiple facets of GVHD treatment? A focus on ECP - Supported throughan unrestricted educational grant by Therakos-Mallinckrodt

Chair: Petr Sedlá?ek, CZ

HDI2-01 10:45 - 11:05When do I use ECP in the treatment of paediatric acute orchronic GvHD?


HDI2-02 11:05 - 11:25When and why do I combine ECP with immunosuppressiveagents in the treatment of acute and chronic GVHD?


HDI2-03 11:25 - 11:45When do I use and when do I avoid ECP in the treatment ofGVHD?


HDI2-04 11:45 - 12:00QA

Patient Advocacy Sessions10:45 - 12:00 South Hall 2A+B / Virtual Hall 5

PA2 - Patient Advocacy: The Dilemma: Will CAR-T therapy replace BMT - What is the real outcomeand impact

Chair: Andrea Linke, DEChair: Guy Bouguet, FR

PA2-01 10:45 - 10:49Introduction by the Chairs

PA2-02 10:49 - 10:58Patient perspective

Speaker: Jonathan Clark, NL

PA2-03 10:58 - 11:07Payer perspective

Speaker: Marcin Czech, PL

PA2-04 11:07 - 11:16Clinician perspective

Speaker: Meletios A. Dimopoulos, GR

PA2-05 11:16 - 11:25Economist perspective

Speaker: Frederick Thielen, NL

PA2-06 11:25 - 12:00Roundtable Panel Discussion

107 / 160



OS02 - Oral session 2: Inborn errors, immunodeficiency

Chair: Ansgar Schulz, DEChair: Despina Moshous, FR

OS02-01 10:45 - 10:54PILOT STUDY ON MEMORY T-CELL ADDBACK AFTERTCRAB/CD19 DEPLETED HAPLOIDENTICAL HEMATOPOIETICCELL TRANSPLANTATION IN CHILDREN WITH NON-SCIDINBORN ERRORS OF IMMUNITY

Oral Presenter: Su Han Lum, GB

OS02-02 10:54 - 11:03OUTCOME OF CHILDREN WITH WISKOTT-ALDRICHSYNDROME (WAS) GIVEN TCRALPHA-BETA/CD19 DEPLETEDHEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)FROM AN HLA-HAPLOIDENTICAL RELATIVE

Oral Presenter: Mattia Algeri, IT

OS02-03 11:03 - 11:12IN DEPTH IMMUNE PROFILING OF IL2RG DEFICIENT PATIENT50 YEARS AFTER HEMATOPOIETIC STEM CELLTRANSPLANTATION REVEALS A DIVERSE NAIVE BUTOLIGOCLONAL MEMORY T CELL COMPARTMENT

Oral Presenter: Janine E. Melsen, NL

OS02-04 11:12 - 11:21HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ARPC1BDEFICIENCY

Oral Presenter: Stefano Giardino, IT

OS02-05 11:21 - 11:30INDIVIDUALIZED ALEMTUZUMAB DOSING FOR INDUCTION OFDISEASE REMISSION PRIOR TO HSCT IN CHILDREN WITH HLH

Oral Presenter: Federica R. Achini-Gutzwiller, CH

OS02-06 11:30 - 11:39TARGETED, MYELOABLATIVE BUSULFAN IS WELLTOLERATED IN INFANTS WITH HURLER SYNDROME

Oral Presenter: Goutomi Chatterjee, GB

OS02-07 11:39 - 11:48EXCELLENT OUTCOMES AFTER HAPLOIDENTICAL BONEMARROW TRANSPLANTATION USING POST-TRANSPLANTCYCLOPHOSPHAMIDE IN 25 PATIENTS WITH WISKOTT-ALDRICH SYNDROME

Oral Presenter: Carmem Bonfim, BR

OS02-08 11:48 - 11:57CD3+ TCR??/CD19+ DEPLETED HAPLOIDENTICALHAEMATOPOIETIC CELL TRANSPLANTATION AS A SALVGESTRATEGY FOR GRAFT FAILURE OR REFRACTORY GRAFTVERSUS HOST DISEASE IN INBORN ERRORS OF IMMUNITY

Oral Presenter: Subramaniam Ramanathan, GB


E2 - Precise medicine in paediatric leukaemia

Chair: Jan Starý, CZChair: Birgitte Strahm, DE


108 / 160


Speaker: Jan Starý, CZ

E2-02 10:50 - 11:05Genetics, epigenetics or HbF as biomarker: how to stratifytherapy in JMML

Speaker: Charlotte Niemeyer, DE

E2-03 11:05 - 11:25Therapeutic options for early relapse of ALL: advantages andlimitations

Speaker: Franco Locatelli, IT

E2-04 11:25 - 11:41Therapeutic options for individual therapy in pediatric AML

Speaker: Patrick Schlegel, AU


Speaker: Birgitte Strahm, DE


W2 - Current place of cellular therapy in multiple myeloma

Chair: Marta Krej?í, CZChair: He Huang, CN


Speaker: Marta Krej?í, CZ

W2-02 10:50 - 11:05Efficacy and outcome of modern standard treatment vs. ASCTin newly diagnosed multiple myeloma patients

Speaker: Meral Beksac, TR

W2-03 11:05 - 11:20CAR T cell therapy as replacement or supplement of ASCT aspart of consolidation in newly diagnosed multiple myelomapatients? Pros and cons


W2-04 11:20 - 11:35Current role of allogeneic SCT in multiple myeloma in thecontext of new drugs and cellular therapies?



Speaker: He Huang, CN


E3 - CAR T cell therapy for leukaemia and lymphoma

Chair: Frantisek Folber, CZ


Speaker: Frantisek Folber, CZ

E3-02 11:55 - 12:10CAR T cell therapy for lymphoma

Speaker: Marie Jose Kersten, NL

E3-04 12:25 - 12:40Management of CAR T cell toxicities

Speaker: Marion Subklewe, DE

109 / 160



W3 - Autoimmune Diseases

Chair: Tomáš Kozák, CZChair: Riccardo Saccardi, IT


Speaker: Tomáš Kozák, CZ

W3-02 11:55 - 12:10Autologous HSCT in MS

Speaker: Joachim Burman, SE

W3-03 12:10 - 12:27Autologous HSCT in SSc

Speaker: Dominique Farge, FR

W3-04 12:27 - 12:42Allogeneic HSCT in ADs

Speaker: Keith Sullivan, US


Speaker: Riccardo Saccardi, IT




IS23 - Start your engines: is transplant still the heart of the MM treatment circuit? - Sanofi(Genzyme) Industry Symposium

Chair: Ivan Spicka, CZ


Speaker: Ivan Spicka, CZ

IS23-02 12:50 - 13:05Will supercharged new regimens leave old practices in thedust?


IS23-03 13:05 - 13:20The race is on: How do subsequent therapies perform post-transplant?


IS23-04 13:20 - 13:35Tuning treatments for modern practice: Case studies

Speaker: Xavier Leleu, FR

IS23-05 13:35 - 13:45Panel discussion with Q&A and concluding remarks


IS24 - Here, Now, and Next: Perspectives on the role of CAR-T Cell Therapy in Lymphomas -Novartis Industry Symposium

Chair: Catherine Thieblemont, FR

IS24-01 12:45 - 12:48Introductions and Opening Remarks

Speaker: Catherine Thieblemont, FR

110 / 160


IS24-02 12:48 - 12:48Now and Next in r/r DLBCL: Optimizing patient journey

IS24-02-01 12:48 - 13:03Discussing efficacy and safety of CAR-T cell therapies acrosspivotal clinical trials and real-world settings

Speaker: Ulrich Jäger, ATSpeaker: Marion Subklewe, DE

IS24-02-02 13:03 - 13:28Exploring key considerations and experiences around theprocess of identifying patients with r/r DLBCL for CAR-T celltherapy

Speaker: Catherine Thieblemont, FRSpeaker: Ulrich Jäger, ATSpeaker: Marion Subklewe, DE

IS24-03 13:28 - 13:43Live Q&A

Speaker: Catherine Thieblemont, FRSpeaker: Ulrich Jäger, ATSpeaker: Marion Subklewe, DE


Speaker: Catherine Thieblemont, FR


IS26 - Delivering ECP to every patient | Therakos Industry Symposium




IS26-02 12:50 - 13:20ECP service improvement in a nurse-led clinic

Speaker: Manda Mootien, GBSpeaker: Sukran Saglam, GB

IS26-03 13:20 - 13:40Delivering integrated Therakos ECP technology – Experiencesfrom Zagreb, Croatia

Speaker: Ines Bojanic, HR

IS26-04 13:40 - 13:45Q&A

Special Session12:45 - 13:45 South Hall 2A+B / Virtual Hall 5

SS1 - Equality, Diversity and Inclusion Session

Chair: Andreu Gusi, ESChair: Silvia Montoto, GB

SS1-01 12:45 - 13:00Impact of COVID in gender inequality in research

Speaker: Pavel Ovseiko, GB

SS1-02 13:00 - 13:15Intersectionality in haematology and impact on patients

Speaker: Nada Hamad, AU

SS1-03 13:15 - 13:30Trainees' views on EDI and inequality experiences

Speaker: Nico Gagelmann, DE

111 / 160


Speaker: Claire Horgan, GB

SS1-04 13:30 - 13:45Q&A

Statistics12:45 - 13:45 North Hall / Virtual Hall 6

Stats1 - Statistics Workshop

Chair: Liesbeth de Wreede, NL

Stats1-1a 12:45 - 13:00How to adjust for confounding in a comparative analysis, andhow to select variables in a Cox multivariable model

Speaker: Jacques-Emmanuel Galimard, FR

Stats1-1b 13:00 - 13:15How to adjust for confounding in a comparative analysis, andhow to select variables in a Cox multivariable model


Stats1-1c 13:15 - 13:30How to adjust for confounding in a comparative analysis, andhow to select variables in a Cox multivariable model

Speaker: Christophe Peczynski, FR

Stats1-2 13:30 - 13:45QA

Industry Symposium12:45 - 13:45 MTE

MTE-S-01 - Meet the Expert lunch session on Allogeneic T-cell immunotherapies for EBV+Post-Transplant Lymphoproliferative Disease by Pierre Fabre

MTE-S-01-1 12:45 - 12:50Introduction

Speaker: Pierre Fabre, FR

MTE-S-01-2 12:50 - 13:10State of the art knowledge on EBV+ PTLD

Speaker: Daan Dierickx, BE

MTE-S-01-3 13:10 - 13:30Allogeneic T-cell immunotherapies for EBV+ PTLD

Speaker: Sylvain Choquet, FR

MTE-S-01-QA 13:30 - 13:45Audience Questions & Answers




GS2 - Presidential Symposium


GS2-01 14:15 - 14:18Van Bekkum Award - Introduction


GS2-02 14:18 - 14:33LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF

112 / 160


CARE (SALVAGE CHEMOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELLTRANSPLANTATION) AS SECOND-LINE THERAPY INRELAPSED/REFRACTORY LBCL: TRANSFORM RESULTS

Oral Presenter: Jeremy Abramson, US

GS2-03 14:33 - 14:36Basic Science Award - Introduction


GS2-04 14:36 - 14:51MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIALRECOVERY VIA THE STING PATHWAY IN MICE AND MEN ANDPROTECT FROM GRAFT-VERSUS-HOST DISEASE

Oral Presenter: Sascha Göttert, DE

GS2-05 14:51 - 15:00DEFIBROTIDE TREATMENT IN PAEDIATRIC AND ADULTPATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVEDISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT):RESULTS FROM THE DEFIFRANCE STUDY

Oral Presenter: Mohamad Mohty, FR

GS2-06 15:00 - 15:09OUTCOMES OF ALLOGENEIC HCT IN PATIENTS WITHHODGKIN LYMPHOMA IN THE ERA OF CHECKPOINTINHIBITORS: A JOINT CIBMTR AND EBMT ANALYSIS.

Oral Presenter: Miguel Angel Perales, US

GS2-07 15:09 - 15:18LATE EFFECTS AFTER HEMATOPOIETIC STEM CELLTRANSPLANTATION IN PATIENTS WITH HLH: A HISTIOCYTESOCIETY, PDWP, IEWP AND TCWP EBMT STUDY

Oral Presenter: Kanchan Rao, GB

GS2-08 15:18 - 15:27LONG TERM OUTCOMES AND RELATIVE MORTALITY INSURVIVORS OF ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: ANANALYSIS FROM THE ALWP OF THE EBMT

Oral Presenter: Vivek Patel, US

GS2-09 15:27 - 15:36POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUSANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ALLTREATED IN CR1 WITH ALLO-HCT FROM MATCHEDUNRELATED DONORS. A STUDY FROM ALWP OF THE EBMT

Oral Presenter: Sebastian Giebel, PL

GS2-10 15:36 - 15:45ENGINEERING T-CELLS TO PREVENT GRAFT-VERSUS-HOSTDISEASE AND LEUKEMIA RELAPSE FOLLOWING ALLOGENEICSTEM CELL TRANSPLANTATION

Oral Presenter: Feiyan Mo, US


NG07 - Oral session: Abstract finalists

Chair: Annika Kisch, SEChair: Eliška Kropá?ková, CZ

NG07-01 14:15 - 14:30INITIAL TRAINING PROGRAM FOR NURSES IN

113 / 160


HEMATOPOIETIC CELLULAR THERAPY PROVIDED BY ANATIONWIDE PLATFORM IN SPAIN

Oral Presenter: Julia Ruiz Pato, ES

NG07-02 14:30 - 14:45COMPLIANCE EVALUATION OF THE TRANSPLANTATIONUNITS BASED ON THE DECISIONS TAKEN DURING TURKEYHEMATOPOIETIC STEM CELL TRANSPLANTATION NURSINGCONSENSUS

Oral Presenter: Seckin Erdal, TR

NG07-03 14:45 - 15:00PERSON-CENTRED SUPPORT FOR FAMILY CAREGIVERS INTHE CONTEXT OF ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION – FEASIBILITY OF A REMOTELYDELIVERED INTERVENTION

Oral Presenter: Jeanette Winterling, SE

NG07-04 15:00 - 15:15SKIN CARE IN PEDIATRIC ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION PATIENTS RECEIVINGTHIOTEPA AND TREOSULFAN

Oral Presenter: Kim van der Niet, NL

NG07-05 15:15 - 15:30SIMILAR NUTRITION SUPPORT PRACTICES BUT DIFFERENTOPINIONS TOWARD GASTROSTOMY USE IN UNITED KINGDOMPEDIATRIC BONE MARROW TRANSPLANT CENTERS

Oral Presenter: James Evans, GB

NG07-6 15:30 - 15:45QA


E4 - The older patients in HSCT

Chair: Rafael Duarte, ESChair: Miriam Lanska, CZ


Speaker: Miriam Lanska, CZ

E4-02 14:20 - 14:35Elderly candidates for HSCT: how to assess their eligibility?

Speaker: Maximilian Christopeit, DE

E4-03 14:35 - 14:50The results of allogeneic HSCT for myeloid malignancies in theelderly

Speaker: Maria Thérèse Rubio, FR

E4-04 14:50 - 15:05Geriatric complications among older patients

Speaker: Andrew Artz, US


Speaker: Rafael Duarte, ES

114 / 160



W4 - Critical care in HCT recipients

Chair: Jan Vydra, CZChair: Colombe Saillard, FR


Speaker: Jan Vydra, CZ

W4-02 14:20 - 14:35Respiratory failure after hematopoietic cell transplantation

Speaker: Boris Boell, DE

W4-03 14:35 - 14:50Severe sepsis and septic shock in immunocompromisedpatients

Speaker: Martin Balík, CZ

W4-04 14:50 - 15:05Which patients should go to intensive care?

Speaker: Thomas Staudinger, AT


Speaker: Colombe Saillard, FR



Industrial Theatre15:50 - 16:10 North Hall / Virtual Hall 6

IT3 - Industry Theatre: Idecabtagene vicleucel for the treatment of patients with relapsed andrefractory multiple myeloma | Bristol Myers Squibb

IT3-01 15:50 - 16:10Idecabtagene vicleucel for the treatment of patients withrelapsed and refractory multiple myeloma


Plenary Session16:15 - 17:30 Congress Hall / Virtual Hall 1

P1 - Cord blood transplantation - do we still need it?

Chair: Petr Sedlá?ek, CZChair: Jaime Sanz Caballer, ES

P1-01 16:15 - 16:35State of the art in Cord Blood Transplantation in Europe

Speaker: Éliane Gluckman, FR

P1-02 16:35 - 16:55Emerging uses of cord blood in regenerative medicine

Speaker: Jessica Sun, US

P1-03 16:55 - 17:15Clinical benefits of ex vivo progenitor cell expansion for cordblood transplantation

Speaker: Guillermo Sanz, ES

P1-04 17:15 - 17:30QA

115 / 160



CTD3 - Cell Therapy Day 3: GoCART updates

Chair: Jurgen Kuball, NLChair: Chiara Bonini, IT

CTD3-01 16:15 - 16:25WP Data harmonization: revision of the EBMT Cellular TherapyForm


CTD3-02 16:25 - 16:35WP Standards of Care: Harmonisation site qualificationprocesses


CTD3-03 16:35 - 16:45WP Education

Speaker: Osman Ahmed, SASpeaker: Michelle Kenyon, GB

CTD3-05 16:45 - 17:05WP Scientific Excellence: Presentation selected studyproposals

Speaker: Bertram Glass, DESpeaker: Sebastian Giebel, PLSpeaker: Valentín Ortiz-Maldonado, ESSpeaker: Matteo Doglio, IT

CTD3-07 17:05 - 17:10Update status Governance Charter

Speaker: Sofie Terwel, NL

CTD3-08 17:10 - 17:30QA

Speaker: Nicolaus Kröger, DESpeaker: John Gribben, GBSpeaker: Martin Dreyling, DESpeaker: Andreu Gusi, ES

How do I… ?16:15 - 17:30 Panorama / Virtual Hall 3

HDI3 - Nurse's How Do I... best support MM patients in my practice? - Supported through anunrestricted educational grant by Janssen

Chair: John Murray, GBChair: Marijke Quaghebeur, BE

HDI3-01 16:15 - 16:35Supporting my patients to live well with myeloma – managingfatigue, memory loss and psychological wellbeing

Speaker: Maaike de Ruijter, NL

HDI3-02 16:35 - 16:55Supporting my patients to live well with myeloma – managingside effects of treatment including PN

Speaker: Matthias Hellberg-Naegele, CH

HDI3-03 16:55 - 17:15Being supported to live well with myeloma – what works for meand what matters to me

Speaker: Pavel Šplechta, CZ

17:15 - 17:30Q&A

116 / 160


Oral Session16:15 - 17:30 South Hall 1A+B / Virtual Hall 4

OS03 - Oral session 3: Various diseases: myeloproliferative neoplasm and myelodysplasticsyndrome

Chair: Marie Robin, FRChair: Thomas Schroeder, DE

OS03-01 16:15 - 16:24ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT FORBLAST PHASE OF PHILADELPHIA-CHROMOSOME NEGATIVEMYELOPROLIFERATIVE NEOPLASMS: A RETROSPECTIVESTUDY FROM THE CHRONIC MALIGNANCIES WORKINGPARTY OF THE EBMT

Oral Presenter: Guillermo Ortí, ES

OS03-02 16:24 - 16:33OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION FOR CHRONIC NEUTROPHILICLEUKEMIA: A COMBINED CIBMTR/EBMT ANALYSIS

Oral Presenter: Bhagirathbhai Dholaria, US

OS03-03 16:33 - 16:42UNRELATED AND HAPLOIDENTICAL DONOR ALLO-HCT FORCML WITH POST TRANSPLANT CYCLOPHOSPHAMIDE ASGVHD PROPHYLAXIS: A STUDY FROM THE CHRONICMALIGNANCIES WORKING PARTY OF THE EBMT

Oral Presenter: Guillermo Ortí, ES

OS03-04 16:42 - 16:51IMPACT OF REDUCED INTENSITY HEMATOPOIETIC STEMCELL TRANSPLANTATION FOR MYELOFIBROSIS INACCELERATED-PHASE AND THE ROLE OF BLASTS

Oral Presenter: Nico Gagelmann, DE

OS03-05 16:51 - 17:00IMPACT OF HIGH RISK MOLECULAR MUTATIONS AFTERALLOGENIC TRANSPLANTATION IN MYELOFIBROSIS: LONGTERM RESULTS OF A PROSPECTIVE GITMO CLINICAL TRIAL

Oral Presenter: Silvia Salmoiraghi, IT

OS03-06 17:00 - 17:09OUTCOME OF ALLOGENEIC HAEMATOPOIETIC CELLTRANSPLANTATION IN EOSINOPHILIC DISORDERS: ARETROSPECTIVE STUDY BY THE CHRONIC MALIGNANCIESWORKING PARTY OF THE EBMT

Oral Presenter: Donal McLornan, GB

OS03-07 17:09 - 17:18ALLOGENEIC TRANSPLANTATION FOR PH+ CHRONICMYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS FROMTHE EBMT CHRONIC MALIGNANCIES WORKING PARTY (EBMT-CMWP) COMPARING OUTCOMES ACCORDING TO DONORTYPE

Oral Presenter: Francesco Onida, IT

OS03-08 17:18 - 17:27ALLOGENEIC HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR MYELODYSPLASTIC SYNDROMEUNCLASSIFIABLE – A RETROSPECTIVE STUDY ON BEHALFOF THE CHRONIC MALIGNANCIES WORKING PARTY OF THEEBMT

Oral Presenter: Joanna Drozd-Sokolowska, PL

117 / 160



HDI4 - How Do I... best implement CAR T cell therapy in DLBCL? From patient eligibility to long termfollow up - Supported through an unrestricted educational grant by BMS


HDI4-01 16:15 - 16:35How do I select the right DLBCL patient for CAR T cell therapy?

Speaker: Avichai Shimoni, IL

HDI4-02 16:35 - 16:55How do I manage short and long term toxicities of CAR T celltherapy?

Speaker: Claire Roddie, GB

HDI4-03 16:55 - 17:15How do I manage the patients with CAR T cell therapy failure?

Speaker: Michael Byrne, US

HDI4-04 17:15 - 17:30QA

Working Party Session16:15 - 17:30 North Hall / Virtual Hall 6

ADWP - Autoimmune Diseases Working Party session

Chair: Raffaella Greco, ITChair: Tobias Alexander, DE

ADWP-01 16:15 - 16:25Summary of ADWP database activity

Speaker: Raffaella Greco, ITSpeaker: Tobias Alexander, DESpeaker: Manuela Badoglio, FR

ADWP-02 16:25 - 16:35Changing a chronic autoimmune disease into a one-timereversible illness

Speaker: Richard Burt, US

ADWP-03 16:35 - 16:50Transplant indications and patient selection in severe crohn'sdisease

Speaker: Elena Ricart, ES

ADWP-04 16:50 - 17:05Transplant indications and patient selection in SSc

Speaker: Nicoletta Del Papa, IT

ADWP-05 17:05 - 17:20Indications and patient selection in autologous haematopoieticstem cell transplantation in MS

Speaker: Basil Sharrack, GB

ADWP-06 17:20 - 17:30Q&A


E5 - Tools for risk stratification of GVHD

Chair: Michal Karas, CZChair: Ernst Holler, DE


Speaker: Michal Karas, CZ

118 / 160


E5-02 16:18 - 16:33MAGIC consortium assessment

Speaker: Francis Ayuk, DE

E5-03 16:33 - 16:44Minnesota GVHD risk score for acute GVHD

Speaker: Daniel Weisdorf, US

E5-04 16:44 - 16:59Risk stratification for Chronic GVHD

Speaker: Stephanie Lee, US


Speaker: Ernst Holler, DE


W5 - Palliative care after BMT


W5-02 16:20 - 16:35Quality of life and dying after BMT

Speaker: Angela Scherwath, DE

W5-03 16:35 - 16:50When to initiate palliative care after BMT

Speaker: William Krüger, DE

W5-04 16:50 - 17:05Palliative care in children after BMT

Speaker: Marta Verna, IT





Oral Session17:45 - 18:45 Congress Hall / Virtual Hall 1

AA1 - EBMT Talks: Best Abstracts

Chair: Anna Sureda, ESChair: Petr Sedlá?ek, CZ

-VAN BEKKUM AWARD - LISOCABTAGENE MARALEUCELVERSUS STANDARD OF CARE (SALVAGE CHEMOTHERAPYFOLLOWED BY HIGH-DOSE CHEMOTHERAPY ANDAUTOLOGOUS STEM CELL TRANSPLANTATION) AS SECOND-LINE THERAPY IN RELAPSED/REFRACTORY LBCL:TRANSFORM RESULTS


-BASIC SCIENCE AWARD - MICROBIAL-DERIVEDMETABOLITES INDUCE EPITHELIAL RECOVERY VIA THESTING PATHWAY IN MICE AND MEN AND PROTECT FROMGRAFT-VERSUS-HOST DISEASE


-JON J. VAN ROOD AWARD - INVARIANT NATURAL KILLER T-

119 / 160


CELL SUBSETS HAVE DIVERSE GRAFT-VERSUS-HOST-DISEASE–PREVENTING AND ANTITUMOR EFFECTS

Oral Presenter: Kristina Maas-Bauer, DE

-JIAN-JIAN LUAN AWARD - DAY+7 ANTI CD19-CAR-T BLOODCONCENTRATIONS IDENTIFY ULTRA-HIGH-RISK GROUP FOREARLY PROGRESSION OF DISEASE IN PATIENTS WITHSTABLE/PROGRESSIVE DLBCL AT LYMPHODEPLETION

Oral Presenter: Ron Ram, IL

-PRESIDENTIAL ABSTRACT - DEFIBROTIDE TREATMENT INPAEDIATRIC AND ADULT PATIENTS WITH SEVERE/VERYSEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDALOBSTRUCTION SYNDROME (VOD/SOS) AFTERHAEMATOPOIETIC CELL TRANSPLANTATION (HCT): RESULTSFROM THE DEFIFRANCE STUDY


-PRESIDENTIAL ABSTRACT - OUTCOMES OF ALLOGENEIC HCTIN PATIENTS WITH HODGKIN LYMPHOMA IN THE ERA OFCHECKPOINT INHIBITORS: A JOINT CIBMTR AND EBMTANALYSIS.

Oral Presenter: Miguel Angel Perales, US

-PRESIDENTIAL ABSTRACT - LATE EFFECTS AFTERHEMATOPOIETIC STEM CELL TRANSPLANTATION INPATIENTS WITH HLH: A HISTIOCYTE SOCIETY, PDWP, IEWPAND TCWP EBMT STUDY

Speaker: Kanchan Rao, GB

-PRESIDENTIAL ABSTRACT - LONG TERM OUTCOMES ANDRELATIVE MORTALITY IN SURVIVORS OF ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION IN ACUTEMYELOID LEUKEMIA: AN ANALYSIS FROM THE ALWP OF THEEBMT

Oral Presenter: Vivek Patel, US

-PRESIDENTIAL ABSTRACT - POST-TRANSPLANTCYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULININ PATIENTS WITH ALL TREATED IN CR1 WITH ALLO-HCTFROM MATCHED UNRELATED DONORS. A STUDY FROMALWP OF THE EBMT


-PRESIDENTIAL ABSTRACT - ENGINEERING T-CELLS TOPREVENT GRAFT-VERSUS-HOST DISEASE AND LEUKEMIARELAPSE FOLLOWING ALLOGENEIC STEM CELLTRANSPLANTATION

Oral Presenter: Feiyan Mo, US



MTE-07 17:45 - 18:45Patient optimization for CAR T therapy: benefit vs. risk of

120 / 160


toxicity

Speaker: Matthew Frigault, US



MTE-09 17:45 - 18:45Novel viral infections in immunocompromised patients

Speaker: Marie von Lilienfeld-Toal, DE



MTE-06 17:45 - 18:45How to select the best haploidentical donor in PTCY platform




MTE-08 17:45 - 18:45Management of myeloma relapse after HSCT




MTE-10 17:45 - 18:45Management of CAR T cell toxicities

Speaker: Philipp Wohlfarth, AT



121 / 160


Tuesday, 22. March 2022

Meetings07:00 - 08:50 Forum Hall / Virtual Hall 2

Transplant Complications Working Party Business Meeting

Chair: Zinaida Peric, HR


ePoster Viewing


On-demand Library

Meetings08:00 - 08:50 Panorama / Virtual Hall 3

NGBM - Nurses Group Business Meeting

Chair: Daphna Hutt, ILChair: Michelle Kenyon, GB

NGBM-01 08:00 - 08:05Introduction

NGBM-02 08:05 - 08:15President report

NGBM-03 08:15 - 08:25Research Committee update

Speaker: Annika Kisch, SE

NGBM-04 08:25 - 08:30Scientific Committee update

Speaker: Kathy Goris, BE

NGBM-05 08:30 - 08:35Paediatric Committee update

Speaker: Hilda Mekelenkamp, NL

NGBM-06 08:35 - 08:40Global Education Committee update

Speaker: Eugenia Trigoso, ES

NGBM-07 08:40 - 08:50Discussion

Quality Management08:00 - 09:00 MTE

QM MTE-03 - Quality Management Meet the Expert 3

QM MTE-03 08:00 - 09:00Adverse events & CAPA




QM MTE-02 08:00 - 09:00Audits & Document development and control

Speaker: Julie Dolva, NO

122 / 160


Speaker: Renza Monteleone, IT



QM MTE-05 08:00 - 09:00Outcome analysis and benchmarking & Validation andverification

Speaker: Mara Magri, ITSpeaker: Kim Orchard, GB



QM MTE-01 08:00 - 09:00Risk & Change Management

Speaker: Olga López, ESSpeaker: Dieter Klarmann, DE



QM MTE-04 08:00 - 09:00Maintaining the QM program & Personnel Competency

Speaker: Phuong Huynh, BESpeaker: Sarah Holtby, GB


QM MTE - Quality Management Meet the Expert


ALWP - Acute Leukaemia Working Party session - Advances in ALL therapy

Chair: Mohamad Mohty, FRChair: Sebastian Giebel, PL

ALWP-01 09:00 - 09:10Introduction


ALWP-02 09:10 - 09:22Progress in allo-HCT for ALL

Speaker: Ali Bazarbachi, LB

ALWP-03 09:22 - 09:34MRD-driven HSCT for ALL


ALWP-04 09:34 - 09:46Management of Philadelphia positive ALL

Speaker: Sebastian Giebel, PL

ALWP-05 09:46 - 09:58Role of bispecific antibodies


ALWP-06 09:58 - 10:10CAR T cell therapy for relapsed/refractory B-ALL

123 / 160


Speaker: Jordan Gauthier, US

ALWP-07 10:10 - 10:15Q&A - Conclusion


Oral Session09:00 - 10:15 Forum Hall / Virtual Hall 2

OS04 - Oral session 4: Infectious complications I

Chair: Andriyana Bankova, CHChair: Oliver Cornely, DE

OS04-01 09:00 - 09:09CAUSES OF DEATHS AFTER HEMATOPOIETIC CELLTRANSPLANTATION IN THE CONTEXT OF LETHALINFECTIOUS COMPLICATIONS: INFECTIOUS DISEASESWORKING PARTY EBMT COD-2 STUDY

Oral Presenter: Jan Styczynski, PL

OS04-02 09:09 - 09:18LISTERIA INFECTION IN HEMATOPOIETIC CELL TRANSPLANTRECIPIENTS: AN INTERNATIONAL CASE-CONTROL STUDY OFTHE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT

Oral Presenter: Dina Averbuch, IL

OS04-03 09:18 - 09:27MARIBAVIR VERSUS INVESTIGATOR-ASSIGNED THERAPYFOR REFRACTORY CMV INFECTION (WITH/WITHOUTRESISTANCE) IN HEMATOPOIETIC CELL TRANSPLANTRECIPIENTS: SUBGROUP SAFETY ANALYSIS OF A PHASE 3STUDY

Oral Presenter: Catherine Cordonnier, FR

OS04-04 09:27 - 09:36POSOLEUCEL, MULTIVIRUS-SPECIFIC T-CELL (VST) THERAPY,FOR PREVENTION OF CLINICALLY SIGNIFICANT VIRALINFECTIONS IN ALLOGENEIC TRANSPLANT RECIPIENTS:PERSISTENCE OF VSTS IN AN OPEN-LABEL PHASE 2 TRIAL

Oral Presenter: Sanjeet Singh Dadwal, US

OS04-05 09:36 - 09:45SAFETY AND IMMUNOGENICITY OF HIGH-DOSE INFLUENZAVACCINE IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTRECIPIENTS

Oral Presenter: Natasha Halasa, US

OS04-06 09:45 - 09:54EASIX FOR PREDICTION OF SEPSIS AFTER ALLOGENEICSTEM CELL TRANSPLANTATION

Oral Presenter: Felix Korell, DE

OS04-07 09:54 - 10:03REAL-WORLD OUTCOMES ASSOCIATED WITH LETERMOVIRUSE FOR CYTOMEGALOVIRUS (CMV) PRIMARY PROPHYLAXISIN ALLOGENEIC-HEMATOPOIETIC CELL TRANSPLANTRECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSISOF OBSERVATIONAL STUDIES

Oral Presenter: Roy F. Chemaly, US

OS04-08 10:03 - 10:12UPPER AND/OR LOWER RESPIRATORY TRACT INFECTIONCAUSED BY HUMAN METAPNEUMOVIRUS AFTERALLOGENEIC STEM CELL TRANSPLANTATION

Oral Presenter: José Luis Piñana, ES

124 / 160



NG08 - Disease management

Chair: Iris Agreiter, IE

NG08-01 09:00 - 09:20AML

Speaker: Victoria Potter, GB

NG08-02 09:20 - 09:40Myeloma

Speaker: Nicolas Kint, BE

NG08-03 09:40 - 10:00Short overview of Bispecifics and CART-cell therapy inLymphoma and Myeloma

Speaker: Ciel De Vriendt, BE

NG08-04 10:00 - 10:15QA

Paediatric Day09:00 - 10:15 South Hall 1A+B / Virtual Hall 4

Paed1 - Paediatrics Diseases Working Party Session

Chair: Selim Corbacioglu, DEChair: Petr Sedlá?ek, CZ

Paed1-01 09:00 - 09:05Dietrich Niethammer Obituary

Speaker: Peter Bader, DE

Paed1-02 09:05 - 09:10Dietrich Niethammer Award

Speaker: Selim Corbacioglu, DESpeaker: Christina Peters, AT

Paed1-03 09:10 - 09:20Towards Predictable Immune Reconstitution

Speaker: Jaap Jan Boelens, US

Paed1-04 09:20 - 09:30Haploidentical HSCT in Thalassemia with novel conditioningregimen

Speaker: Suradej Hongeng, TH

Paed1-05 09:30 - 09:40Update: Idiopathic Pneumonia Syndrome

Speaker: Kenneth Cooke, US

Paed1-06 09:40 - 09:50Development of novel anti-CD45 drug conjugates as targetedconditioning for SCT and gene therapy

Speaker: Persis Amrolia, GB

Paed1-07 09:50 - 10:00Prospective Multi-center Study of Paediatric Cellular TherapyPatients at risk for Endothelial Dysfunction, SinusoidalObstruction Syndrome and/or Multi-Organ DysfunctionSyndrome (MODS): POEM Update

Speaker: Kris Mahadeo, US

Paed1-08 10:00 - 10:15QA

125 / 160



OS05 - Oral session 5: Non-infectious early and late complications

Chair: Enric Carreras, ESChair: Claire Horgan, GB

OS05-01 09:00 - 09:09INCREASED EARLY CARDIAC TOXICITY IN PATIENTSUNDERGOING ALLOGENEIC HEMATOPOIETIC CELLTRANSPLANTATION COMBINED WITH POST-TRANSPLANTCYCLOPHOSPHAMIDE

Oral Presenter: Amanda I Perez-Valencia, ES

OS05-02 09:09 - 09:18INCIDENCE, SEVERITY, MANAGEMENT AND OUTCOME OFSINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVEDISEASE (SOS/VOD) IN ALLOGENEIC HSCT IN ADULTPATIENTS: A RETROSPECTIVE EBMT TRANSPLANTCOMPLICATIONS WORKING PARTY STUDY

Oral Presenter: Tapani Ruutu, FI

OS05-03 09:18 - 09:27LIVER STIFFNESS ASSESSED BEFORE HEMATOPOIETIC STEMCELL TRANSPLANTATION PREDICTS GRAFT-VERSUS-HOSTDISEASE AND NON-RELAPSE MORTALITY

Oral Presenter: Alba Cabirta, ES

OS05-04 09:27 - 09:36TOWARD IMPROVING DIAGNOSTIC CRITERIA FOR TA-TMA:INTERIM ANALYSIS OF A MULTI-CENTER RETROSPECTIVEREVIEW BY THE TA-TMA WORKING GROUP

Oral Presenter: Rafael Duarte, ES

OS05-05 09:36 - 09:45EASIX AND MORTALITY AFTER ALLOGENEIC STEM CELLTRANSPLANTATION – A PROSPECTIVE STUDY BY THE EBMTTRANSPLANT COMPLICATIONS WORKING PARTY

Oral Presenter: Olaf Penack, DE

OS05-06 09:45 - 09:54SECOND TRANSPLANTATION FOR GRAFT FAILURE AFTERHAPLOIDENTICAL HSCT: A SURVEY BY THE TRANSPLANTCOMPLICATIONS WORKING PARTY OF THE EBMT

Oral Presenter: Nadira Durakovi?, HR

OS05-07 09:54 - 10:03CYTOKINE RELEASE SYNDROME AFTER PERIPHERAL BLOODHAPLOIDENTICAL STEM CELL TRANSPLANTATION WITHPOST-TRANSPLANT CYCLOPHOSPHAMIDE: TIME OF ONSETMATTERS

Oral Presenter: Alberto Hernández Sánchez, ES

OS05-08 10:03 - 10:15SAFETY AND EFFICACY OF DEFIBROTIDE IN LATE-ONSETVENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTIONSYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELLTRANSPLANTATION (HCT) FROM THE DEFIFRANCE REGISTRYSTUDY


126 / 160


Quality Management09:00 - 10:15 North Hall / Virtual Hall 6

QM1 - Center's Session

Chair: Laura Medina, ES

QM1-01 09:00 - 09:20Accreditation Processes

Speaker: Carla Sánchez, ESSpeaker: Pietro Merli, ITSpeaker: Vincenzo Iaconianni, IT

QM1-02 09:20 - 09:30Basic quality management concepts

Speaker: Songül Tepebasi, TR

QM1-03 09:30 - 10:00Labeling & Traceability

Speaker: ?lknur Kozanoglu, TR

QM1-04 10:00 - 10:15QA


E6 - Biology and treatment of chronic GVHD

Chair: Pavel Žák, CZChair: Hildegard Greinix, AT


Speaker: Pavel Žák, CZ

E6-02 09:05 - 09:19Novel insights into the biology of chronic GVHD

Speaker: Bruce Blazar, US

E6-03 09:19 - 09:34Update of NIH cGvHD conference 2020

Speaker: Steve Pavletic, US

E6-04 09:34 - 09:50Sclerotic organ manifestations




Educational09:00 - 10:01 Terrace 2B

E7 - Lymphomas

Chair: Marek Trn?ný, CZChair: Bertram Glass, DE


Speaker: Marek Trn?ný, CZ

E7-02 09:05 - 09:21The place of transplantation in Hodgkin Lymphoma in thecontext of targeted immunotherapy (CPI, MoAb conjugates)


E7-03 09:21 - 09:36Time to redefine the role of auto/allo SCT in DLBCL in thecontext of CAR-T?

Speaker: Silvia Montoto, GB

127 / 160


E7-04 09:36 - 09:51Cellular therapies in the management of Mantle cell lymphoma

Speaker: Avichai Shimoni, IL


Speaker: Bertram Glass, DE




IT4 - Industry Theatre - Breaking news in PNH treatment: how to improve life with C3i | Sobi

IT4-01 10:20 - 10:20Changing clinical PNH practice – from innovation to trialfindings

IT4-01-01 10:20 - 10:27MoA, Key data/features/ ’message’ of Aspaveli, QoL data (plusintro and closing statement for after Ilene)

Speaker: Pete Hillmen, GB

IT4-02 10:27 - 10:27Making a difference for people living with PNH

IT4-02-01 10:27 - 10:34Real world experience patient cases (x2). Priority for case: Hb10-12, suffers from anaemia.

Speaker: Ilene Weitz, USSpeaker: Brian Mulherin, US


CTIWP - Cellular Therapy and Immunobiology Working Party session

Chair: Christian Chabannon, FR

CTIWP-01 10:45 - 11:05CTIWP Activities: End of mandate statement


CTIWP-02 11:05 - 11:08Presentation of the Jon van Rood Award

CTIWP-03 11:08 - 11:25INVARIANT NATURAL KILLER T-CELL SUBSETS HAVEDIVERSE GRAFT-VERSUS-HOST-DISEASE–PREVENTING ANDANTITUMOR EFFECTS

Oral Presenter: Kristina Maas-Bauer, DE

CTIWP-04 11:25 - 11:45Keynote lecture: Gene therapy options for globin disorders

Speaker: Franco Locatelli, IT

CTIWP-05 11:45 - 12:00Q&A


OS06 - Oral session 6: Infectious complications II, COVID

Chair: Malgorzata Mikulska, ITChair: Jan Styczynski, PL

128 / 160


OS06-01 10:45 - 10:54HUMORAL IMMUNE RESPONSE AND KINETICS FOLLOWINGDUAL VACCINATION WITH BNT162B2 IN PATIENTS AFTERALLOGENEIC BLOOD STEM CELL TRANSPLANTATION

Oral Presenter: Stefanie Munder, DE

OS06-02 10:54 - 11:03COVID-19 INFECTION OF HSCT RECIPIENTS IS ASSOCIATEDWITH HIGH MORTALITY BUT NO DETECTABLE CYTOKINESTORM AT PRESENTATION.

Oral Presenter: Giovanna Lucchini, GB

OS06-03 11:03 - 11:12ANTIBODY RESPONSE TO A THIRD SARS-COV-2 VACCINEDOSE IN RECIPIENTS OF AN ALLOGENEIC HEMATOPOIETICCELL TRANSPLANTATION

Oral Presenter: Andriyana Bankova, CH

OS06-04 11:12 - 11:21REDUCED IMMUNOGENICITY OF A THIRD COVID-19VACCINATION IN RECIPIENTS OF ALLOGENEIC STEM CELLTRANSPLANTATION

Oral Presenter: Sigrun Einarsdottir, SE

OS06-05 11:21 - 11:30DYNAMICS OF ANTIBODY RESPONSE TO BNT162B2 MRNACOVID-19 VACCINE IN RECIPIENTS OF HEMATOPOIETIC STEMCELL TRANSPLANT COMPARED TO HEALTHY CONTROLS: ALONGITUDINAL PROSPECTIVE STUDY

Oral Presenter: Francesco Saraceni, IT

OS06-06 11:30 - 11:39LONGITUDINAL STUDY OF THE HUMORAL AND CELLULARRESPONSE DEVELOPED IN ALLOSCT PATIENTS DURING ATWO-DOSE VACCINATION SCHEDULE AGAINST COVID-19

Oral Presenter: Magdalena Corona de Lapuerta, ES

OS06-07 11:39 - 11:48EVALUATION OF T AND B LYMPHOCYTES SUBSETS AFTERTWO DOSES OF BNT162B2 ANTI-SARS-COV-2 MRNAVACCINATION IN HEMATOPOIETIC STEM CELLTRANSPLANTATION PATIENTS.

Oral Presenter: Immacolata Attolico, IT

OS06-08 11:48 - 11:57ANTIVIRAL T-CELL FREQUENCIES IN A HEALTHYPOPULATION: REFERENCE VALUES FOR EVALUATINGANTIVIRAL IMMUNE CELL PROFILES INIMMUNOCOMPROMISED PATIENTS

Oral Presenter: Agnes Bonifacius, DE


NG09 - Research session 1: Best nursing research abstracts

Chair: Isabel Salcedo, ESChair: Sabine Valenta, CH

NG09-01 10:45 - 11:05REHABILITATION OF PATIENTS UNDERGOING ALLOGENEICNON-MYELOABLATIVE STEM CELL TRANSPLANTATION: ASINGLE ARM LONGITUDINAL STUDY

Oral Presenter: Astrid Lindman, DK

NG09-02 11:05 - 11:25INFORMAL CAREGIVER OF THE HSCT RECIPIENT: PROFILE,

129 / 160


MENTAL HEALTH AND QUALITY OF LIFE IMPACT.PRELIMINARY RESULTS IN A THIRD-LEVEL SPANISHHOSPITAL

Oral Presenter: Arianna Rosich-Soteras, ES

NG09-03 11:25 - 11:45VIRTUAL REALITY IN BONE MARROW BIOPSY ANDASPIRATION: SAFETY AND USER EXPERIENCE

Oral Presenter: Marthe Bellens, BE

NG09-04 11:45 - 12:00QA


Paed2 - Inborn Errors Working Party session

Chair: Bénédicte Neven, FRChair: Rob Wynn, GB

Paed2-01 10:45 - 11:05HSCT in HLH: Challenges and progress

Speaker: Despina Moshous, FR

Paed2-02 11:05 - 11:25Update on the biological and clinical outcome of ex-vivo genetherapy for MPSI Hurler patients

Speaker: Maria Esther Bernardo, IT

Paed2-03 11:25 - 11:45How can we approach HSCT in AYAs with inborn errors ofimmunity?

Speaker: Michael Albert, DE

Paed2-04 11:45 - 12:00QA


HDI5 - How Do I... conduct effective differential diagnosis of VOD from other post-HSCTcomplications? - This session is supported by Jazz Pharmaceuticals. Jazz Pharmaceuticals havesuggested this topic and have had no subsequent involvement in the development, content ororganisation of this session.

Chair: Pavel Jindra, CZ

HDI5-01 10:45 - 11:05How do I use imaging techniques?


HDI5-02 11:05 - 11:25How do we use biomarkers?

Speaker: Thomas Luft, DE

HDI5-03 11:25 - 11:45How do I diagnose VOD in paediatric patients?


11:45 - 12:00QA


QM2 - 8th Edition of the Standards

Chair: Isabel Sanchez-Ortega, ES

130 / 160


QM2-01 10:45 - 10:57Clinical standards

Speaker: Kim Orchard, GB

QM2-02 10:57 - 11:09Collections Standards


QM2-03 11:09 - 11:21Processing Standards

Speaker: Ivan van Riet, BE

QM2-04 11:21 - 11:33Quality Management Standards


QM2-05 11:33 - 11:45Immune Effector Cells Standards

Speaker: Riccardo Saccardi, IT

QM2-06 11:45 - 12:00QA


E8 - Biology and treatment of acute GVHD

Chair: Lud?k Raida, CZChair: Olaf Penack, DE


Speaker: Lud?k Raida, CZ

E8-02 10:50 - 11:05Endothelial dysfunction in aGVHD

Speaker: Thomas Luft, DE

E8-03 11:05 - 11:20Novel insights into the biology of steroid-refractorygastrointestinal

Speaker: Shernan Holtan, US

E8-04 11:20 - 11:35Biology-driven recent approaches to the treatment of aGVHD




Joint Session10:45 - 12:15 Terrace 2B

JS01 - Joint session EBMT - ASTCT - CIBMTR - APBMT - LABMT: Access to novel cell therapiessuch as CAR T Cells: challenges and strategies

Chair: Brenda Sandmaier, USChair: John Wingard, USChair: Shinichiro Okamoto, JPChair: Gregorio Jaimovich, ARChair: Nicolaus Kröger, DE

JS01-01 10:45 - 11:00US perspective (ASTCT)

Speaker: Miguel Angel Perales, US

JS01-02 11:00 - 11:15CIBMTR perspective

Speaker: Jeffery Auletta, US

131 / 160


JS01-03 11:15 - 11:30European perspective


JS01-04 11:30 - 11:45Asian perspective

Speaker: Shinichiro Okamoto, JP

JS01-05 11:45 - 12:00Latin America perspective

Speaker: Nelson Hamerschlak, BR

JS01-06 12:00 - 12:15Discussion

Workshop11:50 - 12:45 Terrace 2A

W6 - Can we limit infectious complications in transplant setting?

Chair: Vanda Chrenkova, CZChair: Jan Styczynski, PL


Speaker: Vanda Chrenkova, CZ

W6-02 11:55 - 12:10Current diagnosis and management of invasive fungal diseases

Speaker: Malgorzata Mikulska, IT

W6-03 12:10 - 12:25Pneumonia after transplantation

Speaker: Montserrat Rovira, ES

W6-04 12:25 - 12:40Rare infections after transplantation

Speaker: Montserrat Rovira, ES


Speaker: Jan Styczynski, PL




IS27 - State of the art update for managing patients with relapsed/refractory (RRMM) multiplemyeloma and future potential of cellular therapies - Janssen Industry Symposium



IS27-02 12:50 - 13:10Current treatment options for managing patients with relapsedrefractory multiple myeloma

Speaker: Paula Rodríguez Otero, ES

IS27-03 13:10 - 13:30Future directions for triple-class exposed patients with MM

Speaker: Niels van de Donk, NL

IS27-04 13:30 - 13:45Panel discussion with Q&A

132 / 160



IS28 - Prophylaxis versus diagnostic-driven therapy: Best-practice approaches for treating IMD inhaematology patients - Pfizer Industry Symposium

Chair: Alexander Schauwvlieghe, BE


Speaker: Alexander Schauwvlieghe, BE

IS28-02 12:50 - 13:05Aspergillosis in the hematology unit from an ID perspective:Early suspicion and diagnostic-driven management

Speaker: Isabel Ruiz-Camps, ES

IS28-03 13:05 - 13:20Aspergillosis in the haematology unit: Complex patients andprophylaxis

Speaker: Alexander Schauwvlieghe, BE

IS28-04 13:20 - 13:36The changing therapeutic landscape of IMD: The role of existingand upcoming antifungals

Speaker: Cornelia Lass-Flörl, AT

IS28-05 13:36 - 13:45Discussion, Q&A and close

Statistics12:45 - 13:45 South Hall 2A+B / Virtual Hall 5

Stats2 - Statistical Symposium

Chair: Ariane Boumendil, FRChair: Hein Putter, NL

Stats2-1 12:45 - 13:00Answering causal questions with observational data

Speaker: Saskia Le Cessie, NL

Stats2-2 13:00 - 13:15Design, analysis and description issues in haematologicalstudies

Speaker: Richard Szydlo, GB

Stats2-3 13:15 - 13:30Towards cGRFS and other new endpoints: problems andsolutions

Speaker: Liesbeth de Wreede, NL

Stats2-4 13:30 - 13:45QA


QM3 - Boot camp on Accreditation for IEC

Chair: Alvaro Urbano-Ispizua, ES

QM3-01 12:45 - 13:00IEC Collection Perspective

Speaker: Miquel Lozano, ES

QM3-02 13:00 - 13:15IEC - Processing Perspective

Speaker: Sandra Loaiza, GB

QM3-03 13:15 - 13:30IEC Clinical Perspective

Speaker: Robin Sanderson, GB

133 / 160


QM3-04 13:30 - 13:45QA

Industry Symposium12:45 - 13:45 MTE

MTE-S-02 - Meet the Expert lunch session by Therakos-Mallinckrodt

Chair: Zinaida Peric, HR

MTE-S-02-01 12:45 - 13:45Case study discussion – combinatorial strategies using ECP inthe treatment of GvHD





P2 - Optimisation of transplant outcome by modifiable pre- and peri-transplant variables

Chair: Petr Cetkovský, CZChair: Frédéric Baron, BE

P2-01 14:15 - 14:35GVHD prophylaxis: post-transplant CY versus ATG, where dowe stand?


P2-02 14:35 - 14:55Stem cell and donor source – return to the bone marrow or cordblood: for whom and when?

Speaker: Udo Holtick, DE

P2-03 14:55 - 15:15Conditioning & relapse prevention: is there sufficient evidencefor personalized conditioning and posttransplant maintenancetherapy?


P2-04 15:15 - 15:30QA


OS07 - Oral session 7: MRD, chimerism, relapse, and immune reconstitution

Chair: Desiree Kunadt, DEChair: Katrine Kielsen, DK

OS07-01 14:15 - 14:24MEASURABLE-RESIDUAL DISEASE GUIDED TREATMENT WITHAZACITIDINE IN MDS/AML PATIENTS AT IMMINENT RISK OFRELAPSE AFTER ALLOGENEIC STEM CELLTRANSPLANTATION: RESULTS OF THE PROSPECTIVERELAZA2 TRIAL

Oral Presenter: Uwe Platzbecker, DE

OS07-02 14:24 - 14:33LATE RELAPSE AFTER HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR ACUTE LEUKEMIA – ARETROSPECTIVE STUDY FROM THE FRENCH SOCIETY FORSTEM CELL TRANSPLANTATION SFGM-TC)

134 / 160


Oral Presenter: Eléonore Kaphan, FR

OS07-03 14:33 - 14:42AZACITIDINE, LENALIDOMIDE AND DLI AS SALVAGETHERAPY FOR MDS, AML AND CMML RELAPSE AFTERALLOGENEIC SCT - FINAL RESULTS OF THE PROSPECTIVEAZALENA-TRIAL (NCT02472691)

Oral Presenter: Thomas Schroeder, DE

OS07-04 14:42 - 14:51COMBINING BLINATUMOMAB AND DONOR LYMPHOCYTEINFUSION IN B-ALL PATIENTS RELAPSING AFTERALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: ASTUDY OF THE SFGM-TC.

Oral Presenter: Paul Chauvet, FR

OS07-05 14:51 - 15:00TABELECLEUCEL FOR EPSTEIN–BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWINGALLOGENEIC HEMATOPOIETIC CELL (HCT) OR SOLID ORGANTRANSPLANT (SOT) AFTER FAILURE OF RITUXIMAB +/-CHEMOTHERAPY (ALLELE)

Oral Presenter: Susan Prockop, US

OS07-06 15:00 - 15:09GENOMIC DYSFUNCTION OF HUMAN LEUKOCYTE ANTIGENDIVERSITY AS DRIVER OF POST-TRANSPLANT ACUTEMYELOID LEUKEMIA RECURRENCE

Oral Presenter: Simona Pagliuca, FR

OS07-07 15:09 - 15:18PROSPECTIVE PHASE II STUDY OF PREEMPTIVE CHIMERISM-DRIVEN REDUCTION OF IMMUNOSUPPRESSION AFTER NON-MYELOABLATIVE CONDITIONING — SUBANALYSIS OFPATIENTS WITH MYELOID NEOPLASMS - EUDRACT #:2007-002420-15

Oral Presenter: Saskia Hell, DE

OS07-08 15:18 - 15:27THE IMMUNOLOGICAL SYNAPSIS OF ACUTE MYELOIDLEUKEMIA RELAPSING AFTER ALLOGENEIC HEMATOPOIETICCELL TRANSPLANTATION: PLEIOTROPY OF IMMUNE ESCAPE



NG10 - Paediatrics Session - Communication challenges in paediatric HSCT nursing

Chair: Hilda Mekelenkamp, NLChair: Marjola Gjergji, IT

NG10-01 14:15 - 14:35Words as medicine

Speaker: Renee Gregson, NL

NG10-02 14:35 - 14:40QA - part I

NG10-03 14:40 - 15:00Communication over language barriers – Examples frompaediatric oncology

Speaker: Pernilla Pergert, SE

NG10-04 15:00 - 15:05QA - part II

135 / 160


NG10-05 15:05 - 15:30Debate

Speaker: Hilda Mekelenkamp, NLSpeaker: Eugenia Trigoso, ESSpeaker: Marjola Gjergji, IT


Paed3 - Paediatric Diseases Oral Session

Chair: Selim Corbacioglu, DEChair: Jean-Hugues Dalle, FR

Paed3-05 14:15 - 14:23DECISION-MAKING ABOUT HSCT IN PATIENTS WITHHEMOGLOBINOPATHIES, A PDPW/IEWP SCENARIO-BASEDSURVEY ON PHYSICIANS’ PERSPECTIVES.

Oral Presenter: Hilda Mekelenkamp, NL

Paed3-01 14:23 - 14:31EFFECT OF KIR MISMATCH AND NK CELL DOSE ON THEINCIDENCE OF LEUKEMIA RELAPSE AFTER ALFA/BETA TCELL-DEPLETED HAPLO HSCT

Oral Presenter: Svetlana Glushkova, RU

Paed3-02 14:31 - 14:39MATCHED UNRELATED DONOR TRANSPLANTATION WITHATG VERSUS HAPLOIDENTICAL TRANSPLANTATION USINGPOST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITHACUTE MYELOID LEUKEMIA: A STUDY ON BEHALF OF THEPDWP-EBMT

Oral Presenter: Annalisa Ruggeri, IT

Paed3-03 14:39 - 14:47PREDICTORS OF LONG TERM RESPONSE WITH CD28-BASEDCD19 CAR T-CELLS IN CHILDREN AND YOUNG ADULTS WITHB-ALL

Oral Presenter: Elad Jacoby, IL

Paed3-04 14:47 - 14:55T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANTATION INCHILDREN WITH HEMATOLOGICAL MALIGNANCIES: ACOMPARISON OF TRANSPLANT OUTCOMES BETWEENCD3+/CD19+ AND TCR??+/CD19+ DEPLETION PLATFORMS.

Oral Presenter: MARTA GONZALEZ VICENT, ES

Paed3-06 14:55 - 15:03IN CHILDREN WITH SICKLE CELL ANEMIA ANDHYPERSPLENISM, PARTIAL VERSUS TOTAL SPLENECTOMYBEFORE STEM CELL TRANSPLANTATION PRESERVESSPLEEN FUNCTION

Oral Presenter: Françoise Bernaudin, FR

Paed3-07 15:03 - 15:11IMPACT OF INCLUDING ABATACEPT FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN ALLOGENEIC STEM CELLTRANSPLANTATION FOR HEMOGLOBINOPATHY.

Oral Presenter: Niketa Shah, US

Paed3-08 15:11 - 15:19100 HEMATOPOIETIC CELL TRANSPLANTS FOR SICKLE CELLDISEASE: LESSONS LEARNT

Oral Presenter: Gaurav Kharya, IN

Paed3-09 15:19 - 15:27HLA IDENTICAL RELATED CORD BLOOD TRANSPLANTATION

136 / 160


FOR PATIENTS WITH TRANSFUSION-DEPENDENTTHALASSEMIA AND SICKLE CELL DISEASE

Oral Presenter: Vanderson Rocha, BR

General14:15 - 15:15 South Hall 2A+B / Virtual Hall 5

GS3 - General Assembly

Chair: Nicolaus Kröger, DEChair: Harry Dolstra, NLChair: John Snowden, GB

GS3-01 14:15 - 14:40President's Report


GS3-02 14:40 - 14:50Treasurer's Financial Report

Speaker: Harry Dolstra, NL

GS3-03 14:50 - 15:00Secretary's Report

Speaker: John Snowden, GB

GS3-04 15:00 - 15:05Election Results 2022

Speaker: John Snowden, GB

GS3-05 15:05 - 15:10Outgoing Board members


GS3-06 15:10 - 15:15QA


QM4 - Inspectors Session

Chair: Ivana Ferrero, IT

QM4-01 14:15 - 14:25JACIE Activity & Updates on the impact of COVID

Speaker: Raquel Espada, ES

QM4-02a 14:25 - 14:32Inspectors experience inspecting the different accreditationprocesses: Virtual Inspections

Speaker: Frédéric Bernard, FR

QM4-02b 14:32 - 14:39The Jacie inspection through the eyes of an inspector: On-Siteand Hybrid Inspections

Speaker: Victoria Bordon, BE

QM4-02c 14:39 - 14:45Inspectors experience inspecting the different accreditationprocesses: Short Process

Speaker: Korinne Di Leo, IT

QM4-03 14:45 - 14:55Volunteers update

Speaker: Anna Pasztor, ES

QM4-04 14:55 - 15:05JACIE & Data safety

Speaker: Iris Bargalló, ES

QM4-05 15:05 - 15:10Presentation of the QMC

137 / 160


Speaker: Renza Monteleone, IT

QM4-06 15:10 - 15:15Presentation of the JIC

Speaker: Tuula Rintala, GB

QM4-07 15:15 - 15:30QA


E9 - Autologous immune cells in cellular therapy

Chair: Robert Pytlík, CZChair: Annalisa Ruggeri, IT



E9-02 14:20 - 14:35Use of autologous cells as a source for the cellular therapies formalignant diseases


E9-03 14:35 - 14:50Potential of NK cells for the relapse control

Speaker: Monika Holubová, CZ

E9-04 14:50 - 15:05Dendritic Cell-Based Immunotherapy for AML

Speaker: Sébastien Anguille, BE


Speaker: Annalisa Ruggeri, IT


W7 - ABC of immune system I

Chair: Adam Kuba, CZChair: Satu Mustjoki, FI


Speaker: Adam Kuba, CZ

W7-02 14:20 - 14:35Mucosa-associated immune system

Speaker: Ronjon Chakraverty, GB

W7-03 14:35 - 14:50Role of GIT virome in immune response

Speaker: Jerome Legoff, FR

W7-04 14:50 - 15:05Microbiota and mucosal immunity effects on HSCT outcomes

Speaker: Marcel van den Brink, US


Speaker: Satu Mustjoki, FI



138 / 160



IT6 - Industry Theatre: A 1-year Experience of the Multi-Procedural Amicus Blue™ Online ECPSystem in Routine Use by Fresenius Kabi

IT6_1 15:35 - 15:35A 1-year Experience of the Multi-Procedural Amicus Blue™Online ECP System in Routine Use

Speaker: Tarik Kanouni, FR


P3 - Does achievement of MRD-negative disease after HSCT improve survival?

Chair: Michael Doubek, CZChair: Nicolaus Kröger, DE

P3-01 16:00 - 16:20Acute myeloid leukemia


P3-02 16:20 - 16:40Acute lymphoblastic leukemia

Speaker: Nicola Gökbuget, DE

P3-03 16:40 - 17:00Myeloma

Speaker: Francesca Gay, IT

P3-04 17:00 - 17:15QA

Working Party Session16:00 - 17:15 Forum Hall / Virtual Hall 2

TCWP - Transplant Complications Working Party session

Chair: Zinaida Peric, HRChair: Ivan Moiseev, RU

TCWP-1 16:00 - 16:15Endothelial syndromes in HSCT and Cellular therapy

Speaker: Christian Koenecke, DE

TCWP-2 16:15 - 16:30Current Clinical Practice in Chronic GVHD


TCWP-3 16:30 - 16:45Late Effects in HSCT Survivors - What's new

Speaker: Hélène Schoemans, BE

TCWP-4 16:45 - 17:00Modern Technological Approaches in HSCT complications

Speaker: Grzegorz Basak, PL

TCWP-5 D 17:00 - 17:15Discussion


NG11 - How do I… Understand blood counts?

Chair: Teija Schröder, FIChair: Petra Vodi?ková, CZ

NG11-01 16:00 - 16:15Liver diseases in laboratory. What are the main findings inhaematology patients?

Speaker: Katerina Steinerová, CZ

139 / 160


NG11-02 16:15 - 16:30Renal diseases in the laboratory. What are the main findings inhaematology patients?

Speaker: Tereza Dekojová, CZ

NG11-03 16:30 - 16:45Full blood counts

Speaker: Alexandra Jungová, CZ

NG11-04 16:45 - 17:00Crossmatching

Speaker: Veronika Bergerová, CZ

NG11-05 17:00 - 17:15QA


Paed4 - Inborn Errors Oral Session

Chair: Bénédicte Neven, FRChair: Michael Albert, DE

Paed4-01 16:00 - 16:09A RANDOMISED CLINICAL PHASE 2 TRIAL TO COMPARETREOSULFAN WITH BUSULFAN BASED CONDITIONING PRIORTO ALLOGENEIC HAEMATOPOIETIC STEM CELLTRANSPLANTATION IN CHILDREN WITH NON-MALIGNANTDISEASES.

Oral Presenter: Karl-Walter Sykora, DE

Paed4-02 16:09 - 16:18AUTOIMMUNE CYTOPENIA AFTER HAEMATOPOIETIC CELLTRANSPLANTATION FOR CHILDREN WITH INBORN ERRORSOF IMMUNITY: A MULTICENTRE RETROSPECTIVE COHORTANALYSIS


Paed4-03 16:18 - 16:27RADIO-IMMUNOTHERAPY WITH 90YTTRIUM LABELLED ANTI-CD66 MONOCLONAL ANTIBODY IN CHILDREN WITHRELAPSED/REFRACTORY ACUTE LEUKEMIA: A UK PHASE 1STUDY

Oral Presenter: Robert Chiesa, GB

Paed4-04 16:27 - 16:36POPULATION PHARMACOKINETIC ANALYSIS OFALEMTUZUMAB IN IN CHILDREN WITH NON-MALIGNANTDISEASES UNDERGOING ALLOGENEIC HSCT: TOWARDSMODEL INFORMED PRECISION DOSING

Oral Presenter: Federica R. Achini-Gutzwiller, CH

Paed4-05 16:36 - 16:45PREPAD: PREDICTING PATIENT DEATH AFTER ALLOHSCTFOR INBORN ERRORS USING MACHINE LEARNING, AN IEWPSTUDY

Oral Presenter: Erik G J von Asmuth, NL

Paed4-06 16:45 - 16:54ALTERNATIVE DONOR STEM CELL TRANSPLANTATION WITHPOST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN 37CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY(SCID)

Oral Presenter: Rafaella Muratori, BR

Paed4-07 16:54 - 17:03HSCT OUTOME IN HYPOMORPHIC RAG DEFICIENCIES: AN

140 / 160


IEWP/PIDTC STUDY

Oral Presenter: Catharina Schuetz, DE

Paed4-08 17:03 - 17:12CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELLGENE THERAPY IN MPSIIIA

Oral Presenter: Jane Louise Kinsella, GB


OS08 - Oral session 8: CAR-T I

Chair: Maria-Luisa Schubert, DEChair: Frantisek Folber, CZ

OS08-01 16:00 - 16:09LONG-TERM FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) INPATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENTNON-HODGKIN LYMPHOMA (INHL)

Oral Presenter: Julio Chavez, US

OS08-02 16:09 - 16:18PROPHYLACTIC CORTICOSTEROID USE WITHAXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITHRELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/RLBCL): 1-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 (C6)

Oral Presenter: Olalekan O. Oluwole, US

OS08-03 16:18 - 16:27PRIMARY CD33-CAR-NK CELLS EFFICIENTLY TARGET ACUTEMYELOID LEUKEMIA

Oral Presenter: Nawid Albinger, DE

OS08-04 16:27 - 16:36STEM CELL BOOST FOR PERSISTENT CYTOPENIA AFTERCHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A GERMANLYMPHOMA ALLIANCE (GLA) STUDY

Oral Presenter: Nico Gagelmann, DE

OS08-05 16:36 - 16:45SUPERIORITY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) INSECOND-LINE (2L) LARGE B-CELL LYMPHOMA (LBCL) IN THEELDERLY

Oral Presenter: Tom van Meerten, NL

OS08-06 16:45 - 16:54ENHANCING SLAMF7 CAR T CELL PRODUCTION BYPREVENTION OF FATRICIDE

Oral Presenter: Sabrina Prommersberger, DE

OS08-07 16:54 - 17:03TWO-YEAR FOLLOW-UP OF TRANSCEND NHL 001(TRANSCEND), A MULTICENTER PHASE 1 STUDY OFLISOCABTAGENE MARALEUCEL(LISO-CEL) IN RELAPSED ORREFRACTORY (R/R) LARGE B-CELL LYMPHOMAS (LBCL)


OS08-08 17:03 - 17:12ALLOGENEIC CD19-CAR T CELLS: A PROMISING TREATMENTFOR PEDIATRIC PATIENTS WITH HIGHLY REFRACTORY BCP-ALL RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEMCELLS TRANSPLANT (ALLO-HSCT)

Oral Presenter: Francesca Del Bufalo, IT

141 / 160



OS09 - Oral session 9: Cellular therapies other than CARs, cell-based immune therapies, stem cellengineering

Chair: Monika Holubová, CZChair: Eva Wagner, DE

OS09-01 16:00 - 16:09OFF-THE-SHELF INVARIANT NATURAL KILLER T CELLIMMUNOTHERAPY IS FEASIBLE, SAFE AND PROMOTESREGULATORY AND CYTOTOXIC HOST IMMUNE CELLS IN THEDOG

Oral Presenter: Antonia Rotolo, US

OS09-02 16:09 - 16:18EXPANSION OF PHENOTYPICALLY SENESCENT CD57+ CD8 TCELLS IS ASSOCIATED WITH IMPAIREDIMMUNOCOMPETENCE AFTER ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTATION

Oral Presenter: Sarah Morin, CH

OS09-03 16:18 - 16:27MULTISTATE ANALYSIS OF ALLOGENEIC HSCT IN PATIENTS ?70 YEARS COMPARED TO POPULATION MORTALITY BASEDON THE GERMAN REGISTRY FOR STEM CELLTRANSPLANTATION (DRST)

Oral Presenter: Jan Frederic Weller, DE

OS09-04 16:27 - 16:36A PHASE 1/2A STUDY OF DECIDUAL STROMAL CELLS FORTHE TREATMENT OF COVID-19 ARDS.

Oral Presenter: Igor Novitzky-Basso, CA

OS09-05 16:36 - 16:45THE IMPACT OF DONOR-SPECIFIC ANTIBODIES PRESENCEON THE OUTCOME POST ALLOGENEIC HEMATOPOIETICSTEM CELL TRANSPLANTION: A SURVEY FROM A SINGLECENTER.

Oral Presenter: Sabrina Giammarco, IT

OS09-06 16:45 - 16:54UM171 EXPANSION OF SMALL CORD BLOODS PROVIDESACCESS TO SAFE TRANSPLANTATION FOR DONORLESSPATIENTS WITH EXCELLENT LONGTERM FOLLOW-UP

Oral Presenter: Sandra Cohen, CA

OS09-07 16:54 - 17:03GRAFT ENGINEERING: HOW LONG CAN YOU WAIT, HOW LOWCAN YOU GO, AND PANDEMIC READINESS

Oral Presenter: Kasper Westinga, NL

OS09-08 17:03 - 17:12MECHANISMS OF T CELL TOLERANCE AFTER PT-CYHAPLOTRANSPLANTATION

Oral Presenter: Paul Szabolcs, US


E10 - MDS/MPN/SAA

Chair: Anna Jonášová, CZChair: Nicolaus Kröger, DE


142 / 160


Speaker: Anna Jonášová, CZ

E10-02 16:05 - 16:20Transplantations for PMF and secondary MF: current algorithmand results

Speaker: Juan Carlos Hernández-Boluda, ES

E10-03 16:20 - 16:35Current transplant algorithm for MDS

Speaker: Marie Robin, FR

E10-04 16:35 - 16:50SAA – the results with new new transplant and non-transplantapproaches

Speaker: Andrea Bacigalupo, IT

E10-05 16:50 - 17:00Conclusions



W8 - ABC of immune system II

Chair: Edgar Faber, CZChair: Milan Raška, CZ


Speaker: Milan Raška, CZ

W8-02 16:05 - 16:20Identification of essential pathways for CAR-T cytotoxicity

Speaker: Satu Mustjoki, FI

W8-03 16:20 - 16:35Manipulation of regulatory T cell populations in transplantationtolerance

Speaker: Cristiano Scotta, GB

W8-04 16:35 - 16:50Immunomodulation in BMT: Interferons and Cytokines. Lessonsfrom Clinical Immunology

Speaker: Emma Morris, GB


Speaker: Edgar Faber, CZ


IT5 - Kites commitment to manufacturing excellence: Inside CAR T manufacturing | IndustryTheatre: Gilead

Chair: Charles Calderaro, US

IT5-01 17:30 - 17:33Introduction

Speaker: Charles Calderaro, US

IT5-02 17:33 - 17:53Inside Kite’s manufacturing for cellular therapies


IT5-03 17:53 - 17:58Live audience Q&A


IT5-04 17:58 - 18:00Close

143 / 160





MTE-11 17:30 - 18:30Indications for allo-HCT in lymphoid malignancies




MTE-13 17:30 - 18:30Donor selection: HLA and beyond

Speaker: Ann-Margaret Little, GB



MTE-14 17:30 - 18:30COVID-19 in HCT candidates and patients in the post-vaccineera




MTE-15 17:30 - 18:30Vaccinations

Speaker: Catherine Cordonnier, FR



144 / 160


Wednesday, 23. March 2022


SAAWP - Severe Aplastic Anaemia Working Party session

Chair: Beatrice Drexler, CHChair: Alicia Rovo, CH

SAAWP-01 09:00 - 09:20Somatic mutations in acquired aplastic anemia: what do welearn from the RACE trial?

Speaker: Austin Kulasekararaj, GB

SAAWP-02 09:20 - 09:40Current standard of IST in SAA in Europe in the EPAG era?

Speaker: Antonio Risitano, IT

SAAWP-03 09:40 - 10:00Transplantation modalities in acquired aplastic anemia: anychange?

Speaker: Régis Peffault de Latour, FR

SAAWP-04 10:00 - 10:15QA

Working Party Session09:00 - 10:15 Forum Hall / Virtual Hall 2

LWP - Lymphoma Working Party session

Chair: Bertram Glass, DE

LWP-01 09:00 - 09:15Report of the Chairman on activities 2021 and upcoming newprojects


LWP-02 09:15 - 09:17Jian-Jian Luan Award - Introduction

LWP-03 09:17 - 09:40DAY+7 ANTI CD19-CAR-T BLOOD CONCENTRATIONS IDENTIFYULTRA-HIGH-RISK GROUP FOR EARLY PROGRESSION OFDISEASE IN PATIENTS WITH STABLE/PROGRESSIVE DLBCLAT LYMPHODEPLETION

Oral Presenter: Ron Ram, IL

LWP-04 09:40 - 10:15Scientific Debate : Any role for autologous transplantation inlymphoma? - Or will CAR T-cells do the job?

Speaker: Catherine Thieblemont, FRSpeaker: Marek Trn?ný, CZ


NG12 - CAR T

Chair: Ruth Clout, GBChair: Tereza Hasilová, CZ

NG12-01 09:00 - 09:20The principle of CAR T therapy: Why and how CAR T therapyworks


NG12-02 09:20 - 09:40CAR T-cell: Clinical data in ALL, NHL and Myeloma

145 / 160


Speaker: Ji?í Šrámek, CZ

NG12-03 09:40 - 10:00CAR-T cell: Toxicity and management

Speaker: Kamila Polgárová, CZ

NG12-04 10:00 - 10:15QA

Multi-stakeholder Forum on Innovative Cellular Therapies09:00 - 10:15 South Hall 1A+B / Virtual Hall 4

MSF1 - Multi-stakeholder Forum on Innovative Cellular Therapies 1 | AI – opportunities for cell andgene therapies.

Chair: Jurgen Kuball, NLChair: Michael Hudecek, DE

MSF1-01 09:00 - 09:11EU vision/Health strategy from EU

Speaker: Sandra Gallina, IT

MSF1-02 09:11 - 09:31AI in Advanced Therapies

Speaker: Stephen Goldrick, GB

MSF1-03 09:31 - 09:46Impact of AI on healthcare professionals and their patients

Speaker: Manel Juan, ES

MSF1-04 09:46 - 10:01Ethics on AI

Speaker: Michael Morrison, GB

MSF1-05 10:01 - 10:15Q&A


OS10 - Oral session 10: GVHD I, clinical

Chair: Zinaida Peric, HRChair: Mesire Aydin, NL

OS10-01 09:00 - 09:09LONGITUDINAL, INTEGRATED ANALYSIS OF GUTBACTERIOME, MYCOBIOME, VIROME AND METABOLOMEDURING ALLOGENEIC STEM CELL TRANSPLANTATIONREVEALS SUSCEPTIBILITY FOR ACUTE GRAFT-VERSUS-HOSTDISEASE

Oral Presenter: Erik Thiele Orberg, DE

OS10-02 09:09 - 09:18ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY,INDUCES CLEAVAGE OF CELL SURFACE CD6 AND RAPIDONSET OF EFFICACY IN SUBJECTS WITH NEWLY DIAGNOSEDACUTE GRAFT-VERSUS-HOST DISEASE

Oral Presenter: Stephen Connelly, US

OS10-03 09:18 - 09:27RUXOLITINIB VERSUS BEST AVAILABLE THERAPY INPATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE: A COMPARISON OF RESPONSE BYORGAN CLASS FROM THE RANDOMIZED, PHASE 3 REACH2STUDY


OS10-04 09:27 - 09:36UPDATED INTERIM RESULTS FROM THE EQUATE STUDY:

146 / 160


PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, ANOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLYDIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE

Oral Presenter: Corey Cutler, US

OS10-05 09:36 - 09:45PROSPECTIVE TRIAL OF IBRUTINIB FOR THE TREATMENT OFPEDIATRIC CHRONIC GRAFT-VERSUS-HOST DISEASE

Oral Presenter: Marco Zecca, IT

OS10-06 09:45 - 09:54POOLED ALLOGENIC FECAL MICROBIOTHERAPY MAAT013FOR THE TREATMENT OF STEROID-REFRACTORYGASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE:RESULTS FROM THE PHASE IIA HERACLES STUDY ANDEXPANDED ACCESS PROGRAM

Oral Presenter: Florent Malard, FR

OS10-07 09:54 - 10:03MINNESOTA ACUTE GVHD RISK SCORE DEFINES SURVIVALAT ONSET OF ACUTE GVHD AFTER PTCY PROPHYLAXIS.

Oral Presenter: Maria Teresa Lupo-Stanghellini, IT

OS10-08 10:03 - 10:12OVERLAP CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)IS ASSOCIATED AITH AN ADVERSE PROGNOSIS: SECONDARYANALYSIS OF THE ABA2 TRIAL

Oral Presenter: Lev Gorfinkel, US


OS11 - Oral session 11: Aplastic anemia, autoimmune diseases

Chair: Dominique Farge, FRChair: Sujith Samarasinghe, GB

OS11-01 09:00 - 09:09DETERMINANTS OF CLONAL EVOLUTION IN APLASTICANEMIA

Oral Presenter: Carmelo Gurnari, US

OS11-02 09:09 - 09:18LOW DOSE CYCLOPHOSPHAMIDE CONDITIONING IS SAFE INSYSTEMIC SCLEROSIS PATIENTS INELIGIBLE FOR STANDARDDOSE REGIMENS – AN INTERIM ANALYSIS OF THEPROSPECTIVE ASSURE TRIAL

Oral Presenter: John Moore, AU

OS11-03 09:18 - 09:27LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FORAUTOIMMUNE DISEASES: A RETROSPECTIVE STUDY FROMTHE EBMT AUTOIMMUNE DISEASES, TRANSPLANTCOMPLICATIONS AND PAEDIATRIC DISEASES WORKINGPARTIES

Oral Presenter: Kirill Kirgizov, RU

OS11-04 09:27 - 09:36LONGITUDINAL CHANGES ON QUANTITATIVE CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN DIFFUSESYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNGDISEASE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELLTRANSPLANTATION.

Oral Presenter: Grégory Pugnet, FR

147 / 160


OS11-05 09:36 - 09:45IN-DEPTH DIAGNOSTICS OF PEDIATRIC BONE MARROWFAILURE INCREASES DETECTION RATE OF UNDERLYINGCAUSES: A MULTI-CENTER PROSPECTIVE COHORT STUDY

Oral Presenter: Khaled Atmar, NL

OS11-06 09:45 - 09:54LONG-TERM FOLLOW-UP OF HAPLOIDENTICALTRANSPLANTATION IN SEVERE APLASTIC ANAEMIA: AMULTICENTRE PROSPECTIVE STUDY

Oral Presenter: Lanping Xu, CN

OS11-07 09:54 - 10:03IMPROVED SURVIVAL AFTER HAPLOIDENTICAL CELLTRANSPLANTATION WITH POST-TRANSPLANTATIONCYCLOPHOSPHAMIDE COMPARED TO UNRELATED CORDBLOOD TRANSPLANTATION IN PATIENTS WITH FANCONIANEMIA

Oral Presenter: Carmem Bonfim, BR

OS11-08 10:03 - 10:12BULSUFAN DECREASES THE INCIDENCE OF MIXEDCHIMAERISM IN HLA-MATCHED DONOR TRANSPLANTATIONFOR SEVERE APLASTIC ANAEMIA

Oral Presenter: Zhengli Xu, CN


E11 - CMV – still a challenge?

Chair: Petr Hubá?ek, CZChair: Hermann Einsele, DE


Speaker: Petr Hubá?ek, CZ

E11-02 09:05 - 09:20CMV – the transplantation troll – the molecular mechanism ofeffective manipulation with immunity

Speaker: Sebastian Voigt, DE

E11-03 09:20 - 09:35CMV infection and disease – Definitions and clinical impact

Speaker: Christine Robin, FR

E11-04 09:35 - 09:50Therapy and vaccination of CMV infection in HSCT –pharmacological and cellular approaches

Speaker: Tobias Feuchtinger, DE

E11-05 09:50 - 09:59Conclusions

Speaker: Hermann Einsele, DE


W9 - Novel insights into systemic hyperinflammation syndromes

Chair: Ji?í Šrámek, CZChair: Lucrecia Yáñez, ES


Speaker: Ji?í Šrámek, CZ

148 / 160


W9-03 09:20 - 09:35Cytokine release syndrome after CAR-T-Cell therapy

Speaker: Míriam Sánchez-Escamilla, ES

W9-04 09:35 - 09:50Secondary haemophagocytic lymphohistiocytosis

Speaker: Paul La Rosee, DE


Speaker: Lucrecia Yáñez, ES


ePoster Viewing


On-demand Library



Oral Session10:45 - 12:00 Congress Hall / Virtual Hall 1

OS12 - Oral session 12: Acute leukemia

Chair: Frédéric Baron, BEChair: Yasmina Serroukh, NL

OS12-01 10:45 - 10:54PREDICTION OF NON-RELAPSE MORTALITY IN PATIENTSWITH AML AND ALL RECEIVING ALLOSCT IN FIRST CR WITHPOST-TRANSPLANTATION CYCLOPHOSPHAMIDE-BASEDGVHD PROPHYLAXIS

Oral Presenter: Sjoerd J. F. Hermans, NL

OS12-02 10:54 - 11:03ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FORACUTE MYELOID LEUKEMIA WITH HYPERDIPLOID COMPLEXKARYOTYPE: A STUDY FROM THE ACUTE LEUKEMIAWORKING PARTY (ALWP) OF THE EBMT.

Oral Presenter: Xavier Poiré, BE

OS12-03 11:03 - 11:12IMPACT OF IDH1 AND IDH2 MUTATIONAL SUBGROUPS INACUTE MYELOID LEUKEMIA PATIENTS AFTER ALLOGENEICHEMATOPOIETIC CELL TRANSPLANTATION

Oral Presenter: Desiree Kunadt, DE

OS12-04 11:12 - 11:21POST-REMISSION TREATMENT PATTERN AND SURVIVALOUTCOMES IN CONNECT® MYELOID DISEASE REGISTRYPATIENTS WITH ACUTE MYELOID LEUKEMIA

Oral Presenter: Gail Roboz, US

OS12-05 11:21 - 11:30EVALUATION IN TRENDS IN OUTCOME OVER 2 DECADES OFPATIENTS WITH SECONDARY AML UNDERGOING ALLO-HCTFROM SIBLING AND UNRELATED DONORS: AN ALWP EBMTANALYSIS

149 / 160


Oral Presenter: Arnon Nagler, IL

OS12-06 11:30 - 11:39ALLOGENEIC TRANSPLANTATION FOR AML AGED ?70YEARS. A STUDY FROM THE ACUTE LEUKEMIA WORKINGPARTY OF THE EUROPEAN SOCIETY FOR BLOOD ANDMARROW TRANSPLANTATION (EBMT).

Oral Presenter: Enrico Maffini, IT

OS12-07 11:39 - 11:48CD34+ DOSE EFFECTS ON CLINICAL OUTCOMES AFTERFLUDARABINE-BUSULFAN CONDITIONING REGIMEN FORACUTE MYELOID LEUKEMIA USING PERIPHERAL BLOODSTEM CELLS - STUDY FROM THE ALWP OF EBMT

Oral Presenter: Eolia Brissot, FR

OS12-08 11:48 - 11:57SEGREGATION OF HIGH-RESOLUTION B HAPLOTYPESPOINTS TOWARDS PROTECTIVE DONOR KIR GENOTYPESAFTER UNRELATED HEMATOPOIETIC STEM CELLTRANSPLANTATION FOR PATIENTS WITH AML OR MDS

Oral Presenter: Johannes Schetelig, DE


OS13 - Oral session 13: CAR-T II

Chair: Nico Gagelmann, DEChair: Francesca Del Bufalo, IT

OS13-01 10:45 - 10:54CD19 CAR-T THERAPY IN CHILDREN WITH RELAPSED ANDREFRACTORY B-CELL ALL

Oral Presenter: Olga Molostova, RU

OS13-02 10:54 - 11:03PROFILES OF CYTOKINES ARE ASSOCIATED WITHPROLONGED HEMATOLOGIC TOXICITIES AFTER BCMATARGETED CAR-T CELL THERAPY

Oral Presenter: Linqin Wang, CN

OS13-03 11:03 - 11:12IMPACT OF ANAKINRA DOSE ON OUTCOMES IN PATIENTSWITH REFRACTORY CRS AND/OR ICANS AFTER CAR T-CELLTHERAPY

Oral Presenter: Nicolas Gazeau, US

OS13-04 11:12 - 11:21TREATMENT OF ADULT ALL PATIENTS WITH THIRD-GENERATION CD19-DIRECTED CHIMERIC ANTIGENRECEPTOR (CAR) T CELLS - RESULTS OF THE HEIDELBERGTRIAL 1 (HD-CAR-1 TRIAL)

Oral Presenter: Maria-Luisa Schubert, DE

OS13-05 11:21 - 11:30R/R B-ALL RECEIVING HAPLOIDENTICAL HSCT AFTER CAR-TTHERAPY ACHIVES COMPARABLE OUTCOMES TO B-ALLTRANSPLANTED IN CR1 AFTER CHEMOTHERAPY

Oral Presenter: Tingting Yang, CN

OS13-06 11:30 - 11:39PRIMARY ANALYSIS OF ZUMA?7: A PHASE 3 RANDOMIZEDTRIAL OF AXICABTAGENE CILOLEUCEL(AXI-CEL) VERSUSSTANDARD?OF?CARE(SOC) THERAPY IN PATIENTS WITHRELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

150 / 160


Oral Presenter: Tom van Meerten, NL

OS13-07 11:39 - 11:48REAL-LIFE EXPERIENCE WITH COMMERCIAL CAR-T CELLSFOR LYMPHOMA PATIENTS: EARLY EXPANSION KINETICPREDICTS DISEASE RESPONSE AND SURVIVAL

Oral Presenter: Martina Pennisi, IT

OS13-08 11:48 - 11:57DEVELOPMENT, SAFETY AND EFFICACY OF LOCALLYPRODUCED NOVEL BCMA CART CELLS FORRELAPSED/REFRACTORY MULTIPLE MYELOMA

Oral Presenter: Polina Stepensky, IL


NG13 - How do I manage… Palliative care and advanced care planning?

Chair: Sarah Liptrott, CHChair: Michal Kouba, CZ

NG13-01 10:45 - 11:05Advanced care planning

Speaker: Ida Korfage, NL

NG13-02 11:05 - 11:25Symptom management

Speaker: Ellie Cooke, GB

NG13-03 11:25 - 11:45Breathlessness management

Speaker: Ruth Ting, GB

NG13-04 11:45 - 12:00QA

Multi-stakeholder Forum on Innovative Cellular Therapies10:45 - 12:00 South Hall 1A+B / Virtual Hall 4

MSF2 - Multi-stakeholder Forum on Innovative Cellular Therapies 2 | Innovative Therapies: frombench to bedside.

Chair: Christian Chabannon, FRChair: Julio Delgado, ES

MSF2-01 10:45 - 11:00Starting material: Blood, Tissues and Cells

Speaker: Stefaan Van Der Spiegel, BE

MSF2-02 11:00 - 11:15Authorisation of ATMPs in the EU: scientific and regulatoryconsiderations

Speaker: Patrick Celis, NL

MSF2-03 11:15 - 11:30Health system evaluation of ATMPs

Speaker: Karen Facey, GB

MSF2-04 11:30 - 11:45Access to treatment & patient advocacy

Speaker: Natacha Bolaños, ES

MSF2-05 11:45 - 12:00Q&A

151 / 160



OS14 - Oral session 14: GVHD II, clinical and preclinical

Chair: David Michonneau, FRChair: Kim Orchard, GB

OS14-01 10:45 - 10:54IFN-GAMMA PRODUCING REGULATORY T CELLSCOUNTERBALANCE T CELL-MEDIATED INJURY TO THEINTESTINAL STEM CELL COMPARTMENT IN MICE ANDHUMANS


OS14-02 10:54 - 11:03BIOMARKER ANALYSIS IN PATIENTS WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOSTDISEASE TREATED WITH RUXOLITINIB OR BEST AVAILABLETHERAPY IN THE RANDOMIZED PHASE 3 REACH3 STUDY

Oral Presenter: Franco Locatelli, IT

OS14-03 11:03 - 11:12DECIPHERING THE EFFECTS OF GRAFT TREGS ON CHRONICGRAFT-VERSUS-HOST DISEASE: RESULTS FROM AMULTICENTER STUDY OF PATIENTS WITH ACUTE LEUKEMIAUNDERGOING ALLOGENEIC PBSCT

Oral Presenter: Mario Delia, IT

OS14-04 11:12 - 11:21LOW SOLUBLE PROGRAMMED CELL DEATH PROTEIN 1LEVELS AFTER ALLOGENEIC STEM CELL TRANSPLANTATIONPREDICT MODERATE OR SEVERE CHRONIC GVHD ANDINFERIOR OVERALL SURVIVAL

Oral Presenter: Lambros Kordelas, DE

OS14-05 11:21 - 11:30COMPARISON BETWEEN ATG AND POST-TRANSPLANTCYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS INNONMYELOABLATIVE MATCHED UNRELATED DONORHEMATOPOIETIC STEM CELL TRANSPLANTATIONS

Oral Presenter: Mesire Aydin, NL

OS14-06 11:30 - 11:39DECIPHERING ANTIGEN SPECIFICITY OF PROTECTIVEREGULATORY T CELL CLONES IN PATIENTS AFTERALLOGENEIC STEM CELL TRANSPLANTATION

Oral Presenter: Yankai Xiao, DE

OS14-07 11:39 - 11:48EX VIVO GENERATE D THROUGH PHARMACOLOGICALHYPOMETHYLATION HLA-G+ T-REGULATORY CELLS, DO NOTINDUCE ALLOREACTIVITY

Oral Presenter: Panayiota Christofi, GR

OS14-08 11:48 - 11:57DONOR PLASMACYTOID DENDRITIC CELLS REGULATE GVHDAND GVL ACTIVITIES OF DONOR T CELLS IN ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION

Oral Presenter: Pankoj K. Das, US

152 / 160



OS15 - Oral session 15: New drugs, gene therapy, and experimental transplantation

Chair: Despina Moshous, FRChair: Arjan Lankester, NL

OS15-01 10:45 - 10:54HEMATOPOIETIC STEM CELL TRANSPLANT FOR KRABBEDISEASE IS AUGMENTED BY ADDITION OF INTRAVENOUSAAV GENE REPLACEMENT THERAPY

Oral Presenter: Maria Escolar, US

OS15-02 10:54 - 11:03EFFICACY AND SAFETY OF PEGCETACOPLAN TREATMENT INCOMPLEMENT-INHIBITOR NAÏVE PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTSFROM THE PHASE 3 PRINCE STUDY

Oral Presenter: Andrija Bogdanovic, RS

OS15-03 11:03 - 11:12GLYCOLYTIC ENZYME PFKFB3 DETERMINES BONE MARROWENDOTHELIAL PROGENITOR CELL DAMAGE POSTCHEMOTHERAPY AND IRRADIATION

Oral Presenter: Zhong-shi Lyu, CN

OS15-04 11:12 - 11:21A TRANSCRIPTOMIC-BASED RATIONAL APPROACH FORCONSIDERING VISTA AS A NEW MOLECULAR TARGET INACUTE MYELOID LEUKEMIA


OS15-05 11:21 - 11:30THE HISTONE DEMETHYLASE KDM6A REGULATESHEMATOPOIETIC STEM AND PROGENITOR CELLSEMERGENCE AND ITS LOSS CAUSES MYELOID-BIASEDDIFFERENTIATION IN ZEBRAFISH

Oral Presenter: Huiqiao Chen, CN

OS15-06 11:30 - 11:39A COMBINATORIAL TRANSCRIPTIONAL MECHANISM ANDPHARMACOLOGIC REVERSAL OF LEUKEMIA IMMUNEEVASION

Oral Presenter: Maxim Pimkin, US

OS15-07 11:39 - 11:48A PHASE 2 STUDY OF ITACITINIB FOR THE PREVENTION OFCYTOKINE RELEASE SYNDROME (CRS) INDUCED BY IMMUNEEFFECTOR CELL (IEC) THERAPY: PRELIMINARY RESULTS

Oral Presenter: Matthew Frigault, US

OS15-08 11:48 - 11:57?????INCREASED DIAGNOSTIC TELOMERE LENGTHASSOCIATES WITH HIGHER RELAPSE RATES INTRANSPLANTED ACUTE MYELOID LEUKEMIA PATIENTS

Oral Presenter: Lara Bischof, DE


E12 - Update on viral infections in the transplant setting

Chair: Markéta Marková, CZChair: Hans Hirsch, CH


153 / 160


Speaker: Markéta Marková, CZ

E12-02 10:50 - 11:05Herpes viruses (other than CMV)


E12-03 11:05 - 11:20Adenoviruses

Speaker: Thomas Lion, AT

E12-04 11:20 - 11:35Known and emerging RNA viruses

Speaker: Jaap Jan Boelens, US

E12-05 11:35 - 11:38Conclusions

Speaker: Hans Hirsch, CH


W10 - Modulation of microbiome pre-, peri- and post-transplant – is it time to become routinepractice?

Chair: Jakub Radocha, CZChair: Florent Malard, FR


Speaker: Jakub Radocha, CZ

W10-02 10:50 - 11:05The gut microbiota and HSCT: potential roles and impacts ontransplant outcomes

Speaker: Daniele Zama, IT

W10-03 11:05 - 11:20Antibiotics and gut microbiome. Help and harm

Speaker: Elisabeth Meedt, DE

W10-04 11:20 - 11:35Fecal microbiota transplantation for treatment of GVHD

Speaker: Roni Shouval, US

W10-05 11:35 - 11:45Conclusions





P4 - New developments in CAR T cell therapy

Chair: Christian Chabannon, FRChair: Harry Dolstra, NL

P4-01 12:15 - 12:35CRISPR-engineered T cells in patients with refractory cancer

Speaker: Carl June, US

P4-02 12:35 - 12:55“Off the shelf “allogeneic” CAR-T-cells: development andchallenges

Speaker: Michael Bishop, US

154 / 160


P4-03 12:55 - 13:15CAR-NK cells – current status and perspective

Speaker: Evelyn Ullrich, DE

P4-04 13:15 - 13:30QA


OS16 - Oral session 16: Conditioning

Chair: Eolia Brissot, FRChair: Alessandro Rambaldi, IT

OS16-01 12:15 - 12:24TBI/FLUDARABINE VERSUS BUSULFAN/FLUDARABINE AS AMYELOABLATIVE CONDITIONING FOR ADULTS WITH ACUTEMYELOID LEUKEMIA TREATED WITH ALLO-HCT. A STUDYFROM THE ALWP OF THE EBMT

Oral Presenter: Ryszard Swoboda, PL

OS16-02 12:24 - 12:33TOTAL BODY IRRADIATION/FLUDARABINE VERSUSBUSULFAN/FLUDARABINE AS CONDITIONING IN ALLPATIENTS &GT;45 YEARS IN 1ST CR – A REGISTRY-BASEDSTUDY BY THE ALWP OF THE EBMT

Oral Presenter: Klaus Hirschbühl, DE

OS16-03 12:33 - 12:42COMPARISON OF FLUDARABINE PLUS REDUCED VERSUSMYELOABLATIVE DOSE BUSULFAN IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION

Oral Presenter: Kimimori Kamijo, JP

OS16-04 12:42 - 12:51FLUDARABINE VERSUS CYCLOPHOSPAMIDE INCOMBINATION WITH MYELOABLATIVE TBI AS CONDITIONINGFOR PATIENTS WITH AML TREATED WITH ALLO-HCT. ASTUDY FROM THE ALWP OF THE EBMT


OS16-05 12:51 - 13:00SURVIVAL ADVANTAGE OF TREOSULFAN PLUSFLUDARABINE (FT14) COMPARED TO BUSULFAN PLUSFLUDARABINE (FB4) IN ACTIVE ACUTE MYELOID LEUKEMIAPOST ALLOGENEIC TRANSPLANTATION: STUDY OF THEEBMT-ALWP

Oral Presenter: Eleni Gavriilaki, GR

OS16-06 13:00 - 13:09GVHD AND GFRS IN PATIENTS WITH AML UNDERGOINGALLOGENEIC TRANSPLANTATION WITH TREOSULFAN-VERSUS BUSULFAN-BASED CONDITIONING: A SUBGROUPANALYSIS OF THE RANDOMIZED PHASE III MC-FLUDT.14/LTRIAL

Oral Presenter: Friedrich Stölzel, DE

OS16-07 13:09 - 13:18TREOSULFAN-BASED COMPARED TO THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING FOR HAPLOIDENTICALTRANSPLANT IN PATIENTS WITH ACUTE MYELOIDLEUKEMIA.A STUDY FROM THE ACUTE LEUKEMIA WORKINGPARTY OF THE EBMT.

155 / 160


Oral Presenter: Francesco Saraceni, IT

OS16-08 13:18 - 13:27GRAFT-VERSUS-HOST DISEASE (GVHD) AND GVHD-FREE/RELAPSE-FREE SURVIVAL (GRFS) IN PATIENTS WITHMYELODYSPLASTIC SYNDROME (MDS) AFTER TREOSULFAN-VERSUS BUSULFAN-BASED CONDITIONING ANDALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION(ALLOHCT)

Oral Presenter: Matthias Stelljes, DE


NG14 - Nurses Programme: Closing Session

Chair: Michelle Kenyon, GBChair: Klara Kabatová-Maxová, CZ

NG14-01 12:15 - 12:35Supportive care of patients with severe aGVHD

Speaker: Seckin Erdal, TR

NG14-02 12:35 - 12:55The therapeutic world of the ECP nurse

Speaker: Alba Pons Cornado, NO

NG14-03 12:55 - 13:15Mesenchymal stem cells as a treatment of GVHD

Speaker: Daniel Lysak, CZ

NG14-04 13:15 - 13:20Best of the best


NG14-05 13:20 - 13:35Highlights of physician's sessions


NG14-06 13:35 - 13:45Presentation Paris 2023

Speaker: Thomas Jezequel, FR


OS17 - Oral session 17: Stem cell donor, stem cell source, mobilisation and collection

Chair: Bronwen Shaw, USChair: Johannes Schetelig, DE

OS17-01 12:15 - 12:24COMPARISON OF MOBILIZED PERIPHERAL BLOOD STEMCELLS VERSUS UNMANIPULATED BONE MARROWHAPLOIDENTICAL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH OR WITHOUT ATG

Oral Presenter: Claire Lacan, FR

OS17-02 12:24 - 12:33A REFINED MODEL OF HLA-DP PERMISSIVENESS IMPROVESSTRATIFICATION OF ACUTE GVHD AND TRM RISKS AFTERUNRELATED HEMATOPOIETIC CELL TRANSPLANTATION: ARETROSPECTIVE STUDY FROM THE CIBMTR

Oral Presenter: Esteban Arrieta-Bolaños, DE

OS17-03 12:33 - 12:42PBSC ALLOGENEIC GRAFT CRYOPRESERVATION DURINGCOVID-19 PANDEMIC: ANALYSIS OF THE SFGM-TC CENTEREXPERIENCE

156 / 160


Oral Presenter: boris calmels, FR

OS17-04 12:42 - 12:51HLA CLASS I MISMATCHES WITH HIGH PEPTIDE DIVERGENCEIN THE GRAFT-VERSUS-HOST DIRECTION ARE ASSOCIATEDWITH INFERIOR SURVIVAL AFTER 9/10 HLA-MATCHED UD-HCT: A CIBMTR RETROSPECTIVE STUDY.

Oral Presenter: Esteban Arrieta-Bolaños, DE

OS17-05 12:51 - 13:00MATCHING BEYOND THE HLA NAME: A NEW CLASSIFICATIONOF HLA-ALLELE MISMATCHES BASED ON PEPTIDE BINDINGPROFILE

Oral Presenter: Alice Bertaina, US

OS17-06 13:00 - 13:09CORD BLOOD SIGNIFICANTLY OUTPERFORMS OTHER CELLSOURCES IN CLEARING RESIDUAL HOST HEMATOLOGIC ANDLYMPHOID TISSUES

Oral Presenter: RUBIYA NADAF, GB

OS17-07 13:09 - 13:18DOES GRAFT CRYOPRESERVATION AFFECT THE OUTCOMESOF ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTS? AUK MULTICENTRE CASE CONTROL STUDY DURING COVID19PANDEMIC

Oral Presenter: Ruta Maniusyte, GB

OS17-08 13:18 - 13:27HAPLO OR UNRELATED DONOR (UD) ALLOGENEICHEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) FOR PATIENTS OLDER THAN 55 YEARS: ARANDOMIZED MULTICENTER PHASE III STUDY.

Oral Presenter: Raynier Devillier, FR


OS18 - Oral session 18: Paediatrics

Chair: Peter Bader, DEChair: Marianne Ifversen, DK

OS18-01 12:15 - 12:24EXCELLENT OUTCOMES AFTER T-REPLETE UNRELATEDDONOR CORD BLOOD TRANSPLANT TO CURE HIGH RISK ANDREFRACTORY PAEDIATRIC AML AND MDS

Oral Presenter: Claire Horgan, GB

OS18-03 12:24 - 12:33EXPOSURE-RESPONSE ANALYSIS OF ATLG GRAFALON® INPAEDIATRIC ALL PATIENTS: TOWARDS INDIVIDUALIZEDDOSING TO PREVENT ACUTE GVHD AFTER HSCT

Oral Presenter: Lisa V.E. Oostenbrink, NL

OS18-04 12:33 - 12:42OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN813 CHILDREN WITH FANCONI ANAEMIA: A STUDY ONBEHALF OF THE EBMT SAAWP AND PDWP


OS18-05 12:42 - 12:51IMPACT OF ACUTE GVHD ON SURVIVAL AND DISEASERELAPSE IN PAEDIATRIC PATIENTS UNDERGOINGALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTELYMPHOBLASTIC LEUKAEMIA: AN EBMT REGISTRY-BASED

157 / 160


ANALYSIS.


OS18-06 12:51 - 13:00ROLE OF ACUTE GVHD IN PAEDIATRIC PATIENTSUNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATIONFOR ACUTE MYELOID LEUKAEMIA: AN IMPERFECT BALANCE.


OS18-07 13:00 - 13:09SECOND HEMATOPOIETIC STEM CELL TRANSPLANT INCHILDREN WITH RELAPSED JMML: A THERAPEUTIC OPTIONWITH LIMITED TOXICITY.

Oral Presenter: Maria Gabelli, GB

OS18-08 13:09 - 13:18ALLOGENEIC HAEMATOPOIETIC STEM CELLTRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH RUNX1 GERMLINE MUTATIONS: A JOINT EBMT PDWP ANDEWOG-MDS ANALYSIS

Oral Presenter: Birgitte Strahm, DE


OS19 - Oral session 19: Non-infectious late effects and complications

Chair: Monica Cabrero, ESChair: Christian Niederwieser, DE

OS19-01 12:15 - 12:24HCT FRAILTY SCALE FOR ADULTS UNDERGOINGALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Oral Presenter: Maria Queralt Salas, ES

OS19-02 12:24 - 12:33RANDOMISED TRIAL ON THE IMPACT OF VIRTUAL-BASEDMULTIMODAL TRAINING PROGRAMME ON PHYSICAL FITNESSAND QUALITY OF LIFE IN PATIENTS LATE POST-HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT)

Oral Presenter: David Ma, AU

OS19-03 12:33 - 12:42EVALUATION OF SECONDARY MALIGNANT NEOPLASMSAFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION(HSCT): A RETROSPECTIVE MULTICENTRIC GETH (GRUPOESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO) STUDY

Oral Presenter: Maria Huguet, ES

OS19-04 12:42 - 12:51HLA-HAPLO-IDENTICAL DONOR HSCT ACHIEVED BETTERQOL WITHOUT COMPROMISE OF SURVIVAL COMPARED TOHLA-MATCHED-SIBLING DONOR HSCT

Oral Presenter: Xiaoyu Zhang, CN

OS19-06 13:00 - 13:09PREDICTORS AND SIGNIFICANCE OF RENAL DYSFUNCTION INPATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE

Oral Presenter: David Beshensky, US

OS19-07 13:09 - 13:18CARDIOTOXICITY IN PEDIATRIC PATIENTS WHO UNDERWENTSTEM CELL TRANSPLANTATION: RETROSPECTIVE ANALYSISON 289 CHILDREN

Oral Presenter: Francesca Compagno, IT

158 / 160


OS19-08 13:18 - 13:27SEXUAL FUNCTION OF ADULT LONG-TERM SURVIVORS ANDTHEIR PARTNERS AFTER ALLOGENEIC HEMATOPOIETICCELL TRANSPLANTATION (S-FAST): A STUDY BY THE EBMTTCWP AND EBMT NURSES GROUP

Oral Presenter: Lars Klingen Gjærde, DK

Joint Session12:15 - 13:17 Terrace 2A

JS02 - Joint session EBMT-EHA: Academical clinical trials in Europe

Chair: John Gribben, GBChair: Nicolaus Kröger, DE

JS02-1 12:15 - 12:36Breaking down national barriers. Examples from the myelomanetwork

Speaker: Pieter Sonneveld, NL

JS02-2 12:36 - 13:02How this can be translated into the transplant setting. Examplefrom the UK

Speaker: Charles Craddock, GB

JS02-3 13:02 - 13:17Discussion


W11 - Survivorship beyond survival

Chair: Petra Keslova, CZChair: Hélène Schoemans, BE


Speaker: Petra Keslova, CZ

W11-02 12:20 - 12:35Return to work among HSCT survivors

Speaker: André Tichelli, CH

W11-03 12:35 - 12:50Cognitive function in HSCT survivors

Speaker: Smita Bhatia, US

W11-04 12:50 - 13:05Patient peer support

Speaker: Susan Stewart, US

W11-05 13:05 - 13:16Conclusions

Speaker: Hélène Schoemans, BE




GS4 - Closing Session


159 / 160


GS4-01 13:45 - 13:50Presentation of the Springer Nature Poster Awards


GS4-02 13:50 - 13:55Best Young Abstracts

Speaker: Harry Dolstra, NL

GS4-03 13:55 - 14:05Congress Co-Presidents closing remarks

Speaker: Petr Sedlá?ek, CZSpeaker: Pavel Jindra, CZ

GS04-04 14:05 - 14:15Local President for EBMT 2023 Paris: Welcome


GS4-05 14:15 - 14:25EBMT President closing remarks

Speaker: Nicolaus Kröger, DESpeaker: Anna Sureda, ES

GS4-06 14:25 - 14:30New EBMT President Induction: Passing of the hammer

Speaker: Nicolaus Kröger, DESpeaker: Anna Sureda, ES

160 / 160

ebmt 2022 hybrid annual meeting march 19

Documents